
<html lang="en"     class="pb-page"  data-request-id="26985b34-40a6-414c-95d3-cd36528218c2"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/jm400877v;issue:issue:10.1021/jmcmar.2013.56.issue-21;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Synthesis, Radiofluorination, and in Vivo Evaluation of Novel Fluorinated and Iodinated Radiotracers for PET Imaging and Targeted Radionuclide Therapy of Melanoma" /></meta><meta name="dc.Creator" content="Emilie M. F.  Billaud" /></meta><meta name="dc.Creator" content="Latifa  Rbah-Vidal" /></meta><meta name="dc.Creator" content="Aurélien  Vidal" /></meta><meta name="dc.Creator" content="Sophie  Besse" /></meta><meta name="dc.Creator" content="Sébastien  Tarrit" /></meta><meta name="dc.Creator" content="Serge  Askienazy" /></meta><meta name="dc.Creator" content="Aurélie  Maisonial" /></meta><meta name="dc.Creator" content="Nicole  Moins" /></meta><meta name="dc.Creator" content="Jean-Claude  Madelmont" /></meta><meta name="dc.Creator" content="Elisabeth  Miot-Noirault" /></meta><meta name="dc.Creator" content="Jean-Michel  Chezal" /></meta><meta name="dc.Creator" content="Philippe  Auzeloux" /></meta><meta name="dc.Description" content="Our project deals with a multimodal approach using a single fluorinated and iodinated melanin-targeting structure and offering both imaging (positron emission tomography (PET)/fluorine-18) and trea..." /></meta><meta name="Description" content="Our project deals with a multimodal approach using a single fluorinated and iodinated melanin-targeting structure and offering both imaging (positron emission tomography (PET)/fluorine-18) and trea..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 21, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm400877v" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm400877v" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm400877v" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm400877v" /></link>
        
    
    

<title>Synthesis, Radiofluorination, and in Vivo Evaluation of Novel Fluorinated and Iodinated Radiotracers for PET Imaging and Targeted Radionuclide Therapy of Melanoma | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm400877v" /></meta><meta property="og:title" content="Synthesis, Radiofluorination, and in Vivo Evaluation of Novel Fluorinated and Iodinated Radiotracers for PET Imaging and Targeted Radionuclide Therapy of Melanoma" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0008.jpeg" /></meta><meta property="og:description" content="Our project deals with a multimodal approach using a single fluorinated and iodinated melanin-targeting structure and offering both imaging (positron emission tomography (PET)/fluorine-18) and treatment (targeted radionuclide therapy/iodine-131) of melanoma. Six 6-iodoquinoxaline-2-carboxamide derivatives with various side chains bearing fluorine were synthesized and radiofluorinated, and their in vivo biodistribution was studied by PET imaging in B16Bl6 primary melanoma-bearing mice. Among this series, [18F]8 emerged as the most promising compound. [18F]8 was obtained by a fully automated radiosynthesis process within 57 min with an overall radiochemical yield of 21%, decay-corrected. PET imaging of [18F]8 demonstrated very encouraging results as early as 1 h postinjection with high tumor uptake (14.33% ± 2.11% ID/g), high contrast (11.04 ± 2.87 tumor-to-muscle ratio), and favorable clearance properties. These results, associated with the previously reported pharmacokinetic properties and dosimetry of 8, make it a potential agent for both PET imaging and targeted radionuclide therapy of melanoma." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm400877v"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm400877v">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm400877v&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm400877v&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm400877v&amp;href=/doi/10.1021/jm400877v" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 8455-8467</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm4008517" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm400884w" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis, Radiofluorination, and <i>in Vivo</i> Evaluation of Novel Fluorinated and Iodinated Radiotracers for PET Imaging and Targeted Radionuclide Therapy of Melanoma</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emilie+M.+F.++Billaud">Emilie M. F. Billaud</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Latifa++Rbah-Vidal">Latifa Rbah-Vidal</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aur%C3%A9lien++Vidal">Aurélien Vidal</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sophie++Besse">Sophie Besse</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=S%C3%A9bastien++Tarrit">Sébastien Tarrit</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Serge++Askienazy">Serge Askienazy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aur%C3%A9lie++Maisonial">Aurélie Maisonial</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicole++Moins">Nicole Moins</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jean-Claude++Madelmont">Jean-Claude Madelmont</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elisabeth++Miot-Noirault">Elisabeth Miot-Noirault</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jean-Michel++Chezal">Jean-Michel Chezal</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philippe++Auzeloux">Philippe Auzeloux</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Clermont Université, Université d’Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Inserm, U 990, F-63000 Clermont-Ferrand, France</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Cyclopharma Laboratories, Biopôle Clermont-Limagne, Saint-Beauzire F-63360, France</span></div><div class="corresp-info"><strong>*</strong>Author e-mail address: <a href="/cdn-cgi/l/email-protection#1b6b737277726b6b7e357a6e617e77746e635b7275687e6976357d69"><span class="__cf_email__" data-cfemail="cabaa2a3a6a3babaafe4abbfb0afa6a5bfb28aa3a4b9afb8a7e4acb8">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm400877v&amp;href=/doi/10.1021%2Fjm400877v" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 8455–8467</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 17, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 June 2013</li><li><span class="item_label"><b>Published</b> online</span>21 October 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 November 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm400877v" title="DOI URL">https://doi.org/10.1021/jm400877v</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8455%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DEmilie%2BM.%2BF.%2BBillaud%252C%2BLatifa%2BRbah-Vidal%252C%2BAur%25C3%25A9lien%2BVidal%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D21%26contentID%3Djm400877v%26title%3DSynthesis%252C%2BRadiofluorination%252C%2Band%2Bin%2BVivo%2BEvaluation%2Bof%2BNovel%2BFluorinated%2Band%2BIodinated%2BRadiotracers%2Bfor%2BPET%2BImaging%2Band%2BTargeted%2BRadionuclide%2BTherapy%2Bof%2BMelanoma%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8467%26publicationDate%3DNovember%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm400877v"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1338</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">18</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm400877v" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis, Radiofluorination, and in Vivo Evaluation of Novel Fluorinated and Iodinated Radiotracers for PET Imaging and Targeted Radionuclide Therapy of Melanoma&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Emilie&quot;,&quot;last_name&quot;:&quot;M. F. Billaud&quot;},{&quot;first_name&quot;:&quot;Latifa&quot;,&quot;last_name&quot;:&quot;Rbah-Vidal&quot;},{&quot;first_name&quot;:&quot;Aurélien&quot;,&quot;last_name&quot;:&quot;Vidal&quot;},{&quot;first_name&quot;:&quot;Sophie&quot;,&quot;last_name&quot;:&quot;Besse&quot;},{&quot;first_name&quot;:&quot;Sébastien&quot;,&quot;last_name&quot;:&quot;Tarrit&quot;},{&quot;first_name&quot;:&quot;Serge&quot;,&quot;last_name&quot;:&quot;Askienazy&quot;},{&quot;first_name&quot;:&quot;Aurélie&quot;,&quot;last_name&quot;:&quot;Maisonial&quot;},{&quot;first_name&quot;:&quot;Nicole&quot;,&quot;last_name&quot;:&quot;Moins&quot;},{&quot;first_name&quot;:&quot;Jean-Claude&quot;,&quot;last_name&quot;:&quot;Madelmont&quot;},{&quot;first_name&quot;:&quot;Elisabeth&quot;,&quot;last_name&quot;:&quot;Miot-Noirault&quot;},{&quot;first_name&quot;:&quot;Jean-Michel&quot;,&quot;last_name&quot;:&quot;Chezal&quot;},{&quot;first_name&quot;:&quot;Philippe&quot;,&quot;last_name&quot;:&quot;Auzeloux&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;8455-8467&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm400877v&quot;},&quot;abstract&quot;:&quot;Our project deals with a multimodal approach using a single fluorinated and iodinated melanin-targeting structure and offering both imaging (positron emission tomography (PET)/fluorine-18) and treatment (targeted radionuclide therapy/iodine-131) of melanoma. Six 6-iodoquinoxaline-2-carboxamide derivatives with various side chains bearing fluorine were synthesized and radiofluorinated, and their in vivo biodistribution was studied by PET imaging in B16Bl6 primary melanoma-bearing mice. Among this series, [18F]8 emerged as the most promising compound. [18F]8 was obtained by a fully automated radiosynthesis process within 57 min with an overall radiochemical yield of 21%, decay-corrected. PET imaging of [18F]8 demonstrated very encouraging results as early as 1 h postinjection with high tumor uptake (14.33% ± 2.11% ID/g), high contrast (11.04 ± 2.87 tumor-to-muscle ratio), and favorable clearance properties. These results, associated with the previously reported pharmacokinetic properties and dosimetry of 8, mak&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400877v&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400877v" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400877v&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400877v" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400877v&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400877v" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm400877v&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400877v&amp;href=/doi/10.1021/jm400877v" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm400877v" /></input><a href="/doi/pdf/10.1021/jm400877v" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm400877v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm400877v%26sid%3Dliteratum%253Aachs%26pmid%3D24044531%26genre%3Darticle%26aulast%3DBillaud%26date%3D2013%26atitle%3DSynthesis%252C%2BRadiofluorination%252C%2Band%2Bin%2BVivo%2BEvaluation%2Bof%2BNovel%2BFluorinated%2Band%2BIodinated%2BRadiotracers%2Bfor%2BPET%2BImaging%2Band%2BTargeted%2BRadionuclide%2BTherapy%2Bof%2BMelanoma%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D21%26spage%3D8455%26epage%3D8467%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=290723" title="Solutions">Solutions</a>,</li><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jmcmar.2013.56.issue-21/production/jmcmar.2013.56.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/medium/jm-2013-00877v_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400877v&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Our project deals with a multimodal approach using a single fluorinated and iodinated melanin-targeting structure and offering both imaging (positron emission tomography (PET)/fluorine-18) and treatment (targeted radionuclide therapy/iodine-131) of melanoma. Six 6-iodoquinoxaline-2-carboxamide derivatives with various side chains bearing fluorine were synthesized and radiofluorinated, and their <i>in vivo</i> biodistribution was studied by PET imaging in B16Bl6 primary melanoma-bearing mice. Among this series, [<sup>18</sup>F]<b>8</b> emerged as the most promising compound. [<sup>18</sup>F]<b>8</b> was obtained by a fully automated radiosynthesis process within 57 min with an overall radiochemical yield of 21%, decay-corrected. PET imaging of [<sup>18</sup>F]<b>8</b> demonstrated very encouraging results as early as 1 h postinjection with high tumor uptake (14.33% ± 2.11% ID/g), high contrast (11.04 ± 2.87 tumor-to-muscle ratio), and favorable clearance properties. These results, associated with the previously reported pharmacokinetic properties and dosimetry of <b>8</b>, make it a potential agent for both PET imaging and targeted radionuclide therapy of melanoma.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Malignant melanoma affects more than 150 000 new patients per year worldwide. It accounts for up to 90% of all deaths caused by skin cancer and displays a high metastatic potential.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Furthermore, this disease is the second most common cancer among patients aged 20–39.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a></div><div class="NLM_p">Early melanomas (clinical stages I and II, according to the recommendations of the American Joint Commission on Cancer) are usually treated with surgical removal of the tumor. Unfortunately, patients with highly disseminated melanomas (stages III and IV) have a very poor prognosis, with a median survival time of only 6–9 months and a 3-years survival rate of only 10–15%.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> These data indicate an urgent need to find efficient therapies to treat disseminated melanoma.</div><div class="NLM_p">Standard clinical practice for the initial treatment of cutaneous melanoma involves wide local excision of the primary lesion and assessment of metastatic spread to lymph nodes draining the tumor site, usually by Sentinel Lymph Node Biopsy (SLNB).<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> Regarding malignant melanoma treatments, chemotherapy is mostly ineffective. Monochemotherapy with dacarbazine currently represents the most efficient treatment but the obtained response rate remains low (less than 20%) and contributes little to overall patient survival.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> Despite a higher response rate of up to 40% obtained with combination of chemotherapeutics or with combination of chemotherapy and cytokines such as interferon or interleukin-2, no significant impact on survival has been made in the past 40 years.<a onclick="showRef(event, 'ref7 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref7 ref9 ref10 ref11">(7, 9-11)</a> Monoclonal antibodies anti-CTLA4 (ipilimumab) and mutated BRAF-V600E inhibitor (vemurafenib) are two new therapeutic strategies that have been tested with significant improvement of survival. However, these two treatments induced important side effects including autoimmune response (anti-CTLA4) and resistance after initial antitumor response (mutated BRAF-V600E inhibitor).<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a></div><div class="NLM_p">The patient’s best opportunity for a cure still remains early diagnosis of disease together with an accurate assessment of its metastases. Imaging modalities used for malignant melanoma staging are CT, ultrasound, MRI, and PET imaging.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Currently, clinical data on PET/CT are solely based on [<sup>18</sup>F]fluorodeoxyglucose ([<sup>18</sup>F]FDG) imaging, but its sensitivity is recognized to be limited for sentinel lymph node detection. In these cases SLNB, typically performed following intraoperative lymphatic mapping, is still the gold standard.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18">(15-18)</a> Combination of [<sup>18</sup>F]FDG PET imaging and SLNB for evaluation of metastasis can delay definitive management planning and increase the cost of the diagnosis process.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> [<sup>18</sup>F]FDG PET/CT also fails to highlight micrometastatic lesions that are less than 1 cm in diameter and those located mainly in lungs, liver, or brain.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Moreover, the use of this nonspecific radiotracer may be limited by the risk of false-positives due to abnormal inflammatory area uptake, for example. Thus, several scintigraphic studies have been developed over the past years, based on tracers related to specific characteristics of melanoma cells.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">Since α-MSH (α-melanocyte-stimulating hormone) receptor MC1R (melanocortin type 1 receptor) is overexpressed in most murine and human melanomas, it has been investigated as a target for selective imaging and therapeutic agents.<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21-23)</a> [<sup>18</sup>F]Labeled small synthetic peptide [<sup>18</sup>F]FB-NAPamide demonstrated that it could differentiate B16/F10 and A375M with high and low MC1R expression, respectively, but this tracer showed only moderate tumor uptake and retention.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Rhenium-cyclized α-MSH analogs have also been studied <i>in vivo</i> ([<sup>18</sup>F]FB-RMSH-1 and [<sup>18</sup>F]FP-RMSH-1) displaying specific, durable, and high uptake in MC1R-overexpressing melanoma models.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a></div><div class="NLM_p">Different studies demonstrated that melanin pigment, detected in more than 90% of primary melanoma cases, could be a potential target for development of imaging and therapy of melanoma.<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27-29)</a> Recently, [<sup>18</sup>F]<i>N</i>-[2-(diethylamino)ethyl]-6-fluoro-pyridine-3-carboxamide ([<sup>18</sup>F]ICF01006, see Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) exhibited excellent preclinical results as PET tracer for early detection of melanoma lesions in both primary and lung colonies melanoma murine models.<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30-32)</a> Moreover, direct comparison with [<sup>18</sup>F]FDG showed that [<sup>18</sup>F]ICF01006 was superior in terms of contrast and specificity.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> This class of arylcarboxamide compounds with high affinity for melanin-containing cells could also be labeled with high-energy radioisotopes (iodine-131, for example) in order to induce an antitumoral effect. In previous preclinical studies, a new iodinated quinoxaline-carboxamide derivative ([<sup>131</sup>I]ICF01012, [<sup>131</sup>I]<b>2</b>, see Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), demonstrated promising efficacy in a targeted radionuclide therapy (TRT) protocol using murine and human primary melanoma-bearing mice models, with a tumoral concentration primarily correlated to melanin content.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> Affinity studies of aromatic carboxamide compounds for synthetic melanin revealed the presence of two classes of binding sites, one ionic and the other hydrophobic.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Secondary ion mass spectrometry (SIMS) analyses also demonstrated a perfect colocalization of ICF01012 with melanosome, illustrating its melanin-specific binding.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/medium/jm-2013-00877v_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of <b>1</b> (ICF01006),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a><b>2</b> (ICF01012),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and <b>3</b>,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> three examples of arylcarboxamides with high affinity for melanin-containing cells, evaluated in clinical or preclinical studies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400877v&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">These highly favorable results led us to develop a new multimodal approach, designing iodinated and fluorinated analogs of our lead radiotracer <b>2</b>, suitable for both PET imaging (<sup>18</sup>F-radiolabeling) and TRT (<sup>131</sup>I-radiolabeling) of melanoma.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35, 36)</a> Radiofluorinated molecules were designed to select patients with pigmented melanoma lesions, who may be included in the radionuclide therapy protocol, and to monitor the treatment response.</div><div class="NLM_p">Such multimodal concept, with molecules having high affinity for melanin pigment, was first validated with the radiotracer <b>3</b> (see Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> However the radiolabeling of <b>3</b> with <sup>18</sup>F was not transposable to clinical studies due to a two-pot three-step procedure associated with very low radiochemical yields.</div><div class="NLM_p">With the aim of discovering an appropriate clinical candidate for PET imaging and TRT of melanoma, we designed and synthesized six iodinated and fluorinated analogs of the lead radiotracer <b>2</b>.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> All derivatives had in common a 6-iodoquinoxaline-2-carboxamide scaffold, and the side chain bearing the fluorine atom on the tertiary amine differed, leading to saturated ethyl (<b>4</b>) and propyl (<b>5</b>) compounds, alkene (<b>6</b>), alkyne (<b>7</b>), or pegylated structures (<b>8</b> and <b>9</b>) (see Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). After radiolabeling with <sup>125</sup>I, these radiotracers were evaluated <i>in vivo</i> in B16 melanoma-bearing mice by γ-scintigraphic imaging: tumoral uptakes were visualized as early as 1 h postinjection (pi) and up to 10 d pi, in association with high tumor-to-muscle ratios and a fast clearance of radioactivity from nontarget organs. The doses that could be delivered to melanoma tumors ranged from 58.9 to 164.8 cGy/injected MBq. These very favorable dosimetry parameters are suitable for efficient targeted radionuclide therapy of disseminated melanoma.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Based on these promising results, herein we present (i) the syntheses of precursors for <sup>18</sup>F-radiolabeling, (ii) fully automated radiosyntheses with <sup>18</sup>F, and (iii) PET imaging of each tracer with tumor uptake evaluation in B16Bl6 melanoma-bearing mice, compared with <i>ex vivo</i> biodistribution study.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/medium/jm-2013-00877v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of the six iodinated and fluorinated 6-iodoquinoxaline-2-carboxamide derivatives investigated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400877v&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68117" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68117" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">Radiofluorinations of compounds <b>5</b>–<b>9</b> required the syntheses of their corresponding mesylate precursors (Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). The first three steps of alkyne and alkene mesylate precursors syntheses (<b>22</b> and <b>25</b>, respectively) were common: commercially available 2-butyne-1,4-diol (<b>10</b>) was monoprotected using <i>tert</i>-butyldimethylsilyl chloride (TBDMSCl) according to a slightly modified protocol developed by Cai et al.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Iodination of the nonprotected alcohol function of <b>11</b>, in the presence of triphenylphosphine and imidazole, afforded derivative <b>12</b>. Subsequently, nucleophilic substitution using phthalimide <b>13</b><a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and potassium carbonate provided <b>14</b> in 41% yield over three steps. This key intermediate was next used in two different synthetic pathways. First, primary amine deprotection using hydrazine monohydrate immediately followed by peptidic coupling with activated ester <b>19</b><a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> provided silylated derivative <b>20</b>. After deprotection of the alcohol function with tetrabutylammonium fluoride (TBAF), the resulting intermediate <b>21</b> was converted into the mesylate precursor <b>22</b>, using methanesulfonyl chloride (MsCl), distilled triethylamine as organic base, and catalytic 4-(<i>N</i>,<i>N</i>-dimethylamino)pyridine (DMAP) (60 min at rt, 78% yield). Finally, compound <b>22</b> was obtained with 44% overall yield from key intermediate <b>14</b>. Second, the key alkyne <b>14</b> was chemo- and stereoselectively reduced to the corresponding (<i>E</i>)-alkene <b>17</b> in a two-step protocol adapted from Trost et al.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and Fürstner et al.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Briefly, compound <b>14</b> was hydrosilylated with triethoxysilane in the presence of ruthenium complex [Cp*Ru(MeCN)<sub>3</sub>]PF<sub>6</sub> (1.0 mol %) to afford the crude vinylsiloxane intermediate <b>16</b>. This hydrosilylation was followed by a protodesilylation under mild conditions with silver(I) fluoride to give selectively (<i>E</i>)-alkene <b>17</b> in excellent yield (92%). It should be noted that this two-step protocol applied on alkyne <b>21</b> did not afford the corresponding alkene <b>24</b>. Compound <b>17</b> was then subjected to similar protocols as intermediate <b>14</b>, that is, deprotection using hydrazine monohydrate immediately followed by peptidic coupling reaction with activated ester <b>19</b> to provide silylated derivative <b>23</b>. Finally, the deprotection of the alcohol function with TBAF was followed by the conversion of the resulting intermediate <b>24</b> into the corresponding mesylate <b>25</b>, using MsCl, distilled triethylamine, and DMAP (30 min at rt, 70% yield, see Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). Compound <b>25</b> was obtained with 60% overall yield from key intermediate <b>14</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/medium/jm-2013-00877v_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Alcohols <b>21</b> and <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400877v&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) imidazole, TBDMSCl, DMF, rt, 24 h; (ii) imidazole, PPh<sub>3</sub>, I<sub>2</sub>, DCM, 0 °C, 30 min, then rt, 1 h; (iii) K<sub>2</sub>CO<sub>3</sub>, MeCN, rt, 72 h; (iv) NH<sub>2</sub>NH<sub>2</sub>, H<sub>2</sub>O, EtOH, rt, 17 h; (v) THF, rt, 18 h; (vi) TBAF 1 M, THF, rt, 2 h; (vii) (EtO)<sub>3</sub>SiH, [Cp*Ru(MeCN)<sub>3</sub>]PF<sub>6</sub>, DCM, 0 °C, 10 min, then rt, 2 h; (viii) AgF 1 M in MeOH, THF, rt in darkness, 2.5 h.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/medium/jm-2013-00877v_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of Mesylate Precursors <b>22</b>, <b>25</b>, <b>28</b>, <b>29</b>, and <b>31</b> Required for Radiofluorination<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400877v&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) MsCl, NEt<sub>3</sub>, DMAP, DCM, rt, 30–120 min.</p></p></figure><div class="NLM_p">Using the same protocol (i.e., MsCl, distilled triethylamine, and DMAP), mesylate precursors <b>28</b>, <b>29</b>, and <b>31</b> (see Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>), bearing pegylated (<i>n</i> = 3 or <i>n</i> = 7) or propyl moiety were obtained in one step in a rapid way (60–120 min) with excellent yields (92–95%) from the previously synthesized alcohols <b>26</b>, <b>27</b>, and <b>30</b>,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> respectively.</div><div class="NLM_p last">It should be noted that due to their limited stability, mesylate precursors <b>22</b>, <b>25</b>, and <b>31</b> have to be freshly prepared and purified just before radiolabeling with <sup>18</sup>F.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Radiochemistry</h3><div class="NLM_p">Fully automated radiosyntheses of [<sup>18</sup>F]<b>4</b>–<b>9</b> were performed on a SynChrom R&D module (Raytest). For all radiosyntheses, [<sup>18</sup>F]F<sup>–</sup> (Cyclopharma Laboratories) was converted into the dry [<sup>18</sup>F]KF,K<sub>222</sub> complex. Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a> describes radiosyntheses of [<sup>18</sup>F]<b>4</b>–<b>9</b>, and Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> summarizes conditions and results of all radiochemistry processes.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/medium/jm-2013-00877v_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Radiosyntheses of [<sup>18</sup>F]<b>4</b>–<b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400877v&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) [<sup>18</sup>F]KF,K<sub>222</sub> complex, MeCN, 70 °C, 10 min, then 110 °C, 10 min; (ii) [<sup>18</sup>F]KF,K<sub>222</sub> complex, MeCN, 90 °C, 10 min.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. General Conditions for [<sup>18</sup>F]<b>4</b>–<b>9</b> Radiosyntheses</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">precursor quantity (mg)</th><th class="colsep0 rowsep0" align="center">time (min)/temp (°C)</th><th class="colsep0 rowsep0" align="center">vessel recovery<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (%)</th><th class="colsep0 rowsep0" align="center">HPLC system</th><th class="colsep0 rowsep0" align="center">formulation yield<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> (%)</th><th class="colsep0 rowsep0" align="center">radiochemical yield<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> (%)</th><th class="colsep0 rowsep0" align="center">total synthesis time (min)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">[<sup>18</sup>F]<b>4</b></td><td class="colsep0 rowsep0" align="center">6 + 12</td><td class="colsep0 rowsep0" align="center">10/70, 10/110</td><td class="colsep0 rowsep0" align="center">67</td><td class="colsep0 rowsep0" align="center">SiO<sub>2</sub>, DCM/EtOH 98:02</td><td class="colsep0 rowsep0" align="center">97</td><td class="colsep0 rowsep0" align="center">11</td><td class="colsep0 rowsep0" align="center">91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">[<sup>18</sup>F]<b>5</b></td><td class="colsep0 rowsep0" align="center">14</td><td class="colsep0 rowsep0" align="center">10/90</td><td class="colsep0 rowsep0" align="center">87</td><td class="colsep0 rowsep0" align="center">SiO<sub>2</sub>, DCM/EtOH 94:06 in 0.2% NH<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="center">91</td><td class="colsep0 rowsep0" align="center">54</td><td class="colsep0 rowsep0" align="center">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">[<sup>18</sup>F]<b>6</b></td><td class="colsep0 rowsep0" align="center">12</td><td class="colsep0 rowsep0" align="center">10/90</td><td class="colsep0 rowsep0" align="center">82</td><td class="colsep0 rowsep0" align="center">C18, MeOH/H<sub>2</sub>O 75:25 in 0.2% NH<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="center">83</td><td class="colsep0 rowsep0" align="center">16</td><td class="colsep0 rowsep0" align="center">62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">[<sup>18</sup>F]<b>7</b></td><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">10/90</td><td class="colsep0 rowsep0" align="center">91</td><td class="colsep0 rowsep0" align="center">C18, MeOH/H<sub>2</sub>O 75:25 in 0.2% NH<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="center">76</td><td class="colsep0 rowsep0" align="center">22</td><td class="colsep0 rowsep0" align="center">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">[<sup>18</sup>F]<b>8</b></td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="center">10/90</td><td class="colsep0 rowsep0" align="center">96</td><td class="colsep0 rowsep0" align="center">C18, MeOH/H<sub>2</sub>O 75:25 in 0.4% NH<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="center">90</td><td class="colsep0 rowsep0" align="center">21</td><td class="colsep0 rowsep0" align="center">57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">[<sup>18</sup>F]<b>9</b></td><td class="colsep0 rowsep0" align="center">15</td><td class="colsep0 rowsep0" align="center">10/90</td><td class="colsep0 rowsep0" align="center">85</td><td class="colsep0 rowsep0" align="center">SiO<sub>2</sub>, DCM/EtOH 92:08 in 0.2% NH<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="center">93</td><td class="colsep0 rowsep0" align="center">34</td><td class="colsep0 rowsep0" align="center">65</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Determined by measuring the radioactivity in the reactor before and after injection onto HPLC system.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Determined by dividing the final amount of radioactivity by the radioactivity measured after HPLC, non-decay-corrected.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Including formulation step, decay-corrected.</p></div></div></div><div class="NLM_p">For radiosynthesis of [<sup>18</sup>F]<b>4</b>, it was not possible to isolate its sulfonate precursor (data not shown) so a one-pot two-step procedure involving available stable precursors was chosen. The intermediate [<sup>18</sup>F]2-fluoroethyl tosylate <b>33</b> was obtained by nucleophilic substitution of 1,2-bis(tosyloxy)ethane <b>32</b> in MeCN.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44, 45)</a> Then, intermediate <b>33</b> immediately reacted with the secondary amine function of quinoxaline precursor <b>34</b>.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Best radiochemical yield was obtained with a two-step heating procedure (70 °C for 10 min, then 110 °C for 10 min). After a semipreparative HPLC purification, [<sup>18</sup>F]<b>4</b> was manually formulated for biological evaluations: first, the HPLC solvent was evaporated under reduced pressure; then the radiolabeled compound was taken up in a saline/EtOH (<5%) solution (formulation yield was 97%). Following this procedure, [<sup>18</sup>F]<b>4</b> was obtained with 11% overall radiochemical yield (RCY), a radiochemical purity (RCP) higher than 99% and a 91 min total preparation time.</div><div class="NLM_p">Regarding the radiosynthesis of [<sup>18</sup>F]<b>5</b>, the first assay was a similar one-pot two-step procedure starting from 1,3-bis(tosyloxy)propane and quinoxaline derivative <b>34</b>. Despite using various reaction conditions, a very low radiochemical yields was observed (<2%, data not shown). Thus an easier one-step procedure starting from mesylate precursor <b>31</b> was successfully carried out. The aliphatic nucleophilic substitution was successfully achieved by heating a solution of <b>31</b> in MeCN with anhydrous [<sup>18</sup>F]KF,K<sub>222</sub> complex at 90 °C for 10 min (54% overall RCY, RCP higher than 99%, and a total preparation of 70 min).</div><div class="NLM_p last">Compounds [<sup>18</sup>F]<b>6</b>, [<sup>18</sup>F]<b>7</b>, [<sup>18</sup>F]<b>8</b>, and [<sup>18</sup>F]<b>9</b> were successfully radiolabeled using the same strategy from their corresponding mesylate precursors, <b>25</b>, <b>22</b>, <b>28</b>, and <b>29</b>, respectively. Radiotracers [<sup>18</sup>F]<b>5</b> and [<sup>18</sup>F]<b>9</b> were manually formulated for biological evaluations (yields were 91% and 93%, respectively). For [<sup>18</sup>F]<b>6</b>–<b>8</b> radiotracers, the formulation was fully automated: after dilution in saline of the collected HPLC fraction, the radiolabeled compound was trapped on a C18 cartridge and eluted with EtOH then saline (<10% EtOH in the final solution). Formulation yields were 76–90%. Compounds [<sup>18</sup>F]<b>6</b>–<b>9</b> were obtained with 16–34% overall RCY, RCP higher than 99%, and a total preparation time ranging from 57 to 65 min.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Biological Studies</h3><div id="sec2_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> <i>In Vivo</i> PET Imaging</h4><div class="NLM_p">The preclinical evaluation of [<sup>18</sup>F]<b>4</b>–<b>9</b> in B16Bl6 primary melanoma-bearing mice by small animal static PET imaging was performed 1 h post-tracer -injection to compare these tracers. This time point was chosen following a preliminary PET imaging study at 30 min, 1 h, 2 h, and 3 h post-tracer-injection. Results showed that radiotracers were rapidly taken up in target tissues, with a maximal uptake at 1 h pi, which remained stable up to 3 h pi. By contrast, activity in nontarget tissues such as muscle displayed a fast washout as early as 1 h pi (unpublished results). Representative coronal images are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>. For each of the six compounds, tumors were clearly visualized as early as 1 h pi. For compounds [<sup>18</sup>F]<b>5</b>, [<sup>18</sup>F]<b>6</b>, [<sup>18</sup>F]<b>7</b>, [<sup>18</sup>F]<b>8</b>, and [<sup>18</sup>F]<b>9</b>, significant radioactive signal was also observed in eyes, corroborating the specific uptake in melanin-rich tissues. In contrast, no significant radioactive signal was observed in eyes for compound [<sup>18</sup>F]<b>4</b> meaning that tumoral uptake may not be due to specific accumulation. It should be noted that the experiments were performed on the strongly pigmented C57BL/6J mouse model with a high uveal melanin content. Because of murine and human differences in ocular geometry as well as in melanin content, radioactivity uptake in the eyes may not be an issue for clinical transfer.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/medium/jm-2013-00877v_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <i>In vivo</i> PET imaging biodistribution of radioactivity in B16Bl6 primary melanoma-bearing C57BL/6J mice 1 h after injection of [<sup>18</sup>F]<b>4</b> (A), [<sup>18</sup>F]<b>5</b> (B), [<sup>18</sup>F]<b>6</b> (C), [<sup>18</sup>F]<b>7</b> (D), [<sup>18</sup>F]<b>8</b> (E), and [<sup>18</sup>F]<b>9</b> (F) (8–12 MBq, iv). Coronal images represent maximum intensity projections. Tumors are indicated by arrows.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400877v&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For all radiotracers, radioactivity in nontarget tissues was mainly located in the abdominal region in accordance with the previously described clearance of this class of compounds via urinary and hepatobiliary systems.<a onclick="showRef(event, 'ref28 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref28 ref37 ref38">(28, 37, 38)</a> Furthermore, very low radioactivity was detected in nontarget organs, such as muscle, brain, heart, and lung, as early as 1 h pi.</div><div class="NLM_p">Highest tumoral uptakes and tumor-to-muscle ratios were obtained for compounds [<sup>18</sup>F]<b>5</b>, [<sup>18</sup>F]<b>6</b>, [<sup>18</sup>F]<b>8</b>, and [<sup>18</sup>F]<b>9</b>. Specific accumulation of radioactivity in B16Bl6 melanoma tumors was 10.56% ± 1.76% ID/g for [<sup>18</sup>F]<b>5</b>, 6.74% ± 0.73% ID/g for [<sup>18</sup>F]<b>6</b>, 14.33% ± 2.11% ID/g for [<sup>18</sup>F]<b>8</b>, and 6.63% ± 1.64% ID/g for [<sup>18</sup>F]<b>9</b>. These values are consistent with our previously published results (10.0% ± 2.8% ID/g for [<sup>125</sup>I]<b>5</b>, 10.8% ± 2.3% ID/g for [<sup>125</sup>I]<b>6</b>, 11.7% ± 2.2% ID/g for [<sup>125</sup>I]<b>8</b>, and 6.8% ± 1.8% ID/g for [<sup>125</sup>I]<b>9</b>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Tumor-to-muscle ratio was 11.86 ± 2.43 for [<sup>18</sup>F]<b>5</b>, 8.27 ± 2.05 for [<sup>18</sup>F]<b>6</b>, 11.04 ± 2.87 for [<sup>18</sup>F]<b>8</b>, and 6.62 ± 1.90 for [<sup>18</sup>F]<b>9</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. PET Images Quantitative Analysis of Tumors and Major Organs at 1 h pi of [<sup>18</sup>F]<b>4</b>–<b>9</b><a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">[<sup>18</sup>F]<b>4</b>, <i>n</i> = 5</th><th class="colsep0 rowsep0" align="center">[<sup>18</sup>F]<b>5</b>, <i>n</i> = 3</th><th class="colsep0 rowsep0" align="center">[<sup>18</sup>F]<b>6</b>, <i>n</i> = 2</th><th class="colsep0 rowsep0" align="center">[<sup>18</sup>F]<b>7</b>, <i>n</i> = 3</th><th class="colsep0 rowsep0" align="center">[<sup>18</sup>F]<b>8</b>, <i>n</i> = 8</th><th class="colsep0 rowsep0" align="center">[<sup>18</sup>F]<b>9</b><i>n</i> = 3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="center">% ID/g</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tumor</td><td class="colsep0 rowsep0" align="left">2.02 ± 1.06</td><td class="colsep0 rowsep0" align="left">10.56 ± 1.76</td><td class="colsep0 rowsep0" align="left">6.74 ± 0.73</td><td class="colsep0 rowsep0" align="left">4.16 ± 0.41</td><td class="colsep0 rowsep0" align="left">14.33 ± 2.11<a class="ref internalNav" href="#t2fn3" aria-label="d">d</a>,<a class="ref internalNav" href="#t2fn4" aria-label="e">e</a>,<a class="ref internalNav" href="#t2fn5" aria-label="f">f</a>,<a class="ref internalNav" href="#t2fn6" aria-label="g">g</a>,<a class="ref internalNav" href="#t2fn7" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">6.63 ± 1.64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">muscle</td><td class="colsep0 rowsep0" align="left">1.02 ± 0.26</td><td class="colsep0 rowsep0" align="left">0.90 ± 0.11</td><td class="colsep0 rowsep0" align="left">0.83 ± 0.12</td><td class="colsep0 rowsep0" align="left">0.82 ± 0.04</td><td class="colsep0 rowsep0" align="left">1.37 ± 0.37</td><td class="colsep0 rowsep0" align="left">1.01 ± 0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">eyes</td><td class="colsep0 rowsep0" align="left">1.40 ± 0.34</td><td class="colsep0 rowsep0" align="left">10.46 ± 1.08</td><td class="colsep0 rowsep0" align="left">9.49 ± 0.34</td><td class="colsep0 rowsep0" align="left">2.70 ± 0.36</td><td class="colsep0 rowsep0" align="left">10.50 ± 2.95<a class="ref internalNav" href="#t2fn3" aria-label="d">d</a>,<a class="ref internalNav" href="#t2fn6" aria-label="g">g</a>,<a class="ref internalNav" href="#t2fn7" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">5.53 ± 1.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bones</td><td class="colsep0 rowsep0" align="left">1.31 ± 0.01</td><td class="colsep0 rowsep0" align="left">7.05 ± 0.21<a class="ref internalNav" href="#t2fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">3.39 ± 0.31<a class="ref internalNav" href="#t2fn5" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">2.77 ± 0.47</td><td class="colsep0 rowsep0" align="left">1.98 ± 0.56</td><td class="colsep0 rowsep0" align="left">2.48 ± 0.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="center">Ratios</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TMR<a class="ref internalNav" href="#t2fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1.95 ± 0.69</td><td class="colsep0 rowsep0" align="left">11.86 ± 2.43</td><td class="colsep0 rowsep0" align="left">8.27 ± 2.05</td><td class="colsep0 rowsep0" align="left">5.07 ± 0.32</td><td class="colsep0 rowsep0" align="left">11.04 ± 2.87<a class="ref internalNav" href="#t2fn3" aria-label="d">d</a>,<a class="ref internalNav" href="#t2fn4" aria-label="e">e</a>,<a class="ref internalNav" href="#t2fn6" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">6.62 ± 1.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TBR<a class="ref internalNav" href="#t2fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1.31 ± 0.00</td><td class="colsep0 rowsep0" align="left">1.50 ± 0.22</td><td class="colsep0 rowsep0" align="left">1.99 ± 0.03</td><td class="colsep0 rowsep0" align="left">1.46 ± 0.07</td><td class="colsep0 rowsep0" align="left">7.65 ± 2.50<a class="ref internalNav" href="#t2fn3" aria-label="d">d</a>,<a class="ref internalNav" href="#t2fn4" aria-label="e">e</a>,<a class="ref internalNav" href="#t2fn5" aria-label="f">f</a>,<a class="ref internalNav" href="#t2fn6" aria-label="g">g</a>,<a class="ref internalNav" href="#t2fn7" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">2.67 ± 0.49</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>a</sup><p class="last">Dose of 8–12 MBq/mouse, <i>n</i> = 2–5. Data are expressed as percentage of injected dose per gram of tissue (% ID/g) ± SD. Means are compared using Student <i>t</i> test (<i>p</i> < 0.05 is considered statistically significant).</p></div><div class="footnote" id="t2fn1"><sup>b</sup><p class="last">Tumor-to-muscle ratio.</p></div><div class="footnote" id="t2fn2"><sup>c</sup><p class="last">Tumor-to-bone ratio.</p></div><div class="footnote" id="t2fn3"><sup>d</sup><p class="last">Significant difference in comparison of [<sup>18</sup>F]<b>8</b> and [<sup>18</sup>F]<b>4</b>.</p></div><div class="footnote" id="t2fn4"><sup>e</sup><p class="last">Significant difference in comparison of [<sup>18</sup>F]<b>8</b> and [<sup>18</sup>F]<b>5</b>.</p></div><div class="footnote" id="t2fn5"><sup>f</sup><p class="last">Significant difference in comparison of [<sup>18</sup>F]<b>8</b> and [<sup>18</sup>F]<b>6</b>.</p></div><div class="footnote" id="t2fn6"><sup>g</sup><p class="last">Significant difference in comparison of [<sup>18</sup>F]<b>8</b> and [<sup>18</sup>F]<b>7</b>.</p></div><div class="footnote" id="t2fn7"><sup>h</sup><p class="last">Significant difference in comparison of [<sup>18</sup>F]<b>8</b> and [<sup>18</sup>F]<b>9</b>.</p></div></div></div><div class="NLM_p">Defluorination and generation of free [<sup>18</sup>F]fluoride was negligible for [<sup>18</sup>F]<b>4</b>, [<sup>18</sup>F]<b>7</b>, [<sup>18</sup>F]<b>8</b> ,and [<sup>18</sup>F]<b>9</b> at 1 h pi as indicated by the low accumulation of radioactivity in the skeleton, whereas significant uptake in bones was observed in PET images performed with [<sup>18</sup>F]<b>5</b> and [<sup>18</sup>F]<b>6</b>.</div><div class="NLM_p last">Based on chemical stability of precursors, tracer accumulation in pigmented tissues and defluorination, compounds [<sup>18</sup>F]<b>8</b> and [<sup>18</sup>F]<b>9</b> seemed to be the most relevant and promising radiotracers for melanoma PET imaging. Compared with our previously described multimodal radiotracer [<sup>18</sup>F]<b>3</b>,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> a higher melanoma uptake was observed with [<sup>18</sup>F]<b>8</b> (12.72% ± 4.45% ID/g vs 8.30% ± 1.70% ID/g at 2 h pi; <i>p</i> = 0.038). Compared with [<sup>18</sup>F]<b>1</b>, which is currently one of the best melanin-targeting PET radiotracers, [<sup>18</sup>F]<b>8</b> demonstrated a similar tumoral uptake in the same experimental model (14.33% ± 2.11% ID/g vs 11.44% ± 2.67% ID/g for [<sup>18</sup>F]<b>1</b> at 1 h pi; <i>p</i> = 0.18) and a nearly 2-fold greater tumor-to-muscle ratio (11.04 ± 2.87 vs. 6.40 ± 1.73 for [<sup>18</sup>F]<b>1</b> at 1 h pi; <i>p</i> = 0.020).<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a></div></div><div id="sec2_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> <i>Ex Vivo</i> Biodistribution</h4><div class="NLM_p">Selected compounds [<sup>18</sup>F]<b>8</b> and [<sup>18</sup>F]<b>9</b> were studied by <i>ex vivo</i> biodistribution experiments by direct-sampling tumors and tissues of interest at 1, 2, and 3 h post-tracer-injection (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Uptake in pigmented tissues was similar to that obtained by PET imaging at 1 h pi and remained high and stable until 3 h pi for both molecules (i.e., tumoral uptake at 3 h pi was 11.55% ± 1.24% ID/g for [<sup>18</sup>F]<b>8</b> and 6.76% ± 1.35% ID/g for [<sup>18</sup>F]<b>9</b>). Furthermore, a significantly higher tumoral uptake was observed for [<sup>18</sup>F]<b>8</b> compared with [<sup>18</sup>F]<b>9</b> at all time points (<i>p</i> = 0.035, <i>p</i> = 0.0016, and <i>p</i> = 0.0001 at 1, 2, and 3 h pi, respectively). Very low tracer accumulation in muscle and blood led to higher tumor-to-muscle and tumor-to-blood ratios reaching values of 14.46 ± 3.06 (<i>p</i> = 0.0007) and 14.43 ± 1.75 (<i>p</i> = 0.0005), respectively, for [<sup>18</sup>F]<b>8</b> and values of 6.64 ± 2.69 and 5.27 ± 0.20, respectively, for [<sup>18</sup>F]<b>9</b> at 3 h pi. Low bone accumulation was observed at 1 h pi (1.40% ± 0.10% ID/g for [<sup>18</sup>F]<b>8</b> and 1.82% ± 0.55% ID/g for [<sup>18</sup>F]<b>9</b>). Partial <i>in vivo</i> defluorination of [<sup>18</sup>F]<b>8</b> and [<sup>18</sup>F]<b>9</b> occurred at 3 h pi, which was not correlated with <i>in vitro</i> stability in saline (RCP > 99% for at least 6 h). Regarding radiotracer elimination, [<sup>18</sup>F]<b>9</b> demonstrated a significantly higher accumulation in intestine compared with [<sup>18</sup>F]<b>8</b> (<i>p</i> = 0.018, <i>p</i> = 0.0000001, and <i>p</i> = 0.02 at 1, 2, and 3 h pi, respectively), suggesting that despite a higher hydrophilicity of [<sup>18</sup>F]<b>9</b> (log <i>D</i> = 0.95 ± 0.02 vs 1.52 ± 0.03 for [<sup>18</sup>F]<b>8</b>), renal excretion of this tracer was not favored. Hence, the [<sup>18</sup>F]<b>8</b> derivative, bearing a tri(ethylene glycol) side chain, appeared more attractive than compound [<sup>18</sup>F]<b>9</b> bearing an hepta(ethylene glycol) side chain.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. <i>Ex Vivo</i> Biodistribution of [<sup>18</sup>F]<b>8</b> and [<sup>18</sup>F]<b>9</b> in B16Bl6 Primary Melanoma-Bearing C57BL/6J Mice at 1, 2, and 3 h pi<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">[<sup>18</sup>F]<b>8</b></th><th class="rowsep1 colsep0" colspan="3" align="center">[<sup>18</sup>F]<b>9</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">1 h (<i>n</i> = 5)</th><th class="colsep0 rowsep0" align="center">2 h (<i>n</i> = 6)</th><th class="colsep0 rowsep0" align="center">3 h (<i>n</i> = 5)</th><th class="colsep0 rowsep0" align="center">1 h (<i>n</i> = 6)</th><th class="colsep0 rowsep0" align="center">2 h (<i>n</i> = 5)</th><th class="colsep0 rowsep0" align="center">3 h (<i>n</i> = 6)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="center">% ID/g</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tumor</td><td class="colsep0 rowsep0" align="left">14.05 ± 1.42<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">13.07 ± 1.22<a class="ref internalNav" href="#t3fn5" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">11.55 ± 1.24<a class="ref internalNav" href="#t3fn6" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">9.81 ± 2.96</td><td class="colsep0 rowsep0" align="left">5.81 ± 1.37</td><td class="colsep0 rowsep0" align="left">6.76 ± 1.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">muscle</td><td class="colsep0 rowsep0" align="left">1.17 ± 0.12</td><td class="colsep0 rowsep0" align="left">0.92 ± 0.15</td><td class="colsep0 rowsep0" align="left">0.81 ± 0.10<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">1.07 ± 0.35</td><td class="colsep0 rowsep0" align="left">1.04 ± 0.24</td><td class="colsep0 rowsep0" align="left">1.11 ± 0.34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">eyes</td><td class="colsep0 rowsep0" align="left">18.36 ± 4.74</td><td class="colsep0 rowsep0" align="left">18.17 ± 3.15</td><td class="colsep0 rowsep0" align="left">17.96 ± 2.73</td><td class="colsep0 rowsep0" align="left">12.24 ± 4.39</td><td class="colsep0 rowsep0" align="left">12.10 ± 1.85</td><td class="colsep0 rowsep0" align="left">13.43 ± 2.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bones</td><td class="colsep0 rowsep0" align="left">1.40 ± 0.10</td><td class="colsep0 rowsep0" align="left">1.96 ± 0.51</td><td class="colsep0 rowsep0" align="left">3.27 ± 0.70</td><td class="colsep0 rowsep0" align="left">1.82 ± 0.55</td><td class="colsep0 rowsep0" align="left">2.13 ± 0.19<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">3.61 ± 1.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">blood</td><td class="colsep0 rowsep0" align="left">1.42 ± 0.32</td><td class="colsep0 rowsep0" align="left">1.12 ± 0.24</td><td class="colsep0 rowsep0" align="left">0.80 ± 0.07</td><td class="colsep0 rowsep0" align="left">1.15 ± 0.19</td><td class="colsep0 rowsep0" align="left">1.37 ± 0.30</td><td class="colsep0 rowsep0" align="left">0.99 ± 0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">skin</td><td class="colsep0 rowsep0" align="left">1.44 ± 0.19</td><td class="colsep0 rowsep0" align="left">1.51 ± 0.53</td><td class="colsep0 rowsep0" align="left">1.05 ± 0.12</td><td class="colsep0 rowsep0" align="left">1.22 ± 0.22</td><td class="colsep0 rowsep0" align="left">0.94 ± 0.51</td><td class="colsep0 rowsep0" align="left">1.47 ± 0.49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="left">2.56 ± 0.22</td><td class="colsep0 rowsep0" align="left">1.88 ± 0.34</td><td class="colsep0 rowsep0" align="left">1.99 ± 0.45</td><td class="colsep0 rowsep0" align="left">2.02 ± 0.19</td><td class="colsep0 rowsep0" align="left">2.31 ± 0.64</td><td class="colsep0 rowsep0" align="left">2.60 ± 1.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">stomach</td><td class="colsep0 rowsep0" align="left">4.41 ± 1.36</td><td class="colsep0 rowsep0" align="left">2.48 ± 0.88</td><td class="colsep0 rowsep0" align="left">2.81 ± 2.23</td><td class="colsep0 rowsep0" align="left">5.87 ± 3.32</td><td class="colsep0 rowsep0" align="left">7.35 ± 4.79<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">5.39 ± 3.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">small intestine</td><td class="colsep0 rowsep0" align="left">7.58 ± 1.80</td><td class="colsep0 rowsep0" align="left">4.28 ± 1.18</td><td class="colsep0 rowsep0" align="left">3.91 ± 1.05</td><td class="colsep0 rowsep0" align="left">16.68 ± 7.93<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">19.51 ± 5.43<a class="ref internalNav" href="#t3fn6" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">18.62 ± 13.65<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cecum</td><td class="colsep0 rowsep0" align="left">7.27 ± 0.62</td><td class="colsep0 rowsep0" align="left">8.94 ± 1.78</td><td class="colsep0 rowsep0" align="left">10.79 ± 1.54</td><td class="colsep0 rowsep0" align="left">6.37 ± 4.84</td><td class="colsep0 rowsep0" align="left">12.10 ± 10.31</td><td class="colsep0 rowsep0" align="left">29.31 ± 17.94<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">colon+feces</td><td class="colsep0 rowsep0" align="left">7.17 ± 2.93</td><td class="colsep0 rowsep0" align="left">6.05 ± 1.72</td><td class="colsep0 rowsep0" align="left">8.09 ± 5.04</td><td class="colsep0 rowsep0" align="left">7.39 ± 1.36</td><td class="colsep0 rowsep0" align="left">8.14 ± 1.78<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">12.63 ± 7.83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kidney</td><td class="colsep0 rowsep0" align="left">3.46 ± 0.53</td><td class="colsep0 rowsep0" align="left">2.18 ± 0.43</td><td class="colsep0 rowsep0" align="left">2.19 ± 0.36</td><td class="colsep0 rowsep0" align="left">3.60 ± 1.74</td><td class="colsep0 rowsep0" align="left">3.52 ± 1.02</td><td class="colsep0 rowsep0" align="left">2.60 ± 1.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">spleen</td><td class="colsep0 rowsep0" align="left">3.72 ± 1.49<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">2.88 ± 2.11</td><td class="colsep0 rowsep0" align="left">1.87 ± 0.38</td><td class="colsep0 rowsep0" align="left">2.35 ± 0.91</td><td class="colsep0 rowsep0" align="left">2.38 ± 0.87</td><td class="colsep0 rowsep0" align="left">2.35 ± 0.98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pancreas</td><td class="colsep0 rowsep0" align="left">2.09 ± 0.42</td><td class="colsep0 rowsep0" align="left">1.33 ± 0.28</td><td class="colsep0 rowsep0" align="left">1.33 ± 0.35</td><td class="colsep0 rowsep0" align="left">2.63 ± 1.33</td><td class="colsep0 rowsep0" align="left">1.56 ± 0.38</td><td class="colsep0 rowsep0" align="left">1.81 ± 0.66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">1.86 ± 0.15</td><td class="colsep0 rowsep0" align="left">1.65 ± 0.11</td><td class="colsep0 rowsep0" align="left">1.60 ± 0.09</td><td class="colsep0 rowsep0" align="left">1.75 ± 0.18</td><td class="colsep0 rowsep0" align="left">1.72 ± 0.72</td><td class="colsep0 rowsep0" align="left">2.37 ± 0.67<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">heart</td><td class="colsep0 rowsep0" align="left">2.72 ± 0.18</td><td class="colsep0 rowsep0" align="left">2.14 ± 0.33</td><td class="colsep0 rowsep0" align="left">2.32 ± 0.50</td><td class="colsep0 rowsep0" align="left">1.58 ± 0.24</td><td class="colsep0 rowsep0" align="left">1.70 ± 0.24</td><td class="colsep0 rowsep0" align="left">3.00 ± 1.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">brain</td><td class="colsep0 rowsep0" align="left">1.82 ± 0.08<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">1.39 ± 0.25</td><td class="colsep0 rowsep0" align="left">1.37 ± 0.35</td><td class="colsep0 rowsep0" align="left">1.03 ± 0.18</td><td class="colsep0 rowsep0" align="left">1.03 ± 0.10</td><td class="colsep0 rowsep0" align="left">1.72 ± 0.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="center">Ratio</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TMR<a class="ref internalNav" href="#t3fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">12.12 ± 2.29<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">14.46 ± 2.62<a class="ref internalNav" href="#t3fn6" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">14.46 ± 3.06<a class="ref internalNav" href="#t3fn6" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">9.48 ± 2.41</td><td class="colsep0 rowsep0" align="left">5.75 ± 1.45</td><td class="colsep0 rowsep0" align="left">6.64 ± 2.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TBR<a class="ref internalNav" href="#t3fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">10.24 ± 2.83</td><td class="colsep0 rowsep0" align="left">12.19 ± 3.32<a class="ref internalNav" href="#t3fn5" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">14.43 ± 1.75<a class="ref internalNav" href="#t3fn6" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">8.29 ± 2.87</td><td class="colsep0 rowsep0" align="left">4.01 ± 1.12</td><td class="colsep0 rowsep0" align="left">5.27 ± 0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TBoR<a class="ref internalNav" href="#t3fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">10.11 ± 1.87<a class="ref internalNav" href="#t3fn6" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">7.13 ± 2.21<a class="ref internalNav" href="#t3fn6" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">3.70 ± 1.17<a class="ref internalNav" href="#t3fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">5.35 ± 0.82</td><td class="colsep0 rowsep0" align="left">2.75 ± 0.80</td><td class="colsep0 rowsep0" align="left">2.16 ± 1.15</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>a</sup><p class="last">Data are expressed as percentage of injected dose per gram of tissue (% ID/g) ± SD (<i>n</i> = 5–6).</p></div><div class="footnote" id="t3fn1"><sup>b</sup><p class="last">Tumor-to-muscle ratio.</p></div><div class="footnote" id="t3fn2"><sup>c</sup><p class="last">Tumor-to-blood ratio.</p></div><div class="footnote" id="t3fn3"><sup>d</sup><p class="last">Tumor-to-bone ratio.</p></div><div class="footnote" id="t3fn4"><sup>e</sup><p class="last"><i>p</i> < 0.05 as determined by Student <i>t</i> test.</p></div><div class="footnote" id="t3fn5"><sup>f</sup><p class="last"><i>p</i> < 0.01 as determined by Student <i>t</i> test.</p></div><div class="footnote" id="t3fn6"><sup>g</sup><p class="last"><i>p</i> < 0.001 as determined by Student <i>t</i> test.</p></div></div></div></div><div id="sec2_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> [<sup>18</sup>F]<b>8</b> Stability Study</h4><div class="NLM_p">In tumor and eyes (melanin-containing tissues), more than 99% of the radioactive signal corresponded to unchanged [<sup>18</sup>F]<b>8</b> at 1 and 2 h pi (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). In contrast, a fast breakdown of [<sup>18</sup>F]<b>8</b> was observed in blood (15% of unchanged [<sup>18</sup>F]<b>8</b> at 30 min) and liver (8% of unchanged [<sup>18</sup>F]<b>8</b> at 1 h). In urine samples, less than 1% of unchanged radiotracer was detected. These results demonstrated that once linked to melanin in pigmented tissues, [<sup>18</sup>F]<b>8</b> remained unchanged, whereas important and fast metabolic processes occurred in nonspecific tissues.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>In Vivo</i> Stability Study of [<sup>18</sup>F]<b>8</b> in B16Bl6 Primary Melanoma-Bearing C57BL/6J Mice<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="​" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="​">unchanged [<sup>18</sup>F]<b>8</b> (%)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="​">1 h</th><th class="colsep0 rowsep0" align="center" char=".">2 h</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">blood</td><td class="colsep0 rowsep0" align="char" char="​">15<a class="ref internalNav" href="#t4fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#t4fn2" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tumor</td><td class="colsep0 rowsep0" align="char" char="​">>99</td><td class="colsep0 rowsep0" align="char" char=".">>99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">eyes</td><td class="colsep0 rowsep0" align="char" char="​">>99</td><td class="colsep0 rowsep0" align="char" char=".">>99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char="​">8</td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#t4fn2" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">urines</td><td class="colsep0 rowsep0" align="char" char="​">0.1</td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#t4fn2" aria-label="c">c</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup>a</sup><p class="last">Results are expressed as percentage of unchanged [<sup>18</sup>F]<b>8</b> relative to total radioactivity signal.</p></div><div class="footnote" id="t4fn1"><sup>b</sup><p class="last">At 30 min.</p></div><div class="footnote" id="t4fn2"><sup>c</sup><p class="last">Not detectable.</p></div></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56268" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56268" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In summary, six [<sup>18</sup>F]fluorinated 6-iodoquinoxaline-2-carboxamide derivatives with various side chains were synthesized and evaluated. [<sup>18</sup>F]<b>4</b>–<b>9</b> were radiosynthesized on an automated module with good yields and high radiochemical purities, and they displayed excellent chemical stability in physiological serum.</div><div class="NLM_p">Biodistribution studies by <i>in vivo</i> PET imaging in B16Bl6 primary melanoma-bearing mice demonstrated that four compounds out of six exhibited a high tropism for pigmented melanoma and also high tumor-to-background ratios as early as 1 h pi. Regarding PET imaging results and <i>in vivo</i> stability, the two best candidates [<sup>18</sup>F]<b>8</b> and [<sup>18</sup>F]<b>9</b> were then investigated in an <i>ex vivo</i> biodistribution study in B16Bl6-bearing mice. This study confirmed that derivative [<sup>18</sup>F]<b>8</b> had the highest tumoral uptake in this model and exhibited excellent pharmacokinetic features. It displayed lower uptake and faster clearance of radioactivity from nontarget organs, with hepatobiliary/renal excretion pathways, resulting in higher tumor-to-blood and tumor-to-muscle ratios than those for [<sup>18</sup>F]<b>9</b>.</div><div class="NLM_p">Thus, [<sup>18</sup>F]<b>8</b> exhibited high tumoral uptake and favorable kinetics leading to highly contrasted images as early as 1 h pi. This work demonstrated that in terms of chemistry, radiochemistry, and <i>in vivo</i> biodistribution, radiotracer [<sup>18</sup>F]<b>8</b> appears suitable for PET imaging.</div><div class="NLM_p">In addition, as previously reported, [<sup>125</sup>I]<b>8</b> showed high tumoral uptakes up to 5 days pi in the same melanoma-bearing mouse model (12.4% ± 2.3% ID/g, 8.6% ± 3.6% ID/g, 5.8% ± 2.4% ID/g at 24 h, 72 h, and 5 d pi, respectively), and a high calculated tumoral dosimetry (103.5 cGy/MBq for [<sup>131</sup>I]<b>8</b>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> These results make this compound a promising agent for targeted radionuclide therapy of melanoma (assay in progress).</div><div class="NLM_p last">In conclusion, in our multimodality approach, radiotracer <b>8</b> appears as a good candidate for both imaging (PET/fluorine-18) and treatment (TRT/iodine-131) of melanoma.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25182" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25182" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Materials and General Methods</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Chemistry</h4><div class="NLM_p last">All reagents and solvents were purchased from the following commercial suppliers: Sigma-Aldrich, Acros Organics, ThermoFischer, Alfa Aesar, TCI Europe, Carlo Erba, SDS. All solvents were dried using common techniques.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Unless otherwise noted, moisture-sensitive reactions were conducted under dry argon atmosphere. Thin layer chromatography (TLC) was performed on silica gel 60 F<sub>254</sub> plates or neutral aluminum oxide 60 F<sub>254</sub> plates (Merck or SDS) and visualized with UV light or developed with iodine, ninhydrin, or potassium permanganate. Flash chromatography was performed on silica gel 60A normal phase, 35–70 μm (SDS). Florisil was purchased at Sigma Aldrich (Fluka). Uncorrected melting points (mp) were recorded on Reichert–Jung–Koffler apparatus. NMR spectra (200 MHz for <sup>1</sup>H and 50 MHz for <sup>13</sup>C) were recorded on a Bruker Avance 200 instrument; <sup>19</sup>F NMR spectra (470 MHz) were recorded on a Bruker DRX 500 apparatus using tetrafluorotoluene as internal reference (δ −63.7 ppm); δ were expressed in ppm. Infrared spectra (IR) were recorded on a FTIR Nicolet Impact 410, a FT Vector 22, or a Nicolet IS10 with attenuated total reflectance (ATR) accessory. Electron impact mode mass spectra (EI-MS) were obtained on a HP5890 series II chromatograph coupled to HP5985B mass spectrometer. The analysis of samples was performed in MeCN at a final concentration of 1 pmol·μL<sup>–1</sup>. Electrospray ionization mass spectra (ESI-MS) were recorded on a Esquire-LC (Bruker Daltonics, Wissenbourg, France) spectrometer. The analysis of samples was performed in MeCN at a final concentration of 1 pmol·μL<sup>–1</sup>. Microanalyses were performed by Analytical Laboratory of the CNRS (Vernaison, France) for the elements indicated.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Radiochemistry</h4><div class="NLM_p last">No-carrier-added fluorine-18 (half-life 109.8 min) was produced via the [<sup>18</sup>O(p, n)<sup>18</sup>F] nuclear reaction by irradiation of a 2.8 mL of [<sup>18</sup>O]water target (>97%-enriched, Bruce Technology, Chapel Hill, USA) on a CPH14 cyclotron (14 MeV proton beam, Cyclopharma Laboratories, Saint-Beauzire, France). Typical production of [<sup>18</sup>F]fluoride at the end of bombardment for a 90–100 μA·h (120 min) irradiation was 185 GBq (5 Ci). Radiochemistry syntheses and semipreparative HPLC were performed using a monoreactor Synchrom R&D synthesis module (Raytest, Straubenhardt, Germany). Semipreparative HPLC was conducted on a Waters Symmetry Semi-Prep C18 column (300 mm × 7.8 mm; porosity 7 μm) or Waters Spherisorb Semi-Prep SiO<sub>2</sub> column (250 mm × 10 mm; porosity 10 μm) at flow rate 3.0 mL·min<sup>–1</sup>, rt, and absorbance detection at λ = 254 nm. Radio-TLCs were run on Merck precoated neutral aluminum oxide 60 F<sub>254</sub> plates with a mixture of DCM and EtOH as solvents (98:2, v/v). Detection of K<sub>222</sub> was achieved using the standard chloroplatinate color test.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Radioactivity measurements were performed on a γ counter equipped with a NaI(Tl) well type scintillation counter (model 1480 Wizard, Perkin-Elmer Life Sciences, Boston, MA, USA). Analytical HPLC was performed on a PerkinElmer series 200 equipped with a multiwavelength UV diode array detector (DAD) and a GABI Star γ-detector (Raytest, Straubenhardt, Germany) at a flow rate of 0.9 or 1.0 mL·min<sup>–1</sup> with a Waters Symmetry C18 (150 mm × 4.6 mm; porosity 5 μm) or Waters Spherisorb SiO<sub>2</sub> (150 mm × 4.6 mm; porosity 5 μm) column at rt with absorbance detection at λ = 254 nm. Purity and specific activity were determined by analytical HPLC. For each tested compound, purity was >99%. The identity of each [<sup>18</sup>F]fluorinated compound was confirmed by coelution with its nonradioactive counterpart. A delay time of 0.35 min was observed between the first detector (UV) and the second (γ).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Octanol–Water Distribution Coefficient (log <i>D</i>)</h4><div class="NLM_p last">Approximately 74 kBq of radiotracer was added to a mixture of PBS (pH 7.4, 1.0 mL) and octanol (1.0 mL) in an Eppendorf microcentrifuge tube. The mixture was vigorously vortexed for 1 min, three times at rt. After centrifugation (3000 rpm, 5 min), aliquots (100 μL) of both layers were sampled and the radioactivity was measured using the γ counter. Three independent experiments were performed in duplicate.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Cell Culture</h4><div class="NLM_p last">The B16Bl6 syngenic melanoma cells were obtained from Dr. Fidler’s Laboratory (Texas University, Houston, USA). Cell cultures were maintained as monolayers in Dulbecco’s modified Eagle’s medium (DMEM)/Glutamax (Invitrogen, Cergy Pontoise, France) supplemented with 10% calf serum (Sigma, Saint Quentin, Fallavier, France), 1% vitamins (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 1% nonessential amino acids (Invitrogen), and 4 μg·mL<sup>–1</sup> of gentamycin base (Invitrogen). The cells were grown at 37 °C in a humidified incubator containing 5% CO<sub>2</sub>.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Primary Murine Melanoma Model</h4><div class="NLM_p last">Animals were handled and cared for in accordance with the guidelines for the Care and Use of Laboratory Animals (National Research Council, 1996) and European Directive 86/609/EEC. Protocols were performed under the authorization of the French Direction des Services Vétérinaires (authorization no. CE 86-12) and conducted under the supervision of authorized investigators in accordance with the institution’s recommendations for the use of laboratory animals. C57BL/6J male mice (6–8 weeks old) were obtained from Charles River (l′Arbresle, France). Cells in exponential growth phase were trypsinized, washed with phosphate buffer saline (PBS), and resuspended in PBS. Mice anesthetized by isoflurane (2%) inhalation were inoculated with 3 × 10<sup>5</sup> melanoma B16Bl6 cells in PBS (0.1 mL) by subcutaneous injection on the right shoulder.</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>In Vivo</i> PET Imaging</h4><div class="NLM_p">PET imaging sessions were performed at day-10 or day-14 after inoculation (tumoral volume range of 431.8 ± 154.3 mm<sup>3</sup>). Whole-body PET scans were acquired 1 h after intravenous injection of [<sup>18</sup>F]labeled compound (9–12 MBq/0.15 mL) via the tail vein (range 2–8 animals/compound), and mice were anesthetized by intraperitoneal administration (200 μL/20 g-mouse) of a mixture of ketamine (Imalgene 500, Rhône Mérieux, Lyon, France) and xylazine (Rompun, Bayer, France) in saline, 4:1 ratio. Whole-body acquisition (25 min duration) was performed using a small-animal PET device (eXplore Vista, GE Healthcare) with a 250–700 keV energy window set and 6 ns coincidence-timing window. The spatial resolution of this system was 1.4 mm full width at half maximum at the center of the field of view.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Images were reconstructed using a 2D ordered-subset expectation maximization (Fore/2D OSEM) method including corrections for scanner dead time, scatter radiations, and randoms. No corrections were applied for partial volume or attenuation.</div><div class="NLM_p last">Regional radiotracer uptake was quantified by standard region-of-interest (ROI) analysis with eXplore Vista software package (GE Healthcare) as previously described.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Briefly, on decay-corrected whole-body coronal images, a manual 2D-ROI was drawn around the whole tumor and different organs. The reference tissue ROI was drawn on caudal thigh muscle and considered as background. The mean counts per pixel per minute were obtained from the ROI and converted to counts per milliliter per min using a calibration constant. By assuming a tissue density of 1 g·mL<sup>–1</sup>, the ROIs were converted to counts/(g·min). An ROI-derived % ID/g of tissue was then determined by dividing counts per gram per minute by injected dose. <i>In vivo</i> tumor-to-background ratio was calculated by dividing the % ID/g value of tumor by the % ID/g value of muscle.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>Ex Vivo</i> Biodistribution Studies</h4><div class="NLM_p last"><i>Ex vivo</i> biodistribution study was performed for [<sup>18</sup>F]<b>8</b> and [<sup>18</sup>F]<b>9</b>. Experiments were undertaken at day-10 or day-14 after cell implantation (<i>n</i> = 3–6 animals/group). Animals were sacrificed by CO<sub>2</sub> asphyxiation 1, 2, and 3 h after iv injection of [<sup>18</sup>F]labeled compound (9–12 MBq). Tumors, major organs, and tissues were promptly excised, harvested, and weighed, and their radioactivity was counted. After radioactive decay correction, results were expressed as % ID/g.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> [<sup>18</sup>F]<b>8</b> Stability Study</h4><div class="NLM_p last">Six primary melanoma-bearing mice were injected with [<sup>18</sup>F]<b>8</b> (18 MBq, iv) and sacrificed 30 min, 1 h, and 2 h pi. To determine the metabolic stability of [<sup>18</sup>F]<b>8</b>, blood, liver, urine, eyes, and tumor samples were collected. Blood was immediately centrifuged for 5 min at 3000 rpm, and plasma was directly investigated by analytical HPLC. Urine sample was collected in the bladder and directly investigated by analytical HPLC. Tumors, eyes, and livers were pooled, suspended in MeOH/NH<sub>4</sub>OH 99.8:0.2 (5 mL), homogenized using GentleMACS dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany), and centrifuged for 5 min at 3000 rpm. The extraction efficiency was determined by measuring the radioactivity of supernatants and precipitates (extraction yields 61%, 55%, and 99%, respectively). Supernatants were passed through a 0.22 μm Millipore filter and then concentrated to a volume between 200 and 500 μL before injection (duplicate) onto the analytical HPLC (C18 column; MeOH/H<sub>2</sub>O/NH<sub>4</sub>OH 0:99.8:0.2 to 29.9:69.9:0.2 v/v/v linear gradient in 8 min then 29.9:69.9:0.2 to 59.9:39.9:0.2 linear gradient in 1 min then 59.9:39.9:0.2 to 89.9:9.9:0.2 linear gradient in 8 min then 0:99.8:0.2 isocratic during 8 min; 0.9 mL·min<sup>–1</sup>).</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Statistical Analysis</h4><div class="NLM_p last">Quantitative data are expressed as mean ± standard deviation (SD). Means were compared using Student <i>t</i> test. Values were considered statistically significant for <i>p</i> < 0.05.</div></div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Chemistry</h3><div id="sec4_2_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-[2-[<i>N</i>-Ethyl-<i>N</i>-(2-fluoroethyl)amino]ethyl]-6-iodoquinoxaline-2-carboxamide, <b>4</b></h4><div class="NLM_p last">Fluorine-19 standard compound <b>4</b> was prepared as described by Maisonial and Billaud et al.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a><i>R</i><sub><i>f</i></sub> (Al<sub>2</sub>O<sub>3</sub>, DCM/EtOH, 98:2, v/v) 0.72; IR (CCl<sub>4</sub>) ν 1474, 1522, 1685, 2855, 2927 cm<sup>–1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.12 (t, 3H, <i>J</i> = 7.1 Hz), 2.75 (q, 2H, <i>J</i> = 7.1 Hz), 2.87 (t, 1H, <i>J</i> = 6.0 Hz), 2.92 (dt, 2H, <sup>3</sup><i>J</i><sub>H–F</sub> = 26.8 Hz, <i>J</i> = 5.0 Hz), 3.62 (q, 2H, <i>J</i> = 6.0 Hz), 4.58 (dt, 2H, <sup>2</sup><i>J</i><sub>H–F</sub> = 47.7 Hz, <i>J</i> = 5.0 Hz), 7.81 (d, 1H, <i>J</i> = 8.8 Hz), 8.05 (dd, 1H, <i>J</i> = 8.8, 1.8 Hz), 8.45 (br, 1H), 8.58 (d, 1H, <i>J</i> = 1.8 Hz), 9.62 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 11.8, 37.3, 48.5, 52.9, 53.6 (d, <sup>2</sup><i>J</i><sub>C–F</sub> = 20 Hz), 82.5 (d, <sup>1</sup><i>J</i><sub>C–F</sub> = 167 Hz), 98.0, 130.9, 138.6, 139.6, 139.7, 144.0, 144.4, 144.6, 163.1; <sup>19</sup>F NMR (CDCl<sub>3</sub>) δ −220.22; MS <i>m</i>/<i>z</i> 416 (M<sup>+</sup>, 1), 104 (100), 76 (12), 56 (8).</div></div><div id="sec4_2_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-[2-[<i>N</i>-Ethyl-<i>N</i>-(3-fluoropropyl)amino]ethyl]-6-iodoquinoxaline-2-carboxamide, <b>5</b></h4><div class="NLM_p last">Fluorine-19 standard compound <b>5</b> was prepared as described by Maisonial and Billaud et al.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a><i>R</i><sub><i>f</i></sub> (SiO<sub>2</sub>, ethyl acetate) 0.36; <sup>1</sup>H NMR (CD<sub>3</sub>CN) δ 1.05 (t, 3H, <i>J</i> = 7.1 Hz), 1.82 (m, 2H), 2.64 (m, 6H), 3.52 (q, 2H, <i>J</i> = 5.9 Hz), 4.56 (dt, 2H, <sup>2</sup><i>J</i><sub><i>H–F</i></sub> = 47.4 Hz, <i>J</i> = 6.0 Hz),, 7.87 (d, 1H, <i>J</i> = 8.8 Hz), 8.08 (dd, 1H, <i>J</i> = 8.8, 1.9 Hz), 8.41 (br, 1H), 8.60 (d, 1H, <i>J</i> = 1.9 Hz), 9.63 (s, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>CN) δ 11.5, 28.1 (d, <sup>4</sup><i>J</i><sub>C–F</sub> = 1 Hz), 37.3, 47.7, 52.3, 52.9 (d, <sup>3</sup><i>J</i><sub>C–F</sub> = 11 Hz), 82.7 (d, <sup>1</sup><i>J</i><sub>C–F</sub> = 166 Hz), 98.2, 131.0, 138.6, 139.5, 139.8, 143.8, 144.4, 144.6, 162.2; <sup>19</sup>F NMR (CD<sub>3</sub>CN) δ −220.47; ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 431.10.</div></div><div id="sec4_2_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-[2-[<i>N</i>-Ethyl-<i>N</i>-[(<i>E</i>)-4-fluorobut-2-enyl]amino]ethyl]-6-iodoquinoxaline-2-carboxamide, <b>6</b></h4><div class="NLM_p last">Fluorine-19 standard compound <b>6</b> was prepared as described by Maisonial and Billaud et al.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a><i>R</i><sub><i>f</i></sub> (Al<sub>2</sub>O<sub>3</sub>, DCM/EtOH, 99:1, v/v) 0.36; mp 50–52 °C; IR (CCl<sub>4</sub>) ν 1160, 1353, 1475, 1520, 1682, 2817, 2850–3000, 3409 cm<sup>–1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.08 (t, 3H, <i>J</i> = 7.1 Hz), 2.63 (q, 2H, <i>J</i> = 7.1 Hz), 2.72 (t, 2H, <i>J</i> = 6.2 Hz), 3.21 (m, 2H), 3.57 (q, 2H, <i>J</i> = 5.9 Hz), 4.81 (dd, 2H, <sup>2</sup><i>J</i><sub>H–F</sub> = 47.0 Hz, <i>J</i> = 4.3 Hz), 5.90 (m, 2H), 7.81 (d, 1H, <i>J</i> = 8.8 Hz), 8.07 (dd, 1H, <i>J</i> = 8.8, 1.8 Hz), 8.32 (m, 1H), 8.59 (d, 1H, <i>J</i> = 1.8 Hz), 9.63 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 12.2, 37.4, 47.8, 51.9, 55.2 (d, <sup>4</sup><i>J</i><sub>C–F</sub> = 1 Hz), 83.0 (d, <sup>1</sup><i>J</i><sub>C–F</sub> = 162 Hz), 98.1, 127.4 (d, <sup>2</sup><i>J</i><sub>C–F</sub> = 17 Hz), 130.9, 133.2 (d, <sup>3</sup><i>J</i><sub>C–F</sub> = 12 Hz), 138.7, 139.7, 139.8, 144.1, 144.5, 144.7, 163.0; <sup>19</sup>F NMR (CDCl<sub>3</sub>) δ −211.13 (t, <sup>2</sup><i>J</i><sub>H–F</sub> = 48.2 Hz); ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 442.90.</div></div><div id="sec4_2_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>N</i>-[2-[[<i>N</i>-Ethyl-<i>N</i>-(4-fluorobut-2-ynyl)]amino]ethyl]-6-iodoquinoxaline-2-carboxamide, <b>7</b></h4><div class="NLM_p last">Fluorine-19 standard compound <b>7</b> was prepared as described by Maisonial and Billaud et al.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a><i>R</i><sub><i>f</i></sub> (Al<sub>2</sub>O<sub>3</sub>, DCM/EtOH, 99:1, v/v) 0.86; IR (CCl<sub>4</sub>) ν 1475, 1522, 1685, 2928 cm<sup>–1</sup>; <sup>1</sup>H NMR (acetone-<i>d</i><sub>6</sub>) δ 1.11 (t, 3H, <i>J</i> = 7.2 Hz), 2.64 (q, 2H, <i>J</i> = 7.2 Hz), 2.80 (t, 2H, <i>J</i> = 6.1 Hz), 3.59 (m, 4H), 4.97 (dt, 2H, <sup>2</sup><i>J</i><sub>H–F</sub> = 47.5 Hz, <i>J</i> = 1.7 Hz), 7.80 (d, 1H, <i>J</i> = 8.8 Hz), 8.05 (dd, 1H, <i>J</i> = 8.8, 1.8 Hz), 8.25 (br, 1H), 8.58 (d, 1H, <i>J</i> = 1.8 Hz), 9.62 (s, 1H); <sup>13</sup>C NMR (acetone-<i>d</i><sub>6</sub>) δ 12.9, 37.7, 42.2 (d, <sup>4</sup><i>J</i><sub>C–F</sub> = 3 Hz), 48.3, 52.9, 71.5 (d, <sup>1</sup><i>J</i><sub>C–F</sub> = 161 Hz), 80.3 (d, <sup>2</sup><i>J</i><sub>C–F</sub> = 22 Hz), 85.5 (d, <sup>3</sup><i>J</i><sub>C–F</sub> = 12 Hz), 98.3, 131.8, 139.1, 140.2, 140.5, 145.0, 145.3, 145.5, 163.5; <sup>19</sup>F NMR (acetone-<i>d</i><sub>6</sub>) δ −213.79; ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 441.10.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-(12-Ethyl-1-fluoro-3,6,9-trioxa-12-azatetradecan-14-yl)-6-iodoquinoxaline-2-carboxamide, <b>8</b></h4><div class="NLM_p last">Fluorine-19 standard compound <b>8</b> was prepared as described by Maisonial and Billaud et al.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a><i>R</i><sub><i>f</i></sub> (SiO<sub>2</sub>, ethyl acetate/EtOH, 85:15, v/v) 0.30; IR (ATR diamond accessory) ν 1046, 1107, 1352, 1473, 1523, 1592, 1669, 2868, 2916, 3300–3400 cm<sup>–1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.07 (t, 3H, <i>J</i> = 7.1 Hz), 2.65 (q, 2H, <i>J</i> = 7.1 Hz), 2.77 (m, 4H), 3.61 (m, 12H), 3.69 (m, 2H), 4.53 (dt, 2H, <sup>2</sup><i>J</i><sub>H–F</sub> = 47.7 Hz, <i>J</i> = 4.1 Hz), 7.81 (d, 1H, <i>J</i> = 8.8 Hz), 8.07 (dd, 1H, <i>J</i> = 8.8, 1.8 Hz), 8.42 (br, 1H), 8.60 (d, 1H, <i>J</i> = 1.8 Hz), 9.63 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 11.5, 37.1, 48.9, 52.8 (2C), 70.8 (6C), 83.2 (<sup>1</sup><i>J</i><sub>C–F</sub> = 169 Hz), 98.1, 131.0, 138.6, 139.5, 139.7, 144.1, 144.4, 144.7, 163.3; <sup>19</sup>F NMR (CDCl<sub>3</sub>) δ −223.1; ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 549.20.</div></div><div id="sec4_2_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-(24-Ethyl-1-fluoro-3,6,9,12,15,18,21-heptaoxa-24-azahexacosan-26-yl)-6-iodoquinoxaline-2-carboxamide, <b>9</b></h4><div class="NLM_p last">Fluorine-19 standard compound <b>9</b> was prepared as described by Maisonial and Billaud et al.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a><i>R</i><sub><i>f</i></sub> (SiO<sub>2</sub>, ethyl acetate/EtOH, 5:5, v/v containing 0.5% of NH<sub>4</sub>OH) 0.32; IR (ATR diamond accessory) ν 1129, 1353, 1474, 1527, 1593, 1675, 2800–3000, 3300–3400 cm<sup>–1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.07 (t, 3H, <i>J</i> = 7.1 Hz), 2.67 (q, 2H, <i>J</i> = 7.1 Hz), 2.79 (m, 4H), 3.61 (m, 30H), 4.55 (dt, 2H, <sup>2</sup><i>J</i><sub>H–F</sub> = 47.8 Hz, <i>J</i> = 4.1 Hz), 7.83 (d, 1H, <i>J</i> = 8.8 Hz), 8.08 (dd, 1H, <i>J</i> = 8.8, 1.6 Hz), 8.46 (br, 1H), 8.61 (d, 1H, <i>J</i> = 1.6 Hz), 9.64 (s, 1H);<sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 11.5, 37.0, 48.0, 52.9, 53.0, 70.6 (14C), 83.3 (d, <sup>1</sup><i>J</i><sub><i>C–F</i></sub> = 163 Hz), 98.1, 131.0, 138.6, 139.7, 139.7, 144.1, 144.4, 144.7, 163.3; <sup>19</sup>F NMR (CDCl<sub>3</sub>) δ −223.2; ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 725.20.</div></div><div id="sec4_2_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 4-(<i>tert</i>-Butyldimethylsilyloxy)but-2-yn-1-ol, <b>11</b></h4><div class="NLM_p last">To a solution of 2-butyne-1,4-diol <b>10</b> (10.0 g, 116 mmol) in anhydrous <i>N</i>,<i>N</i>-dimethylformamide (DMF) (125 mL) were added successively imidazole (5.9 g, 87.1 mmol) and TBDMSCl (10.5 g, 69.7 mmol). The mixture was stirred at rt for 24 h. The reaction was quenched with MeOH (40 mL) and water (120 mL) and then extracted with ethyl acetate (3 × 200 mL). The organic layers were combined, washed with brine (200 mL), dried on MgSO<sub>4</sub>, filtered, and evaporated under reduced pressure. The residue was taken up in ethyl acetate (200 mL) and washed with water (3 × 200 mL). The organic layer was dried on MgSO<sub>4</sub>, filtered, and evaporated under reduced pressure. The crude product was purified by chromatography (SiO<sub>2</sub>, DCM/EtOH, 98:2, v/v) to give compound <b>11</b> (9.45 g, 47.2 mmol) as a yellow oil. Yield 68%; <i>R</i><sub>f</sub> (SiO<sub>2</sub>, DCM/EtOH, 98:2, v/v) 0.35; IR (NaCl) ν 778, 837, 1084, 1256, 1472, 2350, 2859, 2930, 3200–3500 cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.09 (s, 6H), 0.87 (s, 9H), 2.93 (br, 1H), 4.25 (s, 2H), 4.31 (s, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ −5.1 (2C), 18.4, 25.9 (3C), 51.2, 51.8, 83.1, 84.4. EI-MS <i>m</i>/<i>z</i> 185 (<1) 143 (3), 126 (3), 125 (28), 85 (5), 77 (6), 76 (8), 75 (100), 73 (7), 61 (3), 59 (3), 57 (3).</div></div><div id="sec4_2_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>tert</i>-Butyl(4-iodobut-2-ynyloxy)dimethylsilane, <b>12</b></h4><div class="NLM_p last">To a solution of alcohol <b>11</b> (9.35 g, 46.7 mmol) vigorously stirred at 0 °C in anhydrous DCM (250 mL) were added successively imidazole (4.13 g, 60.7 mmol), triphenylphosphine (15.9 g, 60.7 mmol), and iodine (15.4 g, 60.7 mmol). The mixture was stirred at 0 °C for 30 min and allowed to stand at rt for 1 h before addition of an aqueous solution of 10% sodium bisulfite (320 mL). After decanting, the aqueous layer was extracted with DCM (3 × 150 mL). The organic layers were combined, dried on MgSO<sub>4</sub>, filtered, and evaporated under reduced pressure. The residue containing the desired product was triturated in <i>n</i>-pentane (280 mL) and stirred for 45 min. The precipitate was filtered and washed with <i>n</i>-pentane (50 mL). The filtrate was evaporated under reduced pressure, and the crude product was purified by chromatography (SiO<sub>2</sub>, n-pentane/diethyl ether, 99:1, v/v) to give compound <b>12</b> (11.2 g, 36.1 mmol) as a pale yellow oil. Yield 78%; <i>R</i><sub>f</sub> (SiO<sub>2</sub>, n-pentane/diethyl ether, 99:1, v/v) 0.30; IR (NaCl) ν 778, 837, 1086, 1255, 1471, 2350, 2857, 2929 cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.11 (s, 6H), 0.89 (s, 9H), 3.71 (m, 2H), 4.31 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ −18.5, −5.1 (2C), 18.4, 25.9 (3C), 51.9, 81.6, 84.0.</div></div><div id="sec4_2_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-[2-[<i>N</i>-[4-(<i>tert</i>-Butyldimethylsilyloxy)but-2-ynyl]-<i>N</i>-ethylamino]ethyl]phthalimide, <b>14</b></h4><div class="NLM_p last">To a solution of 2-[2-(ethylamino)ethyl]-1<i>H</i>-phthalimide hydrochloride <b>13</b> (4.51 g, 17.7 mmol)<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> in anhydrous MeCN (85 mL) were successively added potassium carbonate (2.45 g, 17.7 mmol) and compound <b>12</b> (5.50 g, 17.7 mmol). The mixture was stirred at rt for 72 h. Saturated aqueous sodium carbonate solution (250 mL) was added, and the aqueous layer was extracted with DCM (3 × 150 mL). The organic layers were combined, dried on MgSO<sub>4</sub>, filtered, and evaporated under reduced pressure. The obtained residue was purified by chromatography (SiO<sub>2</sub>, DCM/EtOH, 8:2, v/v) to give compound <b>14</b> (5.54 g, 13.8 mmol) as an orange solid. Yield 78%; <i>R</i><sub>f</sub> (SiO<sub>2</sub>, DCM/EtOH, 8:2, v/v) 0.85; mp 49–51 °C. IR (NaCl) ν 777, 837, 1032, 1254, 1335, 1401, 1431, 1470, 1706, 2273, 2858, 2929 cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.10 (s, 6H), 0.88 (s, 9H), 0.96 (t, 3H, <i>J</i> = 7.1 Hz), 2.56 (q, 2H, <i>J</i> = 7.1 Hz), 2.79 (t, 2H, <i>J</i> = 6.4 Hz), 3.51 (s, 2H), 3.78 (t, 2H, <i>J</i> = 6.4 Hz), 4.31 (t, 2H, <i>J</i> = 1.7 Hz), 7.70 (m, 2H), 7.80 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ −5.0 (2C), 12.8, 18.4, 25.9 (3C), 35.9, 41.8, 47.6, 50.8, 51.8, 79.4, 83.9, 123.3 (2C), 132.3 (2C), 133.9 (2C), 168.5 (2C). ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 401.26.</div></div><div id="sec4_2_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-[4-(<i>tert</i>-Butyldimethylsilyloxy)but-2-ynyl]-<i>N</i>-ethyl-1,2-ethylenediamine, <b>15</b></h4><div class="NLM_p last">To a solution of phthalimide <b>14</b> (5.54 g, 13.8 mmol) in EtOH (500 mL) was added hydrazine monohydrate (6.71 mL, 138 mmol, 10 equiv). The mixture was stirred at rt for 17 h. After cooling to 0 °C for 4 h, the precipitate was filtered and washed with EtOH (50 mL). The filtrate was evaporated under reduced pressure and taken up in cold EtOH (50 mL), filtered, and washed with cold EtOH (50 mL). Last steps were repeated until no more white solid appeared after evaporation of the filtrate. Compound <b>15</b> (3.74 g, 13.8 mmol) was obtained as a yellow oil and used without further purification. Yield quant.; <i>R</i><sub>f</sub> (Al<sub>2</sub>O<sub>3</sub>, DCM/EtOH, 8:2, v/v) 0.23; IR (ATR diamond accessory) ν 837, 1116, 1255, 1472, 1641, 2275, 2858, 2931 cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.11 (s, 6H), 0.90 (s, 9H), 1.05 (t, 3H, <i>J</i> = 7.1 Hz), 2.59 (q, 2H, <i>J</i> = 7.1 Hz), 2.71 (t, 2H, <i>J</i> = 5.5 Hz), 3.23 (m, 2H), 3.44 (s, 2H), 4.32 (s, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ −5.0 (2C), 12.8, 18.4, 25.9 (3C), 37.9, 41.5, 47.5, 51.8, 52.4, 79.1, 84.0.</div></div><div id="sec4_2_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-[2-[<i>N</i>-[(<i>E</i>)-4-(<i>tert</i>-Butyldimethylsilyloxy)but-2-enyl]-<i>N</i>-ethylamino]ethyl]phthalimide, <b>17</b></h4><div class="NLM_p last">This protocol was adapted from Trost et al.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and Fürstner et al.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> To a solution of phthalimide <b>14</b> (525 mg, 1.31 mmol) in anhydrous DCM (8 mL) were successively added at 0 °C, triethoxysilane (290 μL, 1.57 mmol) and catalyst [Cp*Ru(MeCN)<sub>3</sub>]PF<sub>6</sub> (7.0 mg, 13.1 μmol). The mixture was stirred at 0 °C for 10 min and then at rt for 2 h. Diethyl ether was added (25 mL), and the mixture was filtered on a Florisil pad (100–200 mesh). The pad was washed with diethyl ether (50 mL) and DCM (25 mL), and then the filtrate was evaporated under reduced pressure. The obtained residue (710 mg, 1.26 mmol) was taken up in tetrahydrofuran (THF) (11 mL), and a suspension of silver fluoride 1 M in MeOH (2.5 mL, 2.51 mmol) was added. The mixture was stirred at rt in darkness for 2.5 h, filtered, and then washed with ether (20 mL) and ethyl acetate (20 mL). The filtrate was evaporated under reduced pressure. The obtained residue was purified by chromatography (SiO<sub>2</sub>, ethyl acetate/cyclohexane, 3:7, v/v) to give compound <b>17</b> (485 mg, 1.21 mmol) as a pale yellow oil. Yield 92%; <i>R</i><sub>f</sub> (SiO<sub>2</sub>, ethyl acetate/cyclohexane, 3:7, v/v) 0.25; IR (ATR diamond accessory) ν 778, 839, 1101, 1257, 1396, 1469, 1718, 2856, 2930 cm<sup>–1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.07 (s, 6H), 0.89 (s, 9H), 0.97 (t, 3H, <i>J</i> = 7.1 Hz), 2.56 (q, 2H, <i>J</i> = 7.1 Hz), 2.71 (t, 2H, <i>J</i> = 6.8 Hz), 3.14 (d, 2H, <i>J</i> = 5.9 Hz), 3.76 (t, 2H, <i>J</i> = 6.8 Hz), 4.11 (d, 2H, <i>J</i> = 4.7 Hz), 5.61 (dt, 1H, <i>J</i> = 15.5, 5.9 Hz), 5.66 (dt, 1H, <i>J</i> = 15.5, 4.7 Hz), 7.70 (m, 2H), 7.83 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ −5.1 (2C), 12.1, 18.4, 26.0 (3C), 36.1, 47.4, 50.5, 55.3, 63.6, 123.2 (2C), 127.4, 132.3 (2C), 132.5, 133.9 (2C), 168.5 (2C). ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 403.32.</div></div><div id="sec4_2_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>-[(<i>E</i>)-4-(<i>tert</i>-Butyldimethylsilyloxy)but-2-enyl]-<i>N</i>-ethyl-1,2-ethylenediamine, <b>18</b></h4><div class="NLM_p last">Compound <b>18</b> was prepared following the same procedure described above for <b>15</b>, starting from phthalimide <b>17</b> (250 mg, 0.62 mmol). Compound <b>18</b> (169 mg, 0.62 mmol) was obtained as a pale yellow oil and used without further purification. Yield quant.; <i>R</i><sub>f</sub> (SiO<sub>2</sub>, ethyl acetate/cyclohexane, 1:1, v/v) 0.12; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.05 (s, 6H), 0.90 (s, 9H), 0.99 (t, 3H, <i>J</i> = 7.1 Hz), 2.50 (m, 4H), 2.60 (br, 2H), 2.73 (t, 2H, <i>J</i> = 6.1 Hz), 3.07 (m, 2H), 4.13 (m, 2H), 5.67 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ −5.1(2C), 11.9, 18.6, 26.0 (3C), 39.6, 47.6, 55.4, 55.8, 63.6, 127.6, 132.3.</div></div><div id="sec4_2_6_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-[2-[[<i>N</i>-Ethyl-<i>N</i>-(4-(<i>tert</i>-Butyldimethylsilyloxy)but-2-ynyl)]amino]ethyl]-6-iodoquinoxaline-2-carboxamide, <b>20</b></h4><div class="NLM_p last">To a suspension of activated ester 4-nitrophenyl 6-iodoquinoxaline-2-carboxylate <b>19</b> (1.00 g, 2.38 mmol) in anhydrous THF (10 mL) was added a solution of compound <b>15</b> (0.71 g, 2.61 mmol) in anhydrous THF (15 mL). The mixture was stirred at rt for 18 h. The solvent was evaporated under reduced pressure, the residue was taken up in DCM (25 mL), and the mixture was poured into a 1 M aqueous NaOH solution (75 mL). The aqueous layer was extracted with DCM (3 × 25 mL); the combined organic layers were washed with a 5% aqueous sodium carbonate solution (2 × 75 mL), dried on MgSO<sub>4</sub>, filtered, and evaporated under reduced pressure. The obtained residue was purified by chromatography (SiO<sub>2</sub>, ethyl acetate/n-pentane, 9:1, v/v) to give compound <b>20</b> (820 mg, 1.48 mmol) as a yellow gum. Yield 63%; <i>R</i><sub>f</sub> (SiO<sub>2</sub>, ethyl acetate/n-pentane, 9:1, v/v) 0.42; IR (NaCl) ν 407, 777, 836, 1074, 1253, 1353, 1387, 1472, 1472, 1518, 1593, 1656, 1683, 2273, 2858, 2929, 3363 cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.08 (s, 6H), 0.82 (s, 9H), 1.04 (t, 3H, <i>J</i> = 7.1 Hz), 2.57 (q, 2H, <i>J</i> = 7.1 Hz), 2.74 (t, 2H, <i>J</i> = 5.9 Hz), 3.46 (br, 2H), 3.53 (q, 2H, <i>J</i> = 5.9 Hz), 4.27 (br, 2H), 7.72 (d, 1H, <i>J</i> = 8.9 Hz), 7.94 (dd, 1H, <i>J</i> = 8.9, 1.8 Hz), 8.22 (m, 1H), 8.47 (d, 1H, <i>J</i> = 1.8 Hz), 9.54 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ −5.1 (2C), 13.0, 18.3, 25.8 (3C), 37.1, 41.7, 47.6, 51.8, 51.9, 79.4, 83.9, 98.0, 130.8, 138.5, 139.4, 139.6, 144.0, 144.3, 144.6, 162.9. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 553.17.</div></div><div id="sec4_2_6_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-[2-[[<i>N</i>-Ethyl-<i>N</i>-(4-hydroxybut-2-ynyl)]amino]ethyl]-6-iodoquinoxaline-2-carboxamide, <b>21</b></h4><div class="NLM_p last">To a solution of protected alcohol <b>20</b> (200 mg, 0.36 mmol) in THF (6 mL) was added a 1 M solution of TBAF in THF (543 μL, 0.54 mmol). The mixture was stirred at rt for 2 h. The reaction was quenched by addition of a saturated aqueous sodium hydrogencarbonate solution (60 mL), followed by distilled water (30 mL) and then ethyl acetate (30 mL). The mixture was extracted with ethyl acetate (3 × 30 mL). The organic layers were combined, washed with brine (30 mL), dried on MgSO<sub>4</sub>, filtered, and evaporated under reduced pressure. The obtained residue was purified by chromatography (SiO<sub>2</sub>, ethyl acetate) to give compound <b>21</b> (140 mg, 0.32 mmol) as a yellow solid. Yield 89%; <i>R</i><sub>f</sub> (SiO<sub>2</sub>, ethyl acetate) 0.17; mp 119–121 °C. IR (NaCl) ν 407, 1022, 1353, 1473, 1523, 1592, 1664, 2273, 2865, 2925, 3200–3600 cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.10 (t, 3H, <i>J</i> = 7.1 Hz), 2.62 (q, 2H, <i>J</i> = 7.1 Hz), 2.74 (t, 2H, <i>J</i> = 6.1 Hz), 3.52 (br, 2H), 3.60 (q, 2H, <i>J</i> = 6.1 Hz), 4.29 (t, 2H, <i>J</i> = 1.8 Hz), 7.81 (d, 1H, <i>J</i> = 8.9 Hz), 8.03 (dd, 1H, <i>J</i> = 8.9, 1.8 Hz), 8.29 (m, 1H), 8.57 (d, 1H, <i>J</i> = 1.7 Hz), 9.61 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 12.9, 37.3, 42.0, 48.0, 51.0, 52.0, 80.2, 83.9, 98.2, 130.8, 138.6, 139.5, 139.8, 143.9, 144.4, 144.6, 163.1. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 439.09.</div></div><div id="sec4_2_6_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-[2-[<i>N</i>-Ethyl-<i>N</i>-[(<i>E</i>)-4-(<i>tert</i>-butyldimethylsilyloxy)but-2-enyl)]amino]ethyl]-6-iodoquinoxaline-2-carboxamide, <b>23</b></h4><div class="NLM_p last">Compound <b>23</b> was prepared following the same procedure described above for <b>20</b>, using compound <b>18</b> (147 mg, 0.54 mmol). Protected alcohol <b>23</b> (180 mg, 0.32 mmol) was obtained as a yellow oil. Yield 93%; <i>R</i><sub>f</sub> (SiO<sub>2</sub>, ethyl acetate) 0.43; IR (ATR diamond accessory) ν 778, 838, 1102, 1257, 1354, 1386, 1473, 1525, 1593, 1683, 2855, 2929, 3300–3400 cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.00 (s, 6H), 0.83 (s, 9H), 1.05 (t, 3H, <i>J</i> = 7.1 Hz), 2.56 (q, 2H, <i>J</i> = 7.1 Hz), 2.70 (t, 2H, <i>J</i> = 6.0 Hz), 3.16 (br, 2H), 3.56 (q, 2H, <i>J</i> = 6.0 Hz), 4.11 (br, 2H), 5.72 (m, 2H), 7.79 (d, 1H, <i>J</i> = 8.8 Hz), 8.03 (dd, 1H, <i>J</i> = 8.8, 1.8 Hz), 8.35 (m, 1H), 8.57 (d, 1H, <i>J</i> = 1.8 Hz), 9.61 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ −5.2 (2C), 12.2, 18.4, 26.0 (3C), 37.3, 47.5, 51.6, 55.3, 63.5, 97.9, 127.3, 130.9, 132.6, 138.6, 139.6 (2C), 144.1, 144.4, 144.7, 162.9. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 555.21.</div></div><div id="sec4_2_6_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-[2-[<i>N</i>-Ethyl-<i>N</i>-[(<i>E</i>)-4-hydroxybut-2-enyl]amino]ethyl]-6-iodoquinoxaline-2-carboxamide, <b>24</b></h4><div class="NLM_p last">Compound <b>24</b> was prepared following the same procedure described above for <b>21</b>, starting from <b>23</b> (171 mg, 0.31 mmol). Alcohol <b>24</b> (135 mg, 0.31 mmol) was obtained as a yellow oil. Yield 99%; <i>R</i><sub>f</sub> (SiO<sub>2</sub>, DCM/EtOH, 9:1, v/v) 0.20; IR (ATR diamond accessory) ν 978, 1355, 1475, 1533, 1593, 1675, 2823, 2934, 3200–3500 cm<sup>–1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.08 (t, 3H, <i>J</i> = 7.1 Hz), 2.63 (q, 2H, <i>J</i> = 7.1 Hz), 2.73 (t, 2H, <i>J</i> = 6.2 Hz), 3.18 (d, 2H, <i>J</i> = 6.1 Hz), 3.56 (q, 2H, <i>J</i> = 6.2 Hz), 4.10 (d, 2H, <i>J</i> = 5.2 Hz), 5.77 (dt, 1H, <i>J</i> = 15.5, 6.1 Hz), 5.86 (dt, 1H, <i>J</i> = 15.5, 5.2 Hz), 7.81 (d, 1H, <i>J</i> = 8.8 Hz), 8.04 (dd, 1H, <i>J</i> = 1.6, 8.8 Hz), 8.33 (m, 1H), 8.57 (d, 1H, <i>J</i> = 1.6 Hz), 9.60 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 12.1, 37.5, 48.1, 51.6, 55.6, 63.2, 98.1, 128.8, 130.8, 132.7, 138.6, 139.6, 139.8, 144.0, 144.4, 144.6, 163.1. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 441.13.</div></div><div id="sec4_2_6_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> General Procedure: Syntheses of Mesylates <b>22</b>, <b>25</b>, <b>28</b>, <b>29</b>, and <b>31</b></h4><div class="NLM_p">To a solution of the corresponding alcohol, distilled triethylamine (1.2 equiv), and DMAP (0.1 equiv) in anhydrous DCM (1–2 mL) was added MsCl (1.2 equiv). The mixture was stirred at rt for 30–120 min and then poured into a saturated aqueous sodium hydrogencarbonate solution (10–30 mL). After decanting, the aqueous layer was extracted with ethyl acetate (3 × 15 mL). The organic layers were combined, washed with brine (15 mL), dried on MgSO<sub>4</sub>, filtered, and evaporated under reduced pressure to afford the crude product.</div><div id="sec4_2_6_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> <i>N</i>-[2-[[<i>N</i>-Ethyl-<i>N</i>-(4-methanesulfonyloxybut-2-ynyl)]amino]ethyl]-6-iodoquinoxaline-2-carboxamide, <b>22</b></h5><div class="NLM_p last">The alcohol <b>21</b> (25 mg, 57 μmol) was treated according to the general method described above (reaction time 60 min) and purified by chromatography (SiO<sub>2</sub>, ethyl acetate) to give compound <b>22</b> (23 mg, 45 μmol) as a yellow gum. Yield 78%; <i>R</i><sub>f</sub> (SiO<sub>2</sub>, ethyl acetate) 0.31; IR (NaCl) ν 732, 907, 1025, 1177, 1370, 1474, 1523, 1674, 2254, 2869, 2928, 3200–3600. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.12 (t, 3H, <i>J</i> = 7.1 Hz), 2.64 (q, 2H, <i>J</i> = 7.1 Hz), 2.81 (t, 2H, <i>J</i> = 6.1 Hz), 3.10 (s, 3H), 3.59 (s, 2H), 3.62 (q, 2H, <i>J</i> = 6.1 Hz), 4.88 (t, 2H, <i>J</i> = 1.8 Hz), 7.81 (d, 1H, <i>J</i> = 8.9 Hz), 8.07 (dd, 1H, <i>J</i> = 8.9, 1.9 Hz), 8.25 (m, 1H), 8.59 (d, 1H, <i>J</i> = 1.9 Hz), 9.62 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 12.9, 37.0, 38.9, 41.8, 47.9, 52.1, 57.6, 80.2, 83.9, 98.2, 130.8, 138.7, 139.5 (2C), 139.8, 143.9 (2C), 144.4 (2C), 144.7, 163.1. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 517.04.</div></div><div id="sec4_2_6_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> <i>N</i>-[2-[<i>N</i>-Ethyl-<i>N</i>-[(<i>E</i>)-4-methanesulfonyloxybut-2-enyl]amino]ethyl]-6-iodoquinoxaline-2-carboxamide, <b>25</b></h5><div class="NLM_p last">The alcohol <b>24</b> (25.5 mg, 58 μmol) was treated according to the general method described above (reaction time 30 min) and purified by chromatography (SiO<sub>2</sub>, ethyl acetate) to give compound <b>25</b> (21 mg, 41 μmol) as a yellow gum. Yield 70%; <i>R</i><sub>f</sub> (SiO<sub>2</sub>, ethyl acetate) 0.35; IR (NaCl) ν 409, 828, 927, 1172, 1352, 1474, 1527, 1592, 1670, 2858, 2929, 3300–3400 cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.09 (t, 3H, <i>J</i> = 7.1 Hz), 2.63 (q, 2H, <i>J</i> = 7.1 Hz), 2.73 (t, 2H, <i>J</i> = 6.1 Hz), 2.99 (s, 3H), 3.21 (m, 2H), 3.58 (q, 2H, <i>J</i> = 6.1 Hz), 4.69 (m, 2H), 5.88 (m, 2H), 7.84 (d, 1H, <i>J</i> = 8.9 Hz), 8.09 (dd, 1H, <i>J</i> = 8.9, 1.7 Hz), 8.36 (m, 1H), 8.61 (d, 1H, <i>J</i> = 1.7 Hz), 9.64 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 12.1, 37.3, 38.1, 47.8, 51.8, 54.9, 69.8, 98.0, 127.3, 130.9, 132.6, 138.6, 139.8, 144.7, 162.9. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 519.07.</div></div><div id="sec4_2_6_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> <i>N</i>-(12-Ethyl-1-methanesulfonyloxy-3,6,9-trioxa-12-azatetradecan-14-yl)-6-iodoquinoxaline-2-carboxamide, <b>28</b></h5><div class="NLM_p last">The alcohol <b>26</b> (80 mg, 146 μmol, prepared as described by Maisonial and Billaud et al.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a>) was treated according to the general method described above (reaction time 60 min) and purified by chromatography (SiO<sub>2</sub>, DCM → DCM/EtOH, 9:1, v/v) to give compound <b>28</b> (85 mg, 136 μmol) as a yellow gum. Yield 93%; <i>R</i><sub>f</sub> (SiO<sub>2</sub>, DCM/EtOH, 9:1, v/v) 0.37; IR (ATR diamond accessory) ν 751, 917, 1106, 1171, 1349, 1473, 1592, 1525, 1668, 2849, 2916, 3300–3400 cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.12 (t, 3H, <i>J</i> = 7.1 Hz), 2.85 (m, 6H), 3.06 (s, 3H), 3.60 (m, 12H), 3.73 (m, 2H), 4.36 (m, 2H), 7.83 (d, 1H, <i>J</i> = 8.8 Hz), 8.06 (dd, 1H, <i>J</i> = 8.8, 1.8 Hz), 8.53 (m, 1H), 8.60 (d, 1H, <i>J</i> = 1.8 Hz), 9.62 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 11.7, 37.2, 37.8, 48.9, 52.9, 53.0, 69.1, 69.3, 70.5 (5C), 98.1, 130.9, 138.6, 139.6, 139.8, 144.1, 144.4, 144.7, 163.2. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 625.25.</div></div><div id="sec4_2_6_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> <i>N</i>-(24-Ethyl-1-methanesulfonyloxy-3,6,9,12,15,18,21-heptaoxa-24-azahexacosan-26-yl)-6-iodoquinoxaline-2-carboxamide (<b>29</b>)</h5><div class="NLM_p last">The alcohol <b>27</b> (91 mg, 126 μmol, prepared as described by Maisonial and Billaud et al.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a>) was treated according to the general method described above (reaction time 120 min) and purified by chromatography (SiO<sub>2</sub>, DCM → DCM/EtOH, 9:1, v/v) to give compound <b>29</b> (95 mg, 119 μmol) as a yellow gum. Yield 95%; <i>R</i><sub>f</sub> (SiO<sub>2</sub>, DCM/EtOH, 8:2, v/v) 0.50; IR (ATR diamond accessory) ν 733, 923, 1128, 1176, 1354, 1474, 1593, 1527, 1675, 2800–3000, 3300–3400 cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.04 (t, 3H, <i>J</i> = 7.1 Hz), 2.64 (q, 2H, <i>J</i> = 7.1 Hz), 2.73 (m, 4H), 3.06 (s, 3H), 3.61 (m, 28H), 3.73 (t, 2H, <i>J</i> = 4.5 Hz), 4.35 (t, 2H, <i>J</i> = 4.5 Hz), 7.80 (d, 1H, <i>J</i> = 8.8 Hz), 8.05 (dd, 1H, <i>J</i> = 8.8, 1.3 Hz), 8.41 (m, 1H), 8.57 (d, 1H, <i>J</i> = 1.3 Hz), 9.61 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 12.2, 37.6, 37.8, 48.7, 52.9, 53.0, 69.1, 69.4, 70.2–70.6 (13C), 98.0, 130.9, 138.6, 139.6, 139.7, 144.2, 144.4, 144.7, 163.0. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 801.33.</div></div><div id="sec4_2_6_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> <i>N</i>-[2-[<i>N</i>-Ethyl-<i>N</i>-(3-methanesulfonyloxypropyl)amino]ethyl]-6-iodoquinoxaline-2-carboxamide, <b>31</b></h5><div class="NLM_p last">The alcohol <b>30</b> (30 mg, 70 μmol, prepared as described by Maisonial and Billaud et al.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a>) was treated according to the general method described above (reaction time 60 min) and purified by chromatography (SiO<sub>2</sub>, DCM → DCM/EtOH, 9:1, v/v) to give compound <b>31</b> (32.5 mg, 64 μmol) as a yellow gum. Yield 92%; <i>R</i><sub>f</sub> (SiO<sub>2</sub>, DCM/EtOH, 9/1, v/v) 0.43; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.07 (t, 3H, <i>J</i> = 7.1 Hz), 1.91 (quint., 2H, <i>J</i> = 6.4 Hz), 2.65 (m, 6H), 2.97 (s, 3H), 3.58 (q, 2H, <i>J</i> = 5.9 Hz), 4.37 (t, 2H, <i>J</i> = 6.2 Hz), 7.86 (d, 1H, <i>J</i> = 8.9 Hz), 8.08 (dd, 1H, <i>J</i> = 8.9, 1.9 Hz), 8.32 (m, 1H), 8.60 (d, 1H, <i>J</i> = 1.9 Hz), 9.62 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 11.8, 27.3, 37.3, 37.5, 47.4, 49.2, 52.3, 67.9, 98.2, 131.0, 138.4, 139.6, 139.8, 144.0, 144.5, 144.6, 163.0. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 507.08.</div></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Radiochemistry</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> [<sup>18</sup>F]KF,K<sub>222</sub> Complex</h4><div class="NLM_p last">The activated [<sup>18</sup>F]KF,K<sub>222</sub> complex was obtained by usual method in 19 min. Briefly, the aqueous [<sup>18</sup>F]F<sup>–</sup> solution from target was flushed through an anion exchange resin (Sep-Pak Light Accell Plus QMA cartridge, Waters). The radioactivity was eluted to the reactor with a K<sub>2</sub>CO<sub>3</sub> (3.0 mg) and Kryptofix (K<sub>222</sub>, 15.0 mg) solution (1 mL, MeCN/H<sub>2</sub>O, 70:30, v/v). Solvents were evaporated under reduced pressure and under a gentle stream of helium at 110 °C for 10 min. A second azeotropic drying was repeated by addition of anhydrous MeCN (1.0 mL).</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> [<sup>18</sup>F]<i>N</i>-[2-[<i>N</i>-Ethyl-<i>N</i>-(2-fluoroethyl)amino]ethyl]-6-iodoquinoxaline-2-carboxamide, [<sup>18</sup>F]<b>4</b></h4><div class="NLM_p last">To the dry [<sup>18</sup>F]KF,K<sub>222</sub> complex were added a solution of ditosylate compound <b>32</b> in dry MeCN (6 mg/0.5 mL) and a solution of amine <b>34</b> in dry MeCN (12 mg/1.0 mL).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The mixture was heated at 70 °C for 10 min and then at 110 °C for 10 min. After cooling to rt, the reaction mixture was diluted with DCM (2 mL) and directly purified by semipreparative HPLC (Semi-Prep SiO<sub>2</sub> column; DCM/EtOH 98:02 v/v; <i>t</i><sub>R</sub> = 14.9 min). The solvent was evaporated under reduced pressure, and the formulation was achieved in EtOH/saline (1:9 v/v; formulation yield = 97%). [<sup>18</sup>F]<b>4</b> was obtained in 91 min with 11% overall RCY (6% non-decay-corrected). RCP was determined by analytical HPLC (SiO<sub>2</sub> column; DCM/EtOH 98:2 v/v; 1 mL·min<sup>–1</sup>; <i>t</i><sub>R</sub> = 12.65 min) and was >99%. Radiotracer was radiochemically stable at rt for at least 6 h after preparation.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> [<sup>18</sup>F]<i>N</i>-[2-[<i>N</i>-Ethyl-<i>N</i>-(3-fluoropropyl)amino]ethyl]-6-iodoquinoxaline-2-carboxamide, [<sup>18</sup>F]<b>5</b></h4><div class="NLM_p last">To the dry [<sup>18</sup>F]KF,K<sub>222</sub> complex was added a solution of mesylate precursor <b>31</b> in dry MeCN (14 mg/1 mL), and the mixture was heated at 90 °C for 10 min. After cooling to rt, the reaction mixture was diluted with HPLC eluent (2.5 mL) and purified by semipreparative HPLC (Semi-Prep SiO<sub>2</sub> column; DCM/EtOH/NH<sub>4</sub>OH 93.8:6:0.2 v/v/v; <i>t</i><sub>R</sub> = 9.4 min). The solvent was evaporated under reduced pressure, and the formulation was achieved in EtOH/saline (1:9 v/v; formulation yield = 91%). [<sup>18</sup>F]<b>5</b> was obtained in 70 min with 54% overall RCY (34% non-decay-corrected). RCP was determined by analytical HPLC (SiO<sub>2</sub> column; DCM/EtOH/NH<sub>4</sub>OH 99.8:0:0.2 to 89.8:10:0.2 in 10 min; 1 mL·min<sup>–1</sup>; <i>t</i><sub>R</sub> = 8.67 min) and was >99%. Radiotracer was radiochemically stable at rt for at least 6 h after preparation. log <i>D</i> = 1.28 ± 0.04.</div></div><div id="sec4_3_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> [<sup>18</sup>F]<i>N</i>-[2-[<i>N</i>-Ethyl-<i>N</i>-[(<i>E</i>)-4-fluorobut-2-enyl]amino]ethyl]-6-iodoquinoxaline-2-carboxamide, [<sup>18</sup>F]<b>6</b></h4><div class="NLM_p last">To the dry [<sup>18</sup>F]KF,K<sub>222</sub> complex was added a solution of mesylate precursor <b>25</b> in dry MeCN (12 mg/1 mL), and the mixture was heated at 90 °C for 10 min. After cooling to rt, the reaction mixture was diluted with HPLC eluent (2.5 mL) and purified by semipreparative HPLC (Semi-Prep C18 column; MeOH/H<sub>2</sub>O/NH<sub>4</sub>OH 74.9:24.9:0.2 v/v/v; <i>t</i><sub>R</sub> = 16.0 min). The collected solution was diluted in saline (20 mL) then passed through a C18 cartridge (Sep-Pak Plus C18, Waters). The cartridge was then washed with water (5 mL) before being eluted with EtOH (1 mL) and then saline (10 mL). The solution was finally passed through a Millipore filter (0.22 μm) and collected in a sterile vial (formulation yield 83%). [<sup>18</sup>F]<b>6</b> was obtained in 62 min with 16% overall RCY (11% non-decay-corrected). RCP was determined by analytical HPLC (C18 column; MeOH/H<sub>2</sub>O/NH<sub>4</sub>OH 74.9:24.9:0.2 v/v/v; 1 mL·min<sup>–1</sup>; <i>t</i><sub>R</sub> = 8.62 min) and was >99%. Radiotracer was radiochemically stable at rt for at least 6 h after preparation. log <i>D</i> = 1.64 ± 0.02.</div></div><div id="sec4_3_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> [<sup>18</sup>F]<i>N</i>-[2-[[<i>N</i>-Ethyl-<i>N</i>-(4-fluorobut-2-ynyl)]amino]ethyl]-6-iodoquinoxaline-2-carboxamide, [<sup>18</sup>F]<b>7</b></h4><div class="NLM_p last">To the dry [<sup>18</sup>F]KF,K<sub>222</sub> complex was added a solution of mesylate precursor <b>22</b> in dry MeCN (10 mg/1 mL), and the mixture was heated at 90 °C for 10 min. After cooling to rt, the reaction mixture was diluted with HPLC eluent (2.5 mL) and purified by semipreparative HPLC (Semi-Prep C18 column; MeOH/H<sub>2</sub>O/NH<sub>4</sub>OH (74.9:24.9:0.2 v/v/v; <i>t</i><sub>R</sub> = 11.2 min). The collected solution was diluted with saline (20 mL) then passed through a C18 cartridge (Sep-Pak Plus C18, Waters). The cartridge was then washed with water (5 mL) before being eluted with EtOH (700 μL) and then saline (10 mL). The solution was finally passed through a Millipore filter (0.22 μm) and collected in a sterile vial (formulation yield 76%). [<sup>18</sup>F]<b>7</b> was obtained in 59 min with 22% overall RCY (15% non-decay-corrected). RCP was determined by analytical HPLC (C18 column; MeOH/H<sub>2</sub>O/NH<sub>4</sub>OH 74.9:24.9:0.2 v/v/v; 1 mL·min<sup>–1</sup>; <i>t</i><sub>R</sub> = 8.33 min) and was >99%. Radiotracer was radiochemically stable at rt for at least 6 h after preparation. log <i>D</i> = 1.90 ± 0.02.</div></div><div id="sec4_3_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> [<sup>18</sup>F]<i>N</i>-(12-Ethyl-1-fluoro-3,6,9-trioxa-12-azatetradecan-14-yl)-6-iodoquinoxaline-2-carboxamide, [<sup>18</sup>F]<b>8</b></h4><div class="NLM_p last">To the dry [<sup>18</sup>F]KF,K<sub>222</sub> complex was added a solution of mesylate precursor <b>28</b> in dry MeCN (13 mg/1 mL), and the mixture was heated at 90 °C for 10 min. After cooling to rt, the reaction mixture was diluted with HPLC eluent (2.5 mL) and purified by semipreparative HPLC (C18 column; MeOH/H<sub>2</sub>O/NH<sub>4</sub>OH (74.7:24.9:0.4 v/v/v; <i>t</i><sub>R</sub> = 12.5 min). The collected solution was diluted with saline (20 mL) then passed through a C18 cartridge (Sep-Pak Plus C18, Waters). The cartridge was then washed with water (5 mL) before being eluted with EtOH (900 μL) and then saline (8 mL). The solution was collected in a sterile vial (formulation yield 90%). [<sup>18</sup>F]<b>8</b> was obtained in 57 min with 21% overall RCY (14% non-decay-corrected) and a specific activity of 45–53 GBq·μmol<sup>–1</sup>. RCP was determined by analytical HPLC (C18 column; MeOH/H<sub>2</sub>O/NH<sub>4</sub>OH v/v/v; 59.9:39.9:0.2 to 89.8:10:0.2 linear gradient in 10 min then 59.9:39.9:0.2 isocratic during 7 min; 0.9 mL·min<sup>–1</sup>; <i>t</i><sub>R</sub> = 12.51 min) and was >99%. Color spot test showed no detection of K<sub>222</sub> in the final injectable [<sup>18</sup>F]<b>8</b> solution. Radiotracer was radiochemically stable at rt for at least 22 h after preparation. log <i>D</i> = 1.52 ± 0.03.</div></div><div id="sec4_3_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> [<sup>18</sup>F]<i>N</i>-(24-Ethyl-1-fluoro-3,6,9,12,15,18,21-heptaoxa-24-azahexacosan-26-yl)-6-iodoquinoxaline-2-carboxamide, [<sup>18</sup>F]<b>9</b></h4><div class="NLM_p last">To the dry [<sup>18</sup>F]KF,K<sub>222</sub> complex was added a solution of mesylate precursor <b>29</b> in dry MeCN (15 mg/1 mL), and the mixture was heated at 90 °C for 10 min. After cooling to rt, the solution was diluted with HPLC eluent (2.5 mL) and purified by semipreparative HPLC (SiO<sub>2</sub> column; DCM/EtOH/NH<sub>4</sub>OH 91.8:8:0.2 v/v/v; <i>t</i><sub>R</sub> = 12.1 min). The solvent was evaporated under reduced pressure, and the formulation was achieved in EtOH/saline (05:95; v/v; formulation yield 93%). [<sup>18</sup>F]<b>9</b> was obtained in 65 min with 34% overall RCY (25% non-decay-corrected) and a specific activity of 81–139 GBq·μmol<sup>–1</sup>. RCP was determined by analytical HPLC (C18 column; MeOH/H<sub>2</sub>O/NH<sub>4</sub>OH v/v/v; 59.9:39.9:0.2 to 89.8:10:0.2 linear gradient in 10 min then 59.9:39.9:0.2 isocratic during 7 min; 0.9 mL·min<sup>–1</sup>; <i>t</i><sub>R</sub> = 12.59 min) and was >99%. Color spot test showed no detection of K<sub>222</sub> in the final injectable [<sup>18</sup>F]<b>9</b> solution. Radiotracer was radiochemically stable at rt for at least 6 h after preparation. log <i>D</i> = 0.95 ± 0.02.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm400877v" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58151" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58151" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philippe Auzeloux</span> - <span class="hlFld-Affiliation affiliation">Clermont
Université, Université d’Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France</span>; 
    <span class="hlFld-Affiliation affiliation">Inserm, U 990, F-63000 Clermont-Ferrand, France</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#74041c1d181d0404115a15010e11181b010c341d1a071106195a1206"><span class="__cf_email__" data-cfemail="77071f1e1b1e0707125916020d121b18020f371e190412051a591105">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emilie M. F. Billaud</span> - <span class="hlFld-Affiliation affiliation">Clermont
Université, Université d’Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France</span>; 
    <span class="hlFld-Affiliation affiliation">Inserm, U 990, F-63000 Clermont-Ferrand, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Latifa Rbah-Vidal</span> - <span class="hlFld-Affiliation affiliation">Clermont
Université, Université d’Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France</span>; 
    <span class="hlFld-Affiliation affiliation">Inserm, U 990, F-63000 Clermont-Ferrand, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aurélien Vidal</span> - <span class="hlFld-Affiliation affiliation">Clermont
Université, Université d’Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France</span>; 
    <span class="hlFld-Affiliation affiliation">Inserm, U 990, F-63000 Clermont-Ferrand, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sophie Besse</span> - <span class="hlFld-Affiliation affiliation">Clermont
Université, Université d’Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France</span>; 
    <span class="hlFld-Affiliation affiliation">Inserm, U 990, F-63000 Clermont-Ferrand, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sébastien Tarrit</span> - <span class="hlFld-Affiliation affiliation">Clermont
Université, Université d’Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France</span>; 
    <span class="hlFld-Affiliation affiliation">Inserm, U 990, F-63000 Clermont-Ferrand, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Serge Askienazy</span> - <span class="hlFld-Affiliation affiliation">Cyclopharma
Laboratories, Biopôle
Clermont-Limagne, Saint-Beauzire F-63360, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aurélie Maisonial</span> - <span class="hlFld-Affiliation affiliation">Clermont
Université, Université d’Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France</span>; 
    <span class="hlFld-Affiliation affiliation">Inserm, U 990, F-63000 Clermont-Ferrand, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicole Moins</span> - <span class="hlFld-Affiliation affiliation">Clermont
Université, Université d’Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France</span>; 
    <span class="hlFld-Affiliation affiliation">Inserm, U 990, F-63000 Clermont-Ferrand, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-Claude Madelmont</span> - <span class="hlFld-Affiliation affiliation">Clermont
Université, Université d’Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France</span>; 
    <span class="hlFld-Affiliation affiliation">Inserm, U 990, F-63000 Clermont-Ferrand, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elisabeth Miot-Noirault</span> - <span class="hlFld-Affiliation affiliation">Clermont
Université, Université d’Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France</span>; 
    <span class="hlFld-Affiliation affiliation">Inserm, U 990, F-63000 Clermont-Ferrand, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-Michel Chezal</span> - <span class="hlFld-Affiliation affiliation">Clermont
Université, Université d’Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France</span>; 
    <span class="hlFld-Affiliation affiliation">Inserm, U 990, F-63000 Clermont-Ferrand, France</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d202e5542-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the CLARA (Cancéropôle Lyon Rhône-Alpes Auvergne), the Auvergne Regional Council, the Puy de Dôme General Council, Clermont Community, the European Regional Development Fund, the European Union, The French Ligue contre le Cancer, and the Bullukian Foundation for their financial support. We also thank Martine Bayle, Laurent Audin, Pierre Labarre (INSERM U 990/Université d’Auvergne), and Raphael Boisgard (CEA/SHFJ, Orsay, France) for technical assistance.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i60" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i60"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i61" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i61"> Abbreviations Used</h2><tr><td class="NLM_term">α-MSH</td><td class="NLM_def"><p class="first last">α-melanocyte-stimulating hormone</p></td></tr><tr><td class="NLM_term">EI-MS</td><td class="NLM_def"><p class="first last">electron impact mode mass spectra</p></td></tr><tr><td class="NLM_term">ESI-MS</td><td class="NLM_def"><p class="first last">electrospray ionization mass spectra</p></td></tr><tr><td class="NLM_term">FDG</td><td class="NLM_def"><p class="first last">fluorodeoxyglucose</p></td></tr><tr><td class="NLM_term">MC1R</td><td class="NLM_def"><p class="first last">melanocortin type 1 receptor</p></td></tr><tr><td class="NLM_term">MsCl</td><td class="NLM_def"><p class="first last">methanesulfonyl chloride</p></td></tr><tr><td class="NLM_term">pi</td><td class="NLM_def"><p class="first last">postinjection</p></td></tr><tr><td class="NLM_term">RCP</td><td class="NLM_def"><p class="first last">radiochemical purity</p></td></tr><tr><td class="NLM_term">RCY</td><td class="NLM_def"><p class="first last">radiochemical yield</p></td></tr><tr><td class="NLM_term">SLNB</td><td class="NLM_def"><p class="first last">sentinel lymph node biopsy</p></td></tr><tr><td class="NLM_term">TBDMSCl</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilyl chloride</p></td></tr><tr><td class="NLM_term">TRT</td><td class="NLM_def"><p class="first last">targeted radionuclide therapy</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32316" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32316" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 48 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peris, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saiag, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spatz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malvehy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton-Bishop, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratigos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pehamberger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A.</span><span> </span><span class="NLM_article-title">Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=270-283&author=C.+Garbeauthor=K.+Perisauthor=A.+Hauschildauthor=P.+Saiagauthor=M.+Middletonauthor=A.+Spatzauthor=J.+J.+Grobauthor=J.+Malvehyauthor=J.+Newton-Bishopauthor=A.+Stratigosauthor=H.+Pehambergerauthor=A.+Eggermont&title=Diagnosis+and+treatment+of+melanoma%3A+European+consensus-based+interdisciplinary+guideline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DPeris%26aufirst%3DK.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DSaiag%26aufirst%3DP.%26aulast%3DMiddleton%26aufirst%3DM.%26aulast%3DSpatz%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DMalvehy%26aufirst%3DJ.%26aulast%3DNewton-Bishop%26aufirst%3DJ.%26aulast%3DStratigos%26aufirst%3DA.%26aulast%3DPehamberger%26aufirst%3DH.%26aulast%3DEggermont%26aufirst%3DA.%26atitle%3DDiagnosis%2520and%2520treatment%2520of%2520melanoma%253A%2520European%2520consensus-based%2520interdisciplinary%2520guideline%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2010%26volume%3D46%26spage%3D270%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiter, U.</span><span> </span><span class="NLM_article-title">Melanoma epidemiology and trends</span> <span class="citation_source-journal">Clin. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1016%2Fj.clindermatol.2008.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=19095149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FktVKjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=3-9&author=C.+Garbeauthor=U.+Leiter&title=Melanoma+epidemiology+and+trends"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Melanoma epidemiology and trends</span></div><div class="casAuthors">Garbe Claus; Leiter Ulrike</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in dermatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Rising incidence rates of cutaneous melanoma have been observed during the last four decades in white populations worldwide.  The cancer statistics in the United States have revealed 6 cases per 100,000 and year at the beginning of the 1970s and 18 cases per 100,000 inhabitants and year at the beginning of 2000, demonstrating a threefold increase in incidence rates.  Incidence rates in central Europe increased in the same time period from 3 to 4 cases to 10 to 15 cases per 100,000 inhabitants and year, which is very similar to the increase in the United States.  Cohort studies from several countries indicate that the trend of increasing incidence rates will continue in the future for at least the next 2 decades; thus, an additional doubling of incidence rates is expected.  The highest incidence rates have been reported from Australia and New Zealand, from 40 to 60 cases per 100,000 inhabitants and year.  Mortality rates likewise slightly increased in the United States and in Europe during the 1970s and 1980s.  In the 1990 s, however, a leveling off of mortality rates was observed in many countries.  Simultaneously, a clear decrease of Breslow tumor thickness was reported in the United States and European countries.  This development indicates improved early recognition of cutaneous melanoma, which is presently the main factor for a more favorable prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPuKSLi1S0zYHWj6b1v8uTfW6udTcc2eZRWRhbF_L5sLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FktVKjug%253D%253D&md5=e740ba030ce6a0e2a9135db1a1e7f752</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.clindermatol.2008.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clindermatol.2008.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DLeiter%26aufirst%3DU.%26atitle%3DMelanoma%2520epidemiology%2520and%2520trends%26jtitle%3DClin.%2520Dermatol.%26date%3D2009%26volume%3D27%26spage%3D3%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Jennings, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, G. M.</span><span> </span><span class="NLM_article-title">Predicting outcome in melanoma: Where are we now?</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">496</span><span class="NLM_x">–</span> <span class="NLM_lpage">503</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1111%2Fj.1365-2133.2009.09324.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=496-503&author=L.+Jenningsauthor=G.+M.+Murphy&title=Predicting+outcome+in+melanoma%3A+Where+are+we+now%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2009.09324.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2009.09324.x%26sid%3Dliteratum%253Aachs%26aulast%3DJennings%26aufirst%3DL.%26aulast%3DMurphy%26aufirst%3DG.%2BM.%26atitle%3DPredicting%2520outcome%2520in%2520melanoma%253A%2520Where%2520are%2520we%2520now%253F%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2009%26volume%3D16%26spage%3D496%26epage%3D503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Balch, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gershenwald, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soong, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzaid, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochran, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coit, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimotty, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMasters, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihm, M. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sober, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondak, V. K.</span><span> </span><span class="NLM_article-title">Final version of 2009 AJCC melanoma staging and classification</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">6199</span><span class="NLM_x">–</span> <span class="NLM_lpage">6206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1200%2FJCO.2009.23.4799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=19917835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BD1MfivFaquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=6199-6206&author=C.+M.+Balchauthor=J.+E.+Gershenwaldauthor=S.+J.+Soongauthor=J.+F.+Thompsonauthor=M.+B.+Atkinsauthor=D.+R.+Byrdauthor=A.+C.+Buzaidauthor=A.+J.+Cochranauthor=D.+G.+Coitauthor=S.+Dingauthor=A.+M.+Eggermontauthor=K.+T.+Flahertyauthor=P.+A.+Gimottyauthor=J.+M.+Kirkwoodauthor=K.+M.+McMastersauthor=M.+C.+Mihmauthor=D.+L.+Mortonauthor=M.+I.+Rossauthor=A.+J.+Soberauthor=V.+K.+Sondak&title=Final+version+of+2009+AJCC+melanoma+staging+and+classification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Final version of 2009 AJCC melanoma staging and classification</span></div><div class="casAuthors">Balch Charles M; Gershenwald Jeffrey E; Soong Seng-Jaw; Thompson John F; Atkins Michael B; Byrd David R; Buzaid Antonio C; Cochran Alistair J; Coit Daniel G; Ding Shouluan; Eggermont Alexander M; Flaherty Keith T; Gimotty Phyllis A; Kirkwood John M; McMasters Kelly M; Mihm Martin C Jr; Morton Donald L; Ross Merrick I; Sober Arthur J; Sondak Vernon K</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">6199-206</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To revise the staging system for cutaneous melanoma on the basis of data from an expanded American Joint Committee on Cancer (AJCC) Melanoma Staging Database.  METHODS:  The melanoma staging recommendations were made on the basis of a multivariate analysis of 30,946 patients with stages I, II, and III melanoma and 7,972 patients with stage IV melanoma to revise and clarify TNM classifications and stage grouping criteria.  RESULTS:  Findings and new definitions include the following: (1) in patients with localized melanoma, tumor thickness, mitotic rate (histologically defined as mitoses/mm(2)), and ulceration were the most dominant prognostic factors. (2) Mitotic rate replaces level of invasion as a primary criterion for defining T1b melanomas. (3) Among the 3,307 patients with regional metastases, components that defined the N category were the number of metastatic nodes, tumor burden, and ulceration of the primary melanoma. (4) For staging purposes, all patients with microscopic nodal metastases, regardless of extent of tumor burden, are classified as stage III.  Micrometastases detected by immunohistochemistry are specifically included. (5) On the basis of a multivariate analysis of patients with distant metastases, the two dominant components in defining the M category continue to be the site of distant metastases (nonvisceral v lung v all other visceral metastatic sites) and an elevated serum lactate dehydrogenase level.  CONCLUSION:  Using an evidence-based approach, revisions to the AJCC melanoma staging system have been made that reflect our improved understanding of this disease.  These revisions will be formally incorporated into the seventh edition (2009) of the AJCC Cancer Staging Manual and implemented by early 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQegqsO8SNrUbxh97K6Vt6fW6udTcc2eZRWRhbF_L5sLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MfivFaquw%253D%253D&md5=c4e7e8e046660cd903056a12cc8949f7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.23.4799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.23.4799%26sid%3Dliteratum%253Aachs%26aulast%3DBalch%26aufirst%3DC.%2BM.%26aulast%3DGershenwald%26aufirst%3DJ.%2BE.%26aulast%3DSoong%26aufirst%3DS.%2BJ.%26aulast%3DThompson%26aufirst%3DJ.%2BF.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26aulast%3DByrd%26aufirst%3DD.%2BR.%26aulast%3DBuzaid%26aufirst%3DA.%2BC.%26aulast%3DCochran%26aufirst%3DA.%2BJ.%26aulast%3DCoit%26aufirst%3DD.%2BG.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DGimotty%26aufirst%3DP.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DMcMasters%26aufirst%3DK.%2BM.%26aulast%3DMihm%26aufirst%3DM.%2BC.%26aulast%3DMorton%26aufirst%3DD.%2BL.%26aulast%3DRoss%26aufirst%3DM.%2BI.%26aulast%3DSober%26aufirst%3DA.%2BJ.%26aulast%3DSondak%26aufirst%3DV.%2BK.%26atitle%3DFinal%2520version%2520of%25202009%2520AJCC%2520melanoma%2520staging%2520and%2520classification%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D6199%26epage%3D6206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Scott, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinley, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trocha, S. D.</span><span> </span><span class="NLM_article-title">Treatment and outcomes of melanoma with a Breslow’s depth greater than or equal to one millimeter in a regional teaching hospital</span> <span class="citation_source-journal">Am. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=15869131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BD2M3jsVGmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2005&pages=198-201&author=J.+D.+Scottauthor=B.+P.+McKinleyauthor=A.+Bishopauthor=S.+D.+Trocha&title=Treatment+and+outcomes+of+melanoma+with+a+Breslow%E2%80%99s+depth+greater+than+or+equal+to+one+millimeter+in+a+regional+teaching+hospital"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment and outcomes of melanoma with a Breslow's depth greater than or equal to one millimeter in a regional teaching hospital</span></div><div class="casAuthors">Scott John D; McKinley Brian P; Bishop Aundie; Trocha Steven D</div><div class="citationInfo"><span class="NLM_cas:title">The American surgeon</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">198-201</span>
        ISSN:<span class="NLM_cas:issn">0003-1348</span>.
    </div><div class="casAbstract">Local control and regional lymph node evaluation are the primary treatment goals for cutaneous primary melanoma.  Historically, primary lesions were excised with large 3- to 5-cm radial margins.  Recent clinical trials have suggested that similar survival and recurrence rates can be achieved with smaller margins of excision.  In addition to excision of the primary lesion, the presence or absence of nodal metastasis is the single most powerful predictor of survival in patients with melanoma.  Based on the available trials, the standard of care for a melanoma 1 mm or greater in depth is a wide local excision with a 2-cm margin and a sentinel lymph node biopsy (SLNB).  The application of this standard in regional teaching hospitals is unknown.  We performed a retrospective review of a cancer registry at a teaching hospital in South Carolina.  This analysis included all patients who underwent surgery for melanoma at our institution between July 1997 and March 2003.  Our single inclusion criterion was that the primary melanoma had to be 1 mm or greater in depth.  Only 42 per cent of the patients underwent excision with a radial margin >2 cm, and only 60 per cent of the patients underwent SLNB.  As time progressed, the use of SLNB at our institution increased; but, even as late as 2003, some patients did not receive SLNB.  Adherence to standards did not appear to have an effect on overall survival.  In conclusion, the current standard for the treatment of invasive melanoma greater than or equal to 1 mm in thickness is a 2-cm margin of excision and a SLNB.  In this regional teaching hospital, surgical treatment and staging of melanoma did not strictly adhere to the standard.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdwdDDqecAz3O4gDb7JggCfW6udTcc2eahbn4tesZrV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3jsVGmtw%253D%253D&md5=4eb1b8868385e667c5a82b62c761b837</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DMcKinley%26aufirst%3DB.%2BP.%26aulast%3DBishop%26aufirst%3DA.%26aulast%3DTrocha%26aufirst%3DS.%2BD.%26atitle%3DTreatment%2520and%2520outcomes%2520of%2520melanoma%2520with%2520a%2520Breslow%25E2%2580%2599s%2520depth%2520greater%2520than%2520or%2520equal%2520to%2520one%2520millimeter%2520in%2520a%2520regional%2520teaching%2520hospital%26jtitle%3DAm.%2520Surg.%26date%3D2005%26volume%3D71%26spage%3D198%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Phan, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messina, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondak, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zager, J. S.</span><span> </span><span class="NLM_article-title">Sentinel lymph node biopsy for melanoma: Indications and rationale</span> <span class="citation_source-journal">Cancer Control.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">234</span><span class="NLM_x">–</span> <span class="NLM_lpage">239</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=234-239&author=G.+Q.+Phanauthor=J.+L.+Messinaauthor=V.+K.+Sondakauthor=J.+S.+Zager&title=Sentinel+lymph+node+biopsy+for+melanoma%3A+Indications+and+rationale"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPhan%26aufirst%3DG.%2BQ.%26aulast%3DMessina%26aufirst%3DJ.%2BL.%26aulast%3DSondak%26aufirst%3DV.%2BK.%26aulast%3DZager%26aufirst%3DJ.%2BS.%26atitle%3DSentinel%2520lymph%2520node%2520biopsy%2520for%2520melanoma%253A%2520Indications%2520and%2520rationale%26jtitle%3DCancer%2520Control.%26date%3D2009%26volume%3D16%26spage%3D234%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigentler, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilholz, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span> </span><span class="NLM_article-title">Systematic review of medical treatment in melanoma: Current status and future prospects</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=5-24&author=C.+Garbeauthor=T.+K.+Eigentlerauthor=U.+Keilholzauthor=A.+Hauschildauthor=J.+M.+Kirkwood&title=Systematic+review+of+medical+treatment+in+melanoma%3A+Current+status+and+future+prospects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DEigentler%26aufirst%3DT.%2BK.%26aulast%3DKeilholz%26aufirst%3DU.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26atitle%3DSystematic%2520review%2520of%2520medical%2520treatment%2520in%2520melanoma%253A%2520Current%2520status%2520and%2520future%2520prospects%26jtitle%3DOncologist%26date%3D2011%26volume%3D16%26spage%3D5%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Tarhini, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwala, S. S.</span><span> </span><span class="NLM_article-title">Cutaneous melanoma: Available therapy for metastatic disease</span> <span class="citation_source-journal">Dermatol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1111%2Fj.1529-8019.2005.00052.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=16405566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FhvF2qsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=19-25&author=A.+A.+Tarhiniauthor=S.+S.+Agarwala&title=Cutaneous+melanoma%3A+Available+therapy+for+metastatic+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cutaneous melanoma: available therapy for metastatic disease</span></div><div class="casAuthors">Tarhini Ahmad A; Agarwala Sanjiv S</div><div class="citationInfo"><span class="NLM_cas:title">Dermatologic therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-25</span>
        ISSN:<span class="NLM_cas:issn">1396-0296</span>.
    </div><div class="casAbstract">Survival of melanoma varies widely by stage, from a potentially highly curable disease when detected in early stages, to a disease with dismal prognosis when it reaches advanced inoperable stages.  Stage IV melanoma defines distant metastasis and continues to comprise an ominous prognosis, with a median survival of 6-9 months.  Currently, there is no therapeutic agent known to prolong survival in patients with metastatic melanoma.  Therapeutic approaches studied in metastatic melanoma include chemotherapy, biochemotherapy, nonspecific immune adjuvants, cancer-specific vaccines, cytokines, monoclonal antibodies, and specific immunostimulants.  Chemotherapy with single-agent dacarbazine is the only United States Food and Drug Administration (US-FDA)-approved chemotherapy agent for metastatic melanoma.  Immunological approaches have yielded the only newly US-FDA-approved agent for metastatic disease in 30 years, high-dose bolus IL-2, based on durable responses in some patients with metastatic melanoma, but with associated high toxicity rate and cost.  A number of novel therapeutic agents are undergoing active clinical investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROWnqd8D7PepI8NvIb08rbfW6udTcc2eahbn4tesZrV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FhvF2qsA%253D%253D&md5=7fe340f6a6a28d6e7d2007467658be90</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1529-8019.2005.00052.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1529-8019.2005.00052.x%26sid%3Dliteratum%253Aachs%26aulast%3DTarhini%26aufirst%3DA.%2BA.%26aulast%3DAgarwala%26aufirst%3DS.%2BS.%26atitle%3DCutaneous%2520melanoma%253A%2520Available%2520therapy%2520for%2520metastatic%2520disease%26jtitle%3DDermatol.%2520Ther.%26date%3D2006%26volume%3D19%26spage%3D19%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigentler, T. K.</span><span> </span><span class="NLM_article-title">Diagnosis and treatment of cutaneous melanoma: State of the art 2006</span> <span class="citation_source-journal">Melanoma Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1097%2FCMR.0b013e328042bb36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=17496787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BD2s3pt12rtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=117-127&author=C.+Garbeauthor=T.+K.+Eigentler&title=Diagnosis+and+treatment+of+cutaneous+melanoma%3A+State+of+the+art+2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosis and treatment of cutaneous melanoma: state of the art 2006</span></div><div class="casAuthors">Garbe Claus; Eigentler Thomas K</div><div class="citationInfo"><span class="NLM_cas:title">Melanoma research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-27</span>
        ISSN:<span class="NLM_cas:issn">0960-8931</span>.
    </div><div class="casAbstract">Although the incidence of melanoma is still rising in Caucasian populations, the increase in mortality has leveled off.  Improvements in early diagnosis, with more frequent diagnosis of low-risk patients (i.e. those with <1 mm of tumor thickness), is the main reason for these divergent developments.  Primary prevention has not yet been successful and recent studies have demonstrated the lack of effectiveness of sunscreen in preventing nevi in children.  Progress was made in early melanoma diagnosis when dermoscopy and digital dermoscopy were introduced, and computer algorithms have proved to be highly efficacious for automated melanoma diagnosis.  Primary melanomas are now excised with narrower surgical margins of 1-2 cm.  Sentinel-node biopsy is recommended as a nodal staging procedure in patients with tumor thickness of 1 mm and more, but the prognostic impact of this procedure has not yet been demonstrated.  New imaging techniques, e.g. whole-body MRI and PET-CT, provide more accurate staging, particularly in patients with apparent metastasis, and facilitate decisions on surgical treatment strategies.  Staging is now based on the 2001 TNM classification including tumor thickness and histopathologic ulceration in stages I and II and lymph node micro and macro-metastasis in stage III.  A stage- and risk-adopted follow-up schedule is proposed for melanoma surveillance.  Adjuvant therapy with interferon-alpha in high-risk patients offers a small benefit in terms of recurrence-free and overall survival; the optimal dosage and duration of this treatment are still to be defined.  Almost no progress has been made in the medical treatment of disseminated metastasis of melanoma.  Therapy with dacarbazine and a few other single agents remains the first-line treatment approach of choice.  A number of new treatment modalities, including targeted molecules and immunologic approaches with monoclonal antibodies, are under development; hopefully, new treatment modalities will be available in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3xPhuLOo0mgpJitSxOdIlfW6udTcc2eahbn4tesZrV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3pt12rtw%253D%253D&md5=84dc2d5b958d4a888152168370f4b44d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1097%2FCMR.0b013e328042bb36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCMR.0b013e328042bb36%26sid%3Dliteratum%253Aachs%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DEigentler%26aufirst%3DT.%2BK.%26atitle%3DDiagnosis%2520and%2520treatment%2520of%2520cutaneous%2520melanoma%253A%2520State%2520of%2520the%2520art%25202006%26jtitle%3DMelanoma%2520Res.%26date%3D2007%26volume%3D17%26spage%3D117%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Punt, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suciu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruit, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lienard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilholz, U.</span><span> </span><span class="NLM_article-title">Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">2991</span><span class="NLM_x">–</span> <span class="NLM_lpage">2995</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=2991-2995&author=C.+J.+Puntauthor=S.+Suciuauthor=M.+A.+Goreauthor=J.+Kollerauthor=W.+H.+Kruitauthor=J.+Thomasauthor=P.+Patelauthor=D.+Lienardauthor=A.+M.+Eggermontauthor=U.+Keilholz&title=Chemoimmunotherapy+with+dacarbazine%2C+cisplatin%2C+interferon-alpha2b+and+interleukin-2+versus+two+cycles+of+dacarbazine+followed+by+chemoimmunotherapy+in+patients+with+metastatic+melanoma%3A+A+randomised+phase+II+study+of+the+European+Organization+for+Research+and+Treatment+of+Cancer+Melanoma+Group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPunt%26aufirst%3DC.%2BJ.%26aulast%3DSuciu%26aufirst%3DS.%26aulast%3DGore%26aufirst%3DM.%2BA.%26aulast%3DKoller%26aufirst%3DJ.%26aulast%3DKruit%26aufirst%3DW.%2BH.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DLienard%26aufirst%3DD.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DKeilholz%26aufirst%3DU.%26atitle%3DChemoimmunotherapy%2520with%2520dacarbazine%252C%2520cisplatin%252C%2520interferon-alpha2b%2520and%2520interleukin-2%2520versus%2520two%2520cycles%2520of%2520dacarbazine%2520followed%2520by%2520chemoimmunotherapy%2520in%2520patients%2520with%2520metastatic%2520melanoma%253A%2520A%2520randomised%2520phase%2520II%2520study%2520of%2520the%2520European%2520Organization%2520for%2520Research%2520and%2520Treatment%2520of%2520Cancer%2520Melanoma%2520Group%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26spage%3D2991%26epage%3D2995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">O’Day, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loquai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutzmer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trefzer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottensmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Boer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hait, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P.</span><span> </span><span class="NLM_article-title">A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1038%2Fbjc.2011.183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=21750555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlOru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=346-352&author=S.+O%E2%80%99Dayauthor=A.+Pavlickauthor=C.+Loquaiauthor=D.+Lawsonauthor=R.+Gutzmerauthor=J.+Richardsauthor=D.+Schadendorfauthor=J.+A.+Thompsonauthor=R.+Gonzalezauthor=U.+Trefzerauthor=P.+Mohrauthor=C.+Ottensmeierauthor=D.+Chaoauthor=B.+Zhongauthor=C.+J.+de+Boerauthor=C.+Uhlarauthor=D.+Marshallauthor=M.+E.+Goreauthor=Z.+Langauthor=W.+Haitauthor=P.+Ho&title=A+randomised%2C+phase+II+study+of+intetumumab%2C+an+anti-%CE%B1v-integrin+mAb%2C+alone+and+with+dacarbazine+in+stage+IV+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma</span></div><div class="casAuthors">O'Day, S.; Pavlick, A.; Loquai, C.; Lawson, D.; Gutzmer, R.; Richards, J.; Schadendorf, D.; Thompson, J. A.; Gonzalez, R.; Trefzer, U.; Mohr, P.; Ottensmeier, C.; Chao, D.; Zhong, B.; de Boer, C. J.; Uhlar, C.; Marshall, D.; Gore, M. E.; Lang, Z.; Hait, W.; Ho, P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">346-352</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: αv integrins are involved in angiogenesis and melanoma tumorigenesis.  Intetumumab (CNTO 95) is a fully human anti-αv-integrin monoclonal antibody.  Methods: In a multicentre, randomized, phase II study, stage IV melanoma patients were randomized 1:1:1:1 to 1000 mg m-2 dacarbazine+placebo (n=32), 1000 mg m-2 dacarbazine+10 mg kg-1 intetumumab (n=32), 10 mg kg-1 intetumumab (n=33), or 5 mg kg-1 intetumumab (n=32) q3w.  The primary endpoint was progression-free survival (PFS).  Secondary endpoints included overall survival (OS), objective response rate (ORR), adverse events, and pharmacokinetics.  Results: No statistically significant differences in efficacy were obsd. between groups.  In the dacarbazine+placebo, dacarbazine+intetumumab, 10 mg kg-1 intetumumab, and 5 mg kg-1 intetumumab groups, median PFS was 1.8, 2.5, 1.4, and 1.4 mo; median OS was 8, 11, 15, and 9.8 mo; and ORR of complete+partial response was 10, 3, 6, and 0%.  Nonlinear intetumumab pharmacokinetics and potential intetumumab-dacarbazine interactions were obsd.  Transient, asymptomatic, nonrecurring, grade 1-2, uveitic reactions that resolved spontaneously or with topical steroids were seen in 22-30% of intetumumab-treated patients.  Low-grade infusion-reaction symptoms (headache, fatigue, nausea, vomiting, fever, chills) were obsd., as expected, in 16-73% of dacarbazine-treated patients.  No intetumumab-related myelosuppression, lab./ECG abnormalities, or deaths occurred.  Conclusion: With its favorable safety profile and a nonsignificant trend towards improved OS, intetumumab merits further investigation in advanced melanoma.  British Journal of Cancer (2011) 105, 346-352; doi:10.1038/bjc.2011.183 www.bjcancer.com Published online 12 July 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH1_VG9tlMO7Vg90H21EOLACvtfcHk0liZt1Cv4A0rRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlOru78%253D&md5=a5f2ce3b20b110d5b0b8a115b7878ccb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.183%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%26aulast%3DPavlick%26aufirst%3DA.%26aulast%3DLoquai%26aufirst%3DC.%26aulast%3DLawson%26aufirst%3DD.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DRichards%26aufirst%3DJ.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DTrefzer%26aufirst%3DU.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DOttensmeier%26aufirst%3DC.%26aulast%3DChao%26aufirst%3DD.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3Dde%2BBoer%26aufirst%3DC.%2BJ.%26aulast%3DUhlar%26aufirst%3DC.%26aulast%3DMarshall%26aufirst%3DD.%26aulast%3DGore%26aufirst%3DM.%2BE.%26aulast%3DLang%26aufirst%3DZ.%26aulast%3DHait%26aufirst%3DW.%26aulast%3DHo%26aufirst%3DP.%26atitle%3DA%2520randomised%252C%2520phase%2520II%2520study%2520of%2520intetumumab%252C%2520an%2520anti-%25CE%25B1v-integrin%2520mAb%252C%2520alone%2520and%2520with%2520dacarbazine%2520in%2520stage%2520IV%2520melanoma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2011%26volume%3D105%26spage%3D346%26epage%3D352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Attia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phan, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maker, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quezado, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherry, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topalian, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kammula, U. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royal, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Restifo, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haworth, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mavroukakis, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichol, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yellin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. A.</span><span> </span><span class="NLM_article-title">Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-CTLA4</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">6043</span><span class="NLM_x">–</span> <span class="NLM_lpage">6053</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1200%2FJCO.2005.06.205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=16087944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKgtb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=6043-6053&author=P.+Attiaauthor=G.+Q.+Phanauthor=A.+V.+Makerauthor=M.+R.+Robinsonauthor=M.+M.+Quezadoauthor=J.+C.+Yangauthor=R.+M.+Sherryauthor=S.+L.+Topalianauthor=U.+S.+Kammulaauthor=R.+E.+Royalauthor=N.+P.+Restifoauthor=L.+R.+Haworthauthor=C.+Levyauthor=S.+A.+Mavroukakisauthor=G.+Nicholauthor=M.+J.+Yellinauthor=S.+A.+Rosenberg&title=Autoimmunity+correlates+with+tumor+regression+in+patients+with+metastatic+melanoma+treated+with+anti-CTLA4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4</span></div><div class="casAuthors">Attia, Peter; Phan, Giao Q.; Maker, Ajay V.; Robinson, Michael R.; Quezado, Martha M.; Yang, James C.; Sherry, Richard M.; Topalian, Suzanne L.; Kammula, Udai S.; Royal, Richard E.; Restifo, Nicholas P.; Haworth, Leah R.; Levy, Catherine; Mavroukakis, Sharon A.; Nichol, Geoff; Yellin, Michael J.; Rosenberg, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6043-6053</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Previously, we reported our experience treating 14 patients with metastatic melanoma using a fully human antibody to cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) in conjunction with peptide vaccination.  We have now treated 56 patients to evaluate two different dose schedules of anti-CTLA-4 and to explore the relationship between autoimmunity and tumor regression.  Patients and Methods: A total of 56 patients with progressive stage IV melanoma were enrolled onto the study.  All had Karnofsky performance status ≥ 60% with no prior history of autoimmunity.  Twenty-nine patients received 3 mg/kg anti-CTLA-4 every 3 wk, whereas 27 received 3 mg/kg as their initial dose with subsequent doses reduced to 1 mg/kg every 3 wk.  In both cohorts patients received concomitant vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-assocd. antigen, gp100:209-217(210M) and gp100:280-288(288V).  Results: Two patients achieved a complete response (ongoing at 30 and 31 mo, resp.) and five patients achieved a partial response (durations of 4, 6, 25+, 26+, and 34+ months, resp.), for an overall objective response rate of 13%.  Tumor regression was seen in lung, liver, brain, lymph nodes, and s.c. sites.  Of 14 patients with grade 3/4 autoimmune toxicity, five (36%) experienced a clin. response compared with only two responses in the 42 patients (5%) with no autoimmune toxicity (P = .008).  There were no significant differences in response rate or toxicity between the two dose schedules.  Conclusion: Administration of anti-CTLA-4 monoclonal antibody plus peptide vaccination can cause durable objective responses, which correlate with the induction of autoimmunity, in patients with metastatic melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxb94fysv4CbVg90H21EOLACvtfcHk0liZt1Cv4A0rRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKgtb3L&md5=7daaac6d96ba23e275e9538f1210bcb3</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.06.205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.06.205%26sid%3Dliteratum%253Aachs%26aulast%3DAttia%26aufirst%3DP.%26aulast%3DPhan%26aufirst%3DG.%2BQ.%26aulast%3DMaker%26aufirst%3DA.%2BV.%26aulast%3DRobinson%26aufirst%3DM.%2BR.%26aulast%3DQuezado%26aufirst%3DM.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DSherry%26aufirst%3DR.%2BM.%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DKammula%26aufirst%3DU.%2BS.%26aulast%3DRoyal%26aufirst%3DR.%2BE.%26aulast%3DRestifo%26aufirst%3DN.%2BP.%26aulast%3DHaworth%26aufirst%3DL.%2BR.%26aulast%3DLevy%26aufirst%3DC.%26aulast%3DMavroukakis%26aufirst%3DS.%2BA.%26aulast%3DNichol%26aufirst%3DG.%26aulast%3DYellin%26aufirst%3DM.%2BJ.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26atitle%3DAutoimmunity%2520correlates%2520with%2520tumor%2520regression%2520in%2520patients%2520with%2520metastatic%2520melanoma%2520treated%2520with%2520anti-CTLA4%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D6043%26epage%3D6053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0ljkqzaIHHYVyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Xing, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cromwell, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cormier, J. N.</span><span> </span><span class="NLM_article-title">Review of diagnostic imaging modalities for the surveillance of melanoma patients</span> <span class="citation_source-journal">Dermatol. Res. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span><span class="NLM_elocation-id">941921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BC3MjpslKnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=Y.+Xingauthor=K.+D.+Cromwellauthor=J.+N.+Cormier&title=Review+of+diagnostic+imaging+modalities+for+the+surveillance+of+melanoma+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Review of diagnostic imaging modalities for the surveillance of melanoma patients</span></div><div class="casAuthors">Xing Yan; Cromwell Kate D; Cormier Janice N</div><div class="citationInfo"><span class="NLM_cas:title">Dermatology research and practice</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">941921</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As melanoma survival rates continue to increase, optimal surveillance strategies for recurrences are needed, as are effective imaging modalities.  Therefore, we performed a meta-analysis to evaluate the current state of imaging modalities for surveillance of melanoma in the published medical literature to determine the sensitivity, specificity, and positive predictive values of ultrasonography, computed tomography (CT), positron emission tomography (PET), and CT-PET combined.  Ultrasonography was found to be the most sensitive and specific for detecting lymph node metastases, and PET-CT was the most sensitive and specific for detecting distant metastases.  In addition to identifying appropriate surveillance methods, future studies should focus on the most effective and cost-effective intervals for performing these tests.  In addition, the results from the meta-analysis related to sensitivity and specificity of the tests should be made available to doctors in community practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1jHmAg29Abi-bLEOO4dYpfW6udTcc2eYdNeiXG6qU6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjpslKnsA%253D%253D&md5=60ae36a57f98a807bf5f402f5d452cd8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DY.%26aulast%3DCromwell%26aufirst%3DK.%2BD.%26aulast%3DCormier%26aufirst%3DJ.%2BN.%26atitle%3DReview%2520of%2520diagnostic%2520imaging%2520modalities%2520for%2520the%2520surveillance%2520of%2520melanoma%2520patients%26jtitle%3DDermatol.%2520Res.%2520Pract.%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Krug, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonneux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baurain, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vander Borght, T.</span><span> </span><span class="NLM_article-title">Role of PET in the initial staging of cutaneous malignant melanoma: Systematic review</span> <span class="citation_source-journal">Radiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">249</span><span class="NLM_x">, </span> <span class="NLM_fpage">836</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=249&publication_year=2008&pages=836-844&author=B.+Krugauthor=R.+Crottauthor=M.+Lonneuxauthor=J.+F.+Baurainauthor=A.+S.+Pirsonauthor=T.+Vander+Borght&title=Role+of+PET+in+the+initial+staging+of+cutaneous+malignant+melanoma%3A+Systematic+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrug%26aufirst%3DB.%26aulast%3DCrott%26aufirst%3DR.%26aulast%3DLonneux%26aufirst%3DM.%26aulast%3DBaurain%26aufirst%3DJ.%2BF.%26aulast%3DPirson%26aufirst%3DA.%2BS.%26aulast%3DVander%2BBorght%26aufirst%3DT.%26atitle%3DRole%2520of%2520PET%2520in%2520the%2520initial%2520staging%2520of%2520cutaneous%2520malignant%2520melanoma%253A%2520Systematic%2520review%26jtitle%3DRadiology%26date%3D2008%26volume%3D249%26spage%3D836%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Veit-Haibach, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogt, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jablonka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuehl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bockisch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahmen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoch, G.</span><span> </span><span class="NLM_article-title">Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma</span> <span class="citation_source-journal">Eur. J. Nucl. Med. Mol. Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">910</span><span class="NLM_x">–</span> <span class="NLM_lpage">918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1007%2Fs00259-008-1049-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=19156409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BD1MzjtValtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=910-918&author=P.+Veit-Haibachauthor=F.+M.+Vogtauthor=R.+Jablonkaauthor=H.+Kuehlauthor=A.+Bockischauthor=T.+Beyerauthor=G.+Dahmenauthor=S.+Rosenbaumauthor=G.+Antoch&title=Diagnostic+accuracy+of+contrast-enhanced+FDG-PET%2FCT+in+primary+staging+of+cutaneous+malignant+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma</span></div><div class="casAuthors">Veit-Haibach Patrick; Vogt Florian M; Jablonka Robert; Kuehl Hilmar; Bockisch Andreas; Beyer Thomas; Dahmen Gerlinde; Rosenbaum Sandra; Antoch Gerald</div><div class="citationInfo"><span class="NLM_cas:title">European journal of nuclear medicine and molecular imaging</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">910-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To evaluate the diagnostic accuracy of contrast-enhanced FDG-PET/CT (ce-PET/CT), PET-only, and CT-only in patients with newly diagnosed and resected cutaneous malignant melanoma.  METHODS:  A final group of 56 patients (mean age 62 years, range 23-86 years; 29 women, 27 men) were staged with ce-PET/CT after resection of the primary tumour.  Histopathology as well as clinical follow-up (mean 780 days, range 102-1,390 days) served as the standards of reference.  Differences between the staging modalities were tested for statistical significance with McNemar's test.  RESULTS:  All imaging procedures provided low sensitivities in the detection of lymph nodes (sensitivity N-stage: PET/CT and PET-only 38.5%; CT-only 23.1%) and distant metastases (sensitivity M-stage: PET/CT 41.7%, PET-only 33.3%, CT-only 25.0%) in initial staging after resection of the primary tumour.  No statistically significant differences were detected between the imaging procedures (p > 0.05).  PET/CT resulted in an alteration in further treatment in two patients compared to PET-only and in four patients compared to CT-only.  CONCLUSION:  All imaging modalities had a low sensitivity on initial staging of patients with malignant melanoma.  Thus, close patient follow-up must be considered mandatory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkiCuZ-WEFgySm0e6ZOaemfW6udTcc2eYdNeiXG6qU6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzjtValtw%253D%253D&md5=8453d33e91dd9a35a0c26254d0e3bf4b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs00259-008-1049-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-008-1049-x%26sid%3Dliteratum%253Aachs%26aulast%3DVeit-Haibach%26aufirst%3DP.%26aulast%3DVogt%26aufirst%3DF.%2BM.%26aulast%3DJablonka%26aufirst%3DR.%26aulast%3DKuehl%26aufirst%3DH.%26aulast%3DBockisch%26aufirst%3DA.%26aulast%3DBeyer%26aufirst%3DT.%26aulast%3DDahmen%26aufirst%3DG.%26aulast%3DRosenbaum%26aufirst%3DS.%26aulast%3DAntoch%26aufirst%3DG.%26atitle%3DDiagnostic%2520accuracy%2520of%2520contrast-enhanced%2520FDG-PET%252FCT%2520in%2520primary%2520staging%2520of%2520cutaneous%2520malignant%2520melanoma%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2009%26volume%3D36%26spage%3D910%26epage%3D918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Mirk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salsano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basile, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonomo, L.</span><span> </span><span class="NLM_article-title">Comparison between <sup>18</sup>F-Fluorodeoxyglucose positron emission tomography and sentinel lymph node biopsy for regional lymph nodal staging in patients with melanoma: A review of the literature</span> <span class="citation_source-journal">Radiol. Res. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span><span class="NLM_elocation-id">912504</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BC387kt1artQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=P.+Mirkauthor=G.+Tregliaauthor=M.+Salsanoauthor=P.+Basileauthor=A.+Giordanoauthor=L.+Bonomo&title=Comparison+between+18F-Fluorodeoxyglucose+positron+emission+tomography+and+sentinel+lymph+node+biopsy+for+regional+lymph+nodal+staging+in+patients+with+melanoma%3A+A+review+of+the+literature"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison between F-Fluorodeoxyglucose Positron Emission Tomography and Sentinel Lymph Node Biopsy for Regional Lymph Nodal Staging in Patients with Melanoma: A Review of the Literature</span></div><div class="casAuthors">Mirk Paoletta; Treglia Giorgio; Salsano Marco; Basile Pietro; Giordano Alessandro; Bonomo Lorenzo</div><div class="citationInfo"><span class="NLM_cas:title">Radiology research and practice</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">912504</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aim. to compare (18)F-Fluorodeoxyglucose positron emission tomography (FDG-PET) to sentinel lymph node biopsy (SLNB) for regional lymph nodal staging in patients with melanoma.  Methods.  We performed a literature review discussing original articles which compared FDG-PET to SLNB for regional lymph nodal staging in patients with melanoma.  Results and Conclusions.  There is consensus in the literature that FDG-PET cannot replace SLNB for regional lymph nodal staging in patients with melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqkqTRv89izn6oPH0mYWL1fW6udTcc2eYwwOz8da5Znbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387kt1artQ%253D%253D&md5=f4ccde3a2a8e0da686c87de708200c14</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMirk%26aufirst%3DP.%26aulast%3DTreglia%26aufirst%3DG.%26aulast%3DSalsano%26aufirst%3DM.%26aulast%3DBasile%26aufirst%3DP.%26aulast%3DGiordano%26aufirst%3DA.%26aulast%3DBonomo%26aufirst%3DL.%26atitle%3DComparison%2520between%252018F-Fluorodeoxyglucose%2520positron%2520emission%2520tomography%2520and%2520sentinel%2520lymph%2520node%2520biopsy%2520for%2520regional%2520lymph%2520nodal%2520staging%2520in%2520patients%2520with%2520melanoma%253A%2520A%2520review%2520of%2520the%2520literature%26jtitle%3DRadiol.%2520Res.%2520Pract.%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Jiménez-Requena, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delgado-Bolton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Pérez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambhir, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwimmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Vasquez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreras-Delgado, J. L.</span><span> </span><span class="NLM_article-title">Meta-analysis of the performance of <sup>18</sup>F-FDG PET in cutaneous melanoma</span> <span class="citation_source-journal">Eur. J. Nucl. Med. Mol. Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1007%2Fs00259-009-1224-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=19727717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FotFCqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=284-300&author=F.+Jim%C3%A9nez-Requenaauthor=R.+C.+Delgado-Boltonauthor=C.+Fernandez-P%C3%A9rezauthor=S.+S.+Gambhirauthor=J.+Schwimmerauthor=J.+M.+P%C3%A9rez-Vasquezauthor=J.+L.+Carreras-Delgado&title=Meta-analysis+of+the+performance+of+18F-FDG+PET+in+cutaneous+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma</span></div><div class="casAuthors">Jimenez-Requena Felisa; Delgado-Bolton Roberto C; Fernandez-Perez Cristina; Gambhir Sanjiv S; Schwimmer Judy; Perez-Vazquez Jose M; Carreras-Delgado Jose L</div><div class="citationInfo"><span class="NLM_cas:title">European journal of nuclear medicine and molecular imaging</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">284-300</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  The aim of this study was to perform a systematic review of the literature to evaluate the accuracy of FDG-PET in staging and restaging of cutaneous melanoma.  METHODS:  Systematic methods were used to identify, select, and evaluate the methodologic quality of the studies as well as to summarize the overall findings of sensitivity and specificity.  The search strategy consisted of identifying studies published between 2000 and 2006.  Inclusion criteria were studies that evaluated the diagnostic performance of FDG-PET in staging/restaging of cutaneous melanoma.  The results were compared and pooled with a meta-analysis published previously that included studies published until 1999.  The meta-analysis included 95% confidence intervals (CI) of sensitivity, specificity, likelihood-ratio (LR), and diagnostic-odds-ratio (DOR).  RESULTS:  The quantitative meta-analysis included 24 studies that were analysed in two groups: eight studies were included only in the regional staging analysis (group I), 13 studies were included only in the detection of distant metastases analysis (group II), and three studies were included in both analyses.  Compliance with the methodologic-quality criteria was acceptable.  We analysed the results of data presented in patients, lesions, basins, lymph-nodes, areas, and scans.  Regarding the performance of FDG-PET in the detection of metastases, the pooled studies presented homogeneity for the negative-LR (0.15; 95% CI, 0.10-0.22) when analyzing lesions.  When analyzing scans, there was global homogeneity for specificity (0.86; 95% CI, 0.77-0.92), positive-LR (5.86; 95% CI, 3.64-9.43), and DOR (37.89; 95% CI, 15.80-90.86).  The pooled studies presented heterogeneity for the other items analysed.  Regarding the detection of regional metastases, when analyzing lymph-nodes there was global homogeneity for specificity (0.99; 95% CI, 0.97-0.99; P = 0.101).  The meta-regression evidenced that the variable that most influenced the DOR of the different studies and that can explain the heterogeneity was the year of publication; this may be related to the evolution of PET technology and an improvement of sensitivity/specificity.  CONCLUSION:  FDG-PET is not useful in the evaluation of regional metastases, as it does not detect microscopic disease.  However, FDG-PET could be useful in the detection of distant metastases, and could suggest its utility in the management of patients with cutaneous melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8sCIMQI56vkH3Rlp_k91zfW6udTcc2eYwwOz8da5Znbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FotFCqsg%253D%253D&md5=d7b0a340299feaa670b0dfc4d979f173</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs00259-009-1224-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-009-1224-8%26sid%3Dliteratum%253Aachs%26aulast%3DJim%25C3%25A9nez-Requena%26aufirst%3DF.%26aulast%3DDelgado-Bolton%26aufirst%3DR.%2BC.%26aulast%3DFernandez-P%25C3%25A9rez%26aufirst%3DC.%26aulast%3DGambhir%26aufirst%3DS.%2BS.%26aulast%3DSchwimmer%26aufirst%3DJ.%26aulast%3DP%25C3%25A9rez-Vasquez%26aufirst%3DJ.%2BM.%26aulast%3DCarreras-Delgado%26aufirst%3DJ.%2BL.%26atitle%3DMeta-analysis%2520of%2520the%2520performance%2520of%252018F-FDG%2520PET%2520in%2520cutaneous%2520melanoma%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2010%26volume%3D37%26spage%3D284%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Wagner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerdoud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Julian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevreau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payoux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courbon, F.</span><span> </span><span class="NLM_article-title">Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">1235</span><span class="NLM_x">–</span> <span class="NLM_lpage">1240</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1111%2Fj.1365-2133.2011.10247.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=21332457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BC3Mrlt1CqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=1235-1240&author=T.+Wagnerauthor=N.+Meyerauthor=S.+Zerdoudauthor=A.+Julianauthor=C.+Chevreauauthor=P.+Payouxauthor=F.+Courbon&title=Fluorodeoxyglucose+positron+emission+tomography+fails+to+detect+distant+metastases+at+initial+staging+of+melanoma+patients+with+metastatic+involvement+of+sentinel+lymph+node"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node</span></div><div class="casAuthors">Wagner T; Meyer N; Zerdoud S; Julian A; Chevreau C; Payoux P; Courbon F</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of dermatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1235-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Positron emission tomography (PET) using fluorodeoxyglucose (FDG) has proven to be more sensitive and accurate than other imaging modalities for the detection of distant metastases in patients with melanoma.  Sentinel lymph node (SLN) status is the most important prognostic factor in melanoma patients with no evidence of distant metastasis.  OBJECTIVES:  To assess the rate of distant metastases in patients with a positive SLN biopsy (SLNB).  METHODS:  Forty-six consecutive patients with a positive SLNB underwent PET or PET-computed tomography within 6 weeks of the SLNB procedure.  The patients did not present any clinical sign of nodal involvement or of distant metastasis.  PET findings were classified as positive, negative or nonconclusive.  RESULTS:  No patient had a positive PET scan for distant metastasis.  Six patients (13%) had a nonconclusive PET scan; none of them presented distant metastasis within 12 months.  Forty patients (87%) had a negative PET scan; among them five (12%) presented with distant metastasis within 12 months.  CONCLUSIONS:  Fluorodeoxyglucose positron emission tomography failed to detect distant metastases at initial staging in patients with a positive SLNB, even in patients who presented with distant metastases within 12 months after the FDG PET scan.  These results could be explained by the low prevalence of macroscopic metastatic disease at this stage and by the important delay between the onset of the spread of microscopic metastatic disease and the identification by PET scan of macroscopic metastatic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnA1uipPWCys-crCu0nI_sfW6udTcc2eYwwOz8da5Znbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mrlt1CqtQ%253D%253D&md5=91097b6aa9a4ee4d2a2f52bf263f4984</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2011.10247.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2011.10247.x%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DMeyer%26aufirst%3DN.%26aulast%3DZerdoud%26aufirst%3DS.%26aulast%3DJulian%26aufirst%3DA.%26aulast%3DChevreau%26aufirst%3DC.%26aulast%3DPayoux%26aufirst%3DP.%26aulast%3DCourbon%26aufirst%3DF.%26atitle%3DFluorodeoxyglucose%2520positron%2520emission%2520tomography%2520fails%2520to%2520detect%2520distant%2520metastases%2520at%2520initial%2520staging%2520of%2520melanoma%2520patients%2520with%2520metastatic%2520involvement%2520of%2520sentinel%2520lymph%2520node%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2011%26volume%3D164%26spage%3D1235%26epage%3D1240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Minn, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vihinen, P.</span><span> </span><span class="NLM_article-title">Melanoma imaging with highly specific PET probes: Ready for prime time?</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=5-7&author=H.+Minnauthor=P.+Vihinen&title=Melanoma+imaging+with+highly+specific+PET+probes%3A+Ready+for+prime+time%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMinn%26aufirst%3DH.%26aulast%3DVihinen%26aufirst%3DP.%26atitle%3DMelanoma%2520imaging%2520with%2520highly%2520specific%2520PET%2520probes%253A%2520Ready%2520for%2520prime%2520time%253F%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2011%26volume%3D52%26spage%3D5%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Sturm, R. A.</span><span> </span><span class="NLM_article-title">Skin colour and skin cancer - MC1R, the genetic link</span> <span class="citation_source-journal">Melanoma Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1097%2F00008390-200209000-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=12394181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVOisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=405-416&author=R.+A.+Sturm&title=Skin+colour+and+skin+cancer+-+MC1R%2C+the+genetic+link"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Skin colour and skin cancer - MC1R, the genetic link</span></div><div class="casAuthors">Sturm, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Melanoma Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">405-416</span>CODEN:
                <span class="NLM_cas:coden">MREEEH</span>;
        ISSN:<span class="NLM_cas:issn">0960-8931</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Pigmentary traits such as red hair, fair skin, lack of tanning ability and propensity to freckle (the RHC phenotype) were identified as genetic risk factors for both melanoma and non-melanocytic skin cancers when combined with the environmental risk factor of high UV light exposure.  The human melanocortin-1 receptor (MC1R) is a key determinant of the pigmentation process and can account in large part for the diverse range of variation in human pigmentation phenotypes and skin phototypes.  The coding sequence is highly polymorphic in human populations, with several of these variant forms of the receptor now known to be assocd. with the RHC phenotype.  We have examd. MC1R variant allele frequencies in the general population and in a collection of adolescent dizygotic and monozygotic twins with defined pigmentation characteristics.  Variant allele frequencies were also detd. in several case-control studies of sporadic melanoma, basal cell carcinoma and squamous cell carcinoma, and in familial melanoma kindreds collected within Australia.  These studies have shown that 3 RHC alleles - Arg151Cys, Arg160Trp and Asp294His - were assocd. with increased risk in all forms of skin cancer and with penetrance and age of onset in familial melanoma in CDKN2A mutation carriers.  There is a significant RHC allele heterozygote carrier effect on skin phototype and skin cancer risk, which indicates that variant MC1R alleles do not behave in a strictly recessive manner.  Ultimately, the genetic and chem. assessment of melanin synthesis rather than skin color will be the best indicator for skin cancer risk, and such genetic assocn. studies combined with functional anal. of MC1R variant alleles should provide the link to understanding skin phototypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSlNKqRPktlbVg90H21EOLACvtfcHk0lhXS-aa4v-WlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVOisr4%253D&md5=3e7a370dc1b0e813addf3f1deca6e088</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1097%2F00008390-200209000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00008390-200209000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DSturm%26aufirst%3DR.%2BA.%26atitle%3DSkin%2520colour%2520and%2520skin%2520cancer%2520-%2520MC1R%252C%2520the%2520genetic%2520link%26jtitle%3DMelanoma%2520Res.%26date%3D2002%26volume%3D12%26spage%3D405%26epage%3D416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Miao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitener, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, T. P.</span><span> </span><span class="NLM_article-title">Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1177</span><span class="NLM_x">–</span> <span class="NLM_lpage">1184</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc034069i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlOmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2003&pages=1177-1184&author=Y.+Miaoauthor=D.+Whitenerauthor=W.+Fengauthor=N.+K.+Owenauthor=J.+Chenauthor=T.+P.+Quinn&title=Evaluation+of+the+human+melanoma+targeting+properties+of+radiolabeled+alpha-melanocyte+stimulating+hormone+peptide+analogues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the Human Melanoma Targeting Properties of Radiolabeled α-Melanocyte Stimulating Hormone Peptide Analogues</span></div><div class="casAuthors">Miao, Yubin; Whitener, Donna; Feng, Weiwei; Owen, Nellie K.; Chen, Jianqing; Quinn, Thomas P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1177-1184</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The purpose of this study was to evaluate the human MC1 receptor-mediated melanoma targeting properties of two metal cyclized α-MSH peptide analogs, 188Re-(Arg11)CCMSH and 188Re-CCMSH.  Initially, the presence and d. of the MC1 receptor were detd. on a bank of human melanoma cell lines.  All eight human melanoma cell lines tested in this study displayed the MC1 receptor at a d. of 900 to 5700 receptors per cell.  Receptor affinity and biodistribution properties of 188Re-(Arg11)CCMSH and 188Re-CCMSH were evaluated in a cultured TXM13 human melanoma-xenografted Scid mouse model.  Biodistribution results demonstrated that 3.06 ± 0.68 %ID/g of 188Re-(Arg11)CCMSH accumulated in the tumors 1 h postinjection and greater than 65% of the activity at 1 h postinjection remained in the tumors at 4 h after dose administration.  Whole body clearance of 188Re-(Arg11)CCMSH was very rapid, with approx. 82% of injected dose cleared through urinary system at 4 h postinjection.  There was very little activity in blood and major organs such as liver, lung, and muscle except for the kidney.  188Re-CCMSH exhibited similar tumor uptake and retention in TXM13 human melanoma-xenografted Scid mice as 188Re-(Arg11)CCMSH.  However, the kidney uptake value of 188Re-CCMSH was two times higher than that of 188Re-(Arg11)CCMSH.  The results of this study indicate that the MC1 receptor is present on the surface of a large no. of human melanoma cells, which makes the MC1 receptor a good imaging or therapeutic target.  Moreover, the biodistribution properties of 188Re-(Arg11)CCMSH and 188Re-CCMSH highlight their potential as therapeutic agents for human melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVLaDK3J0sirVg90H21EOLACvtfcHk0lhXS-aa4v-WlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlOmsr4%253D&md5=c86c29a23da9eff01178cccb3e035ed9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fbc034069i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc034069i%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DY.%26aulast%3DWhitener%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DW.%26aulast%3DOwen%26aufirst%3DN.%2BK.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DQuinn%26aufirst%3DT.%2BP.%26atitle%3DEvaluation%2520of%2520the%2520human%2520melanoma%2520targeting%2520properties%2520of%2520radiolabeled%2520alpha-melanocyte%2520stimulating%2520hormone%2520peptide%2520analogues%26jtitle%3DBioconjugate%2520Chem.%26date%3D2003%26volume%3D14%26spage%3D1177%26epage%3D1184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gershman, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sklar, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Y.</span><span> </span><span class="NLM_article-title">Metastatic melanoma imaging with an <sup>111</sup>In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide</span> <span class="citation_source-journal">Nucl. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">276</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1016%2Fj.nucmedbio.2009.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=19324272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvVOrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=267-276&author=H.+Guoauthor=N.+Shenoyauthor=B.+M.+Gershmanauthor=J.+Yangauthor=L.+A.+Sklarauthor=Y.+Miao&title=Metastatic+melanoma+imaging+with+an+111In-labeled+lactam+bridge-cyclized+alpha-melanocyte+stimulating+hormone+peptide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Metastatic melanoma imaging with an 111In-labeled lactam bridge-cyclized α-melanocyte-stimulating hormone peptide</span></div><div class="casAuthors">Guo, Haixun; Shenoy, Nalini; Gershman, Benjamin M.; Yang, Jianquan; Sklar, Larry A.; Miao, Yubin</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-276</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Introduction: The purpose of this study was to examine whether a novel lactam bridge-cyclized 111In-labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-Gly-Glu-c[Lys-Nle-Glu-His--Phe-Arg-Trp-Gly-Arg-Pro-Val-Asp] {DOTA-GlyGlu-CycMSH} could be an effective imaging probe for metastatic melanoma detection.  Methods: 111In-DOTA-GlyGlu-CycMSH was prepd. and purified by reverse-phase high-performance liq. chromatog. (RP-HPLC).  The internalization and efflux of 111In-DOTA-GlyGlu-CycMSH were examd. in B16/F10 melanoma cells.  The biodistribution of 111In-DOTA-GlyGlu-CycMSH was detd. in B16/F10 pulmonary metastatic melanoma-bearing and normal C57 mice.  Pulmonary metastatic melanoma imaging was performed by small-animal single-photon emission computed tomog. (SPECT)/CT (Nano-SPECT/CT) using 111In-DOTA-GlyGlu-CycMSH as an imaging probe and compared with 2-[18F]fluoro-2-deoxy-glucose ([18F]FDG) positron emission tomog. (PET) imaging.  Results: 111In-DOTA-GlyGlu-CycMSH was readily prepd. with greater than 95% radiolabeling yield. 111In-DOTA-GlyGlu-CycMSH displayed rapid internalization and extended efflux in B16/F10 cells.  111In-DOTA-GlyGlu-CycMSH exhibited significantly (P<.05) higher uptakes (2.00±0.74%ID/g at 2 h post-injection and 1.83±0.12%ID/g at 4 h post-injection) in metastatic melanoma-bearing lung than that in normal lung (0.08±0.08%ID/g and 0.05±0.05%ID/g at 2 and 4 h post-injection, resp.).  The activity accumulation in normal organs was low (<0.5%ID/g) except for the kidneys 2 and 4 h post-injection.  B16/F10 pulmonary melanoma metastases were clearly visualized with 111In-DOTA-GlyGlu-CycMSH 2 h post-injection rather than with [18F]FDG 1 h post-injection.  Conclusions: 111In-DOTA-GlyGlu-CycMSH exhibited favorable metastatic melanoma-targeting and -imaging properties, highlighting its potential as an effective imaging probe for metastatic melanoma detection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS5-8BSvRDU7Vg90H21EOLACvtfcHk0lifNgaIy9gaEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvVOrs7s%253D&md5=e2ccf662da2c0c05841c6e8b93f91c53</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2009.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2009.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DShenoy%26aufirst%3DN.%26aulast%3DGershman%26aufirst%3DB.%2BM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DSklar%26aufirst%3DL.%2BA.%26aulast%3DMiao%26aufirst%3DY.%26atitle%3DMetastatic%2520melanoma%2520imaging%2520with%2520an%2520111In-labeled%2520lactam%2520bridge-cyclized%2520alpha-melanocyte%2520stimulating%2520hormone%2520peptide%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2009%26volume%3D36%26spage%3D267%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Cheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandekar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambhir, S. S.</span><span> </span><span class="NLM_article-title">Small-animal PET of melanocortin 1 receptor expression using a <sup>18</sup>F-labeled alpha-melanocyte-stimulating hormone analog</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">987</span><span class="NLM_x">–</span> <span class="NLM_lpage">994</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=987-994&author=Z.+Chengauthor=L.+Zhangauthor=E.+Gravesauthor=Z.+Xiongauthor=M.+Dandekarauthor=X.+Chenauthor=S.+S.+Gambhir&title=Small-animal+PET+of+melanocortin+1+receptor+expression+using+a+18F-labeled+alpha-melanocyte-stimulating+hormone+analog"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGraves%26aufirst%3DE.%26aulast%3DXiong%26aufirst%3DZ.%26aulast%3DDandekar%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGambhir%26aufirst%3DS.%2BS.%26atitle%3DSmall-animal%2520PET%2520of%2520melanocortin%25201%2520receptor%2520expression%2520using%2520a%252018F-labeled%2520alpha-melanocyte-stimulating%2520hormone%2520analog%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2007%26volume%3D48%26spage%3D987%26epage%3D994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Ren, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subbarayan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambhir, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Z.</span><span> </span><span class="NLM_article-title">PET of Malignant melanoma using labeled metallopeptides</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1865</span><span class="NLM_x">–</span> <span class="NLM_lpage">1872</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=1865-1872&author=G.+Renauthor=Z.+Liuauthor=Z.+Miaoauthor=H.+Liuauthor=M.+Subbarayanauthor=F.+T.+Chinauthor=L.+Zhangauthor=S.+S.+Gambhirauthor=Z.+Cheng&title=PET+of+Malignant+melanoma+using+labeled+metallopeptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSubbarayan%26aufirst%3DM.%26aulast%3DChin%26aufirst%3DF.%2BT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGambhir%26aufirst%3DS.%2BS.%26aulast%3DCheng%26aufirst%3DZ.%26atitle%3DPET%2520of%2520Malignant%2520melanoma%2520using%2520labeled%2520metallopeptides%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2009%26volume%3D50%26spage%3D1865%26epage%3D1872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Ren, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Z.</span><span> </span><span class="NLM_article-title">Radiofluorinated rhenium cyclized α-MSH analogues for PET imaging of melanocortin receptor 1</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2355</span><span class="NLM_x">–</span> <span class="NLM_lpage">2360</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc100391a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWhsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=2355-2360&author=G.+Renauthor=S.+Liuauthor=H.+Liuauthor=Z.+Miaoauthor=Z.+Cheng&title=Radiofluorinated+rhenium+cyclized+%CE%B1-MSH+analogues+for+PET+imaging+of+melanocortin+receptor+1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Radiofluorinated Rhenium Cyclized α-MSH Analogues for PET Imaging of Melanocortin Receptor 1</span></div><div class="casAuthors">Ren, Gang; Liu, Shuanlong; Liu, Hongguang; Miao, Zheng; Cheng, Zhen</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2355-2360</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to accomplish in vivo mol. imaging of melanoma biomarker melanocortin 1 receptor (MC1R), several α-MSH (α-MSH) analogs have been labeled with N-succinimidyl-4-18F-fluorobenzoate (18F-SFB) and studied as positron emission tomog. (PET) probes in our recent studies.  To further pursue a radiofluorinated α-MSH peptide with high clin. translation potential, we utilized 4-nitrophenyl 2-18F-fluoropropionate (18F-NFP) to radiofluorinate the transition metal rhenium cyclized α-MSH metallopeptides for PET imaging of MC1R pos. malignant melanoma.  Metallopeptides Ac-d,Lys-ReCCMSH(Arg11) (two isomers, namely RMSH-1 and RMSH-2) were synthesized using conventional solid phase peptide synthesis chem. and rhenium cyclization reaction.  The two isomers were then conjugated with 19F-NFP or 18F-NFP.  The resulting cold or radiofluorinated metallopeptides, 18/19F-FP-RMSH-1 and 18/19F-FP-RMSH-2, were further evaluated for their in vitro receptor binding affinities, in vivo biodistribution, and small-animal PET imaging properties.  The binding affinities of 19F-FP-RMSH-1 and 19F-FP-RMSH-2 were detd. to be within low nanomolar range.  In vivo studies revealed that both 18F-labeled metallopeptides possessed good tumor uptake in the B16F10 murine model with high MC1R expression, while possessing much lower uptake in A375M human melanoma xenografts.  Moreover, 18F-FP-RMSH-1 displayed more favorable in vivo performance in terms of higher tumor uptake and much lower accumulation in the kidney and liver, when compared to that of 18F-FP-RMSH-2 at 2 h postinjection (p.i.). 18F-FP-RMSH-1 also displayed lower liver and lung uptake when compared with that of the same peptide labeled with 18F-SFB (named as 18F-FB-RMSH-1).  Small animal PET imaging of 18F-FP-RMSH-1 in mice bearing B16F10 tumors at 1 and 2 h showed good tumor imaging quality.  As expected, much lower tumor uptake and poorer tumor/normal organ contrast were obsd. for A375M model compared to those of the B16F10 model. 18F-FP-RMSH-1 also exhibited higher tumor uptake and better tumor retention when compared with 18F-FB-RMSH-1. 18F-FP-RMSH-1 demonstrates significant advantages over 18F-FB-RMSH-1 and 18F-FP-RMSH-2.  It is a promising PET probe for imaging MC1R pos. melanoma and MC1R expression in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIgR0Y5vfCj7Vg90H21EOLACvtfcHk0lifNgaIy9gaEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWhsbfJ&md5=f6b101d037e51662c80c5e439cab65e6</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fbc100391a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc100391a%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DZ.%26atitle%3DRadiofluorinated%2520rhenium%2520cyclized%2520%25CE%25B1-MSH%2520analogues%2520for%2520PET%2520imaging%2520of%2520melanocortin%2520receptor%25201%26jtitle%3DBioconjugate%2520Chem.%26date%3D2010%26volume%3D21%26spage%3D2355%26epage%3D2360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Eisenhut, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hull, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Just, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorgas, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberkorn, U.</span><span> </span><span class="NLM_article-title">Radioiodinated <i>N</i>-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: Structure–affinity relationships, metabolic fate, and intracellular localization</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3913</span><span class="NLM_x">–</span> <span class="NLM_lpage">3922</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm991079p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3913-3922&author=M.+Eisenhutauthor=W.+E.+Hullauthor=A.+Mohammedauthor=W.+Mierauthor=D.+Layauthor=W.+Justauthor=K.+Gorgasauthor=W.+D.+Lehmannauthor=U.+Haberkorn&title=Radioiodinated+N-%282-diethylaminoethyl%29benzamide+derivatives+with+high+melanoma+uptake%3A+Structure%E2%80%93affinity+relationships%2C+metabolic+fate%2C+and+intracellular+localization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm991079p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm991079p%26sid%3Dliteratum%253Aachs%26aulast%3DEisenhut%26aufirst%3DM.%26aulast%3DHull%26aufirst%3DW.%2BE.%26aulast%3DMohammed%26aufirst%3DA.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DLay%26aufirst%3DD.%26aulast%3DJust%26aufirst%3DW.%26aulast%3DGorgas%26aufirst%3DK.%26aulast%3DLehmann%26aufirst%3DW.%2BD.%26aulast%3DHaberkorn%26aufirst%3DU.%26atitle%3DRadioiodinated%2520N-%25282-diethylaminoethyl%2529benzamide%2520derivatives%2520with%2520high%2520melanoma%2520uptake%253A%2520Structure%25E2%2580%2593affinity%2520relationships%252C%2520metabolic%2520fate%252C%2520and%2520intracellular%2520localization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3913%26epage%3D3922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Chezal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labarre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lartigue, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galmier, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decombat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavignon, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maublant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teulade, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madelmont, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moins, N.</span><span> </span><span class="NLM_article-title">Evaluation of radiolabeled (hetero)aromatic analogues of <i>N</i>-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3133</span><span class="NLM_x">–</span> <span class="NLM_lpage">3144</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701424g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3133-3144&author=J.+M.+Chezalauthor=J.+Paponauthor=P.+Labarreauthor=C.+Lartigueauthor=M.+J.+Galmierauthor=C.+Decombatauthor=O.+Chavignonauthor=J.+Maublantauthor=J.+C.+Teuladeauthor=J.+C.+Madelmontauthor=N.+Moins&title=Evaluation+of+radiolabeled+%28hetero%29aromatic+analogues+of+N-%282-diethylaminoethyl%29-4-iodobenzamide+for+imaging+and+targeted+radionuclide+therapy+of+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm701424g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701424g%26sid%3Dliteratum%253Aachs%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26aulast%3DPapon%26aufirst%3DJ.%26aulast%3DLabarre%26aufirst%3DP.%26aulast%3DLartigue%26aufirst%3DC.%26aulast%3DGalmier%26aufirst%3DM.%2BJ.%26aulast%3DDecombat%26aufirst%3DC.%26aulast%3DChavignon%26aufirst%3DO.%26aulast%3DMaublant%26aufirst%3DJ.%26aulast%3DTeulade%26aufirst%3DJ.%2BC.%26aulast%3DMadelmont%26aufirst%3DJ.%2BC.%26aulast%3DMoins%26aufirst%3DN.%26atitle%3DEvaluation%2520of%2520radiolabeled%2520%2528hetero%2529aromatic%2520analogues%2520of%2520N-%25282-diethylaminoethyl%2529-4-iodobenzamide%2520for%2520imaging%2520and%2520targeted%2520radionuclide%2520therapy%2520of%2520melanoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3133%26epage%3D3144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Madelmont, J. C.; Chezal, J. M.; Moins, N.; Teulade, J. C.; Chavignon, O.</span><span> </span><span class="NLM_article-title">Labeled analogues of halobenzamides as radiopharmaceuticals</span>. World Patent WO2008012782,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=J.+C.+Madelmont&author=J.+M.+Chezal&author=N.+Moins&author=J.+C.+Teulade&author=O.+Chavignon&title=Labeled+analogues+of+halobenzamides+as+radiopharmaceuticals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMadelmont%26aufirst%3DJ.%2BC.%26atitle%3DLabeled%2520analogues%2520of%2520halobenzamides%2520as%2520radiopharmaceuticals%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Greguric, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denoyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballantyne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghofer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roselt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, T. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourdier, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neels, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorow, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loc’h, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsifis, A.</span><span> </span><span class="NLM_article-title">Discovery of [<sup>18</sup>F]<i>N</i>-(2-(diethylamino)ethyl)-6-fluoronicotinamide: A melanoma positron emission tomography imaging radiotracer with high tumour to body contrast ratio and rapid renal clearance</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5299</span><span class="NLM_x">–</span> <span class="NLM_lpage">5302</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9008423" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5299-5302&author=I.+Greguricauthor=S.+R.+Taylorauthor=D.+Denoyerauthor=P.+Ballantyneauthor=P.+Berghoferauthor=P.+Roseltauthor=T.+Q.+Phamauthor=F.+Mattnerauthor=T.+Bourdierauthor=O.+C.+Neelsauthor=D.+S.+Dorowauthor=C.+Loc%E2%80%99hauthor=R.+J.+Hicksauthor=A.+Katsifis&title=Discovery+of+%5B18F%5DN-%282-%28diethylamino%29ethyl%29-6-fluoronicotinamide%3A+A+melanoma+positron+emission+tomography+imaging+radiotracer+with+high+tumour+to+body+contrast+ratio+and+rapid+renal+clearance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm9008423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9008423%26sid%3Dliteratum%253Aachs%26aulast%3DGreguric%26aufirst%3DI.%26aulast%3DTaylor%26aufirst%3DS.%2BR.%26aulast%3DDenoyer%26aufirst%3DD.%26aulast%3DBallantyne%26aufirst%3DP.%26aulast%3DBerghofer%26aufirst%3DP.%26aulast%3DRoselt%26aufirst%3DP.%26aulast%3DPham%26aufirst%3DT.%2BQ.%26aulast%3DMattner%26aufirst%3DF.%26aulast%3DBourdier%26aufirst%3DT.%26aulast%3DNeels%26aufirst%3DO.%2BC.%26aulast%3DDorow%26aufirst%3DD.%2BS.%26aulast%3DLoc%25E2%2580%2599h%26aufirst%3DC.%26aulast%3DHicks%26aufirst%3DR.%2BJ.%26aulast%3DKatsifis%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520%255B18F%255DN-%25282-%2528diethylamino%2529ethyl%2529-6-fluoronicotinamide%253A%2520A%2520melanoma%2520positron%2520emission%2520tomography%2520imaging%2520radiotracer%2520with%2520high%2520tumour%2520to%2520body%2520contrast%2520ratio%2520and%2520rapid%2520renal%2520clearance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5299%26epage%3D5302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Denoyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greguric, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roselt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neels, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aide, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsifis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorow, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, R. J.</span><span> </span><span class="NLM_article-title">High-contrast PET of melanoma using [<sup>18</sup>F]MEL050, a selective probe for melanin with predominantly renal clearance</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=441-447&author=D.+Denoyerauthor=I.+Greguricauthor=P.+Roseltauthor=O.+C.+Neelsauthor=N.+Aideauthor=S.+R.+Taylorauthor=A.+Katsifisauthor=D.+S.+Dorowauthor=R.+J.+Hicks&title=High-contrast+PET+of+melanoma+using+%5B18F%5DMEL050%2C+a+selective+probe+for+melanin+with+predominantly+renal+clearance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDenoyer%26aufirst%3DD.%26aulast%3DGreguric%26aufirst%3DI.%26aulast%3DRoselt%26aufirst%3DP.%26aulast%3DNeels%26aufirst%3DO.%2BC.%26aulast%3DAide%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BR.%26aulast%3DKatsifis%26aufirst%3DA.%26aulast%3DDorow%26aufirst%3DD.%2BS.%26aulast%3DHicks%26aufirst%3DR.%2BJ.%26atitle%3DHigh-contrast%2520PET%2520of%2520melanoma%2520using%2520%255B18F%255DMEL050%252C%2520a%2520selective%2520probe%2520for%2520melanin%2520with%2520predominantly%2520renal%2520clearance%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2010%26volume%3D51%26spage%3D441%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Rbah-Vidal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cachin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Askienazy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dollé, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degoul, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miot-Noirault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moins, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auzeloux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chezal, J. M.</span><span> </span><span class="NLM_article-title">Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [<sup>18</sup>F]ICF01006, a highly promising melanoma PET tracer</span> <span class="citation_source-journal">Eur. J. Nucl. Med. Mol. Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1449</span><span class="NLM_x">–</span> <span class="NLM_lpage">1461</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1007%2Fs00259-012-2168-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=22707183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKis7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=1449-1461&author=L.+Rbah-Vidalauthor=A.+Vidalauthor=S.+Besseauthor=F.+Cachinauthor=M.+Bonnetauthor=L.+Audinauthor=S.+Askienazyauthor=F.+Doll%C3%A9author=F.+Degoulauthor=E.+Miot-Noiraultauthor=N.+Moinsauthor=P.+Auzelouxauthor=J.+M.+Chezal&title=Early+detection+and+longitudinal+monitoring+of+experimental+primary+and+disseminated+melanoma+using+%5B18F%5DICF01006%2C+a+highly+promising+melanoma+PET+tracer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [18F]ICF01006, a highly promising melanoma PET tracer</span></div><div class="casAuthors">Rbah-Vidal, Latifa; Vidal, Aurelien; Besse, Sophie; Cachin, Florent; Bonnet, Mathilde; Audin, Laurent; Askienazy, Serge; Dolle, Frederic; Degoul, Francoise; Miot-Noirault, Elisabeth; Moins, Nicole; Auzeloux, Philippe; Chezal, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1449-1461</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose Here, we report a new and rapid radiosynthesis of 18F-N-[2-(diethylamino)ethyl]-6-fluoro-pyridine-3-carboxamide ([18F]ICF01006), a mol. with a high specificity for melanotic tissue, and its evaluation in a murine model for early specific detection of pigmented primary and disseminated melanoma.  Methods [18F]ICF01006 was synthesized using a new one-step bromine-for-fluorine nucleophilic heteroarom. substitution.  Melanoma models were induced by s.c. (primary tumor) or i.v. (lung colonies) injection of B16BL6 melanoma cells in C57BL/6J mice.  The relevance and sensitivity of positron emission tomog. (PET) imaging using [18F]ICF01006 were evaluated at different stages of tumoral growth and compared to 18F-fluorodeoxyglucose ([18F]FDG).  Results The fully automated radiosynthesis of [18F]ICF01006 led to a radiochem. yield of 61 % and a radiochem. purity >99 % (specific activity 70-80 GBq/μmol; total synthesis time 42 min).  Tumors were visualized before they were palpable as early as 1 h post-injection with [18F]ICF01006 tumoral uptake of 1.64 ± 0.57, 3.40 ± 1.47 and 11.44 ± 2.67 percentage of injected dose per g of tissue (%ID/g) at days 3, 5 and 14, resp. [18F]ICF01006 PET imaging also allowed detection of melanoma pulmonary colonies from day 9 after tumor cell inoculation, with a lung radiotracer accumulation correlated with melanoma invasion.  At day 21, radioactivity uptake in lungs reached a value of 5.23 ± 2.08 %ID/g (vs. 0.41 ± 0.90 %ID/g in control mice).  In the two models, comparison with [18F]FDG showed that both radiotracers were able to detect melanoma lesions, but [18F]ICF01006 was superior in terms of contrast and specificity.  Conclusion Our promising results provide further preclin. data, reinforcing the excellent potential of [18F]ICF01006 PET imaging for early specific diagnosis and follow-up of melanin-pos. disseminated melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6icg8of-5SrVg90H21EOLACvtfcHk0lg7mryLe6ucbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKis7nM&md5=52a508a0f0a56f9b0b1f07d513995934</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs00259-012-2168-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-012-2168-y%26sid%3Dliteratum%253Aachs%26aulast%3DRbah-Vidal%26aufirst%3DL.%26aulast%3DVidal%26aufirst%3DA.%26aulast%3DBesse%26aufirst%3DS.%26aulast%3DCachin%26aufirst%3DF.%26aulast%3DBonnet%26aufirst%3DM.%26aulast%3DAudin%26aufirst%3DL.%26aulast%3DAskienazy%26aufirst%3DS.%26aulast%3DDoll%25C3%25A9%26aufirst%3DF.%26aulast%3DDegoul%26aufirst%3DF.%26aulast%3DMiot-Noirault%26aufirst%3DE.%26aulast%3DMoins%26aufirst%3DN.%26aulast%3DAuzeloux%26aufirst%3DP.%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26atitle%3DEarly%2520detection%2520and%2520longitudinal%2520monitoring%2520of%2520experimental%2520primary%2520and%2520disseminated%2520melanoma%2520using%2520%255B18F%255DICF01006%252C%2520a%2520highly%2520promising%2520melanoma%2520PET%2520tracer%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2012%26volume%3D39%26spage%3D1449%26epage%3D1461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Bonnet-Duquennoy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishellany, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labarre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerquin-Kern, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardette, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maublant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penault-Llorca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miot-Noirault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cayre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madelmont, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chezal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moins, N.</span><span> </span><span class="NLM_article-title">Targeted radionuclide therapy of melanoma: Anti-tumoural efficacy studies of a new <sup>131</sup>I labelled potential agent</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">708</span><span class="NLM_x">–</span> <span class="NLM_lpage">716</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1002%2Fijc.24413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=19437532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsleqt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2009&pages=708-716&author=M.+Bonnet-Duquennoyauthor=J.+Paponauthor=F.+Mishellanyauthor=P.+Labarreauthor=J.+L.+Guerquin-Kernauthor=T.+D.+Wuauthor=M.+Gardetteauthor=J.+Maublantauthor=F.+Penault-Llorcaauthor=E.+Miot-Noiraultauthor=A.+Cayreauthor=J.+C.+Madelmontauthor=J.+M.+Chezalauthor=N.+Moins&title=Targeted+radionuclide+therapy+of+melanoma%3A+Anti-tumoural+efficacy+studies+of+a+new+131I+labelled+potential+agent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted radionuclide therapy of melanoma: Anti-tumoural efficacy studies of a new 131I labelled potential agent</span></div><div class="casAuthors">Bonnet-Duquennoy, Mathilde; Papon, Janine; Mishellany, Florence; Labarre, Pierre; Guerquin-Kern, Jean-Luc; Wu, Ting-Di; Gardette, Maryline; Maublant, Jean; Penault-Llorca, Frederique; Miot-Noirault, Elisabeth; Cayre, Anne; Madelmont, Jean-Claude; Chezal, Jean-Michel; Moins, Nicole</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">708-716</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">In recent years, there has been dramatic worldwide increase in incidence of malignant melanoma.  Although localised disease is often curable by surgical excision, metastatic melanoma is inherently resistant to most treatments.  In this context, targeted radionuclide therapy could be an efficient alternative.  After pharmacomodulation study, we selected a quinoxaline deriv. mol. (ICF01012) for its high, specific and long-lasting uptake in melanoma with rapid clearance from nontarget organs providing suitable dosimetry parameters for targeted radiotherapy.  Aim of this study was to investigate, in vivo, efficacy of [131I]ICF01012 on nonmetastatic B16F0, metastatic B16Bl6 or human M4Beu melanoma tumors.  First, colocalisation of ICF01012 with melanin by SIMS imaging was obsd.  Second, we showed that treatment drastically inhibited growth of B16F0, B16Bl6 and M4beu tumors whereas [131I]NaI or unlabeled ICF01012 treatment was without significant effect.  Histol. anal. and measure of PCNA proliferation marker expression showed that residual B16 tumor cellsexhibit a significant loss of aggressiveness after treatment.  This effect is assocd. with a lengthening of the treated-mice survival time.  Moreover, with B16Bl6 model, 55% of the untreated mice had lung metastases whereas no metastasis was counted on treated group.  Our data demonstrated a strong anti-tumoral effect of [131I]ICF01012 for radionuclide therapy on murine and human in vivo pigmented melanoma models, whatever their dissemination profiles and their melanin content be.  Further studies will attempt to optimize therapy protocol by increasing the balance between the anti-tumoral effect and the safety on nontarget organs. © 2009 UICC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8zBsnkS4UObVg90H21EOLACvtfcHk0lg7mryLe6ucbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsleqt78%253D&md5=f74ebc292d1b6c8004b547d2946e8323</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fijc.24413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.24413%26sid%3Dliteratum%253Aachs%26aulast%3DBonnet-Duquennoy%26aufirst%3DM.%26aulast%3DPapon%26aufirst%3DJ.%26aulast%3DMishellany%26aufirst%3DF.%26aulast%3DLabarre%26aufirst%3DP.%26aulast%3DGuerquin-Kern%26aufirst%3DJ.%2BL.%26aulast%3DWu%26aufirst%3DT.%2BD.%26aulast%3DGardette%26aufirst%3DM.%26aulast%3DMaublant%26aufirst%3DJ.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DMiot-Noirault%26aufirst%3DE.%26aulast%3DCayre%26aufirst%3DA.%26aulast%3DMadelmont%26aufirst%3DJ.%2BC.%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26aulast%3DMoins%26aufirst%3DN.%26atitle%3DTargeted%2520radionuclide%2520therapy%2520of%2520melanoma%253A%2520Anti-tumoural%2520efficacy%2520studies%2520of%2520a%2520new%2520131I%2520labelled%2520potential%2520agent%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2009%26volume%3D125%26spage%3D708%26epage%3D716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Bonnet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishellany, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cayre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penault-Llorca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madelmont, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miot-Noirault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chezal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moins, N.</span><span> </span><span class="NLM_article-title">Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution</span> <span class="citation_source-journal">Pigm. Cell Melanoma Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1</span><span class="NLM_x">–</span> <span class="NLM_lpage">e11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=e1-e11&author=M.+Bonnetauthor=F.+Mishellanyauthor=J.+Paponauthor=A.+Cayreauthor=F.+Penault-Llorcaauthor=J.+C.+Madelmontauthor=E.+Miot-Noiraultauthor=J.+M.+Chezalauthor=N.+Moins&title=Anti-melanoma+efficacy+of+internal+radionuclide+therapy+in+relation+to+melanin+target+distribution"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonnet%26aufirst%3DM.%26aulast%3DMishellany%26aufirst%3DF.%26aulast%3DPapon%26aufirst%3DJ.%26aulast%3DCayre%26aufirst%3DA.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DMadelmont%26aufirst%3DJ.%2BC.%26aulast%3DMiot-Noirault%26aufirst%3DE.%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26aulast%3DMoins%26aufirst%3DN.%26atitle%3DAnti-melanoma%2520efficacy%2520of%2520internal%2520radionuclide%2520therapy%2520in%2520relation%2520to%2520melanin%2520target%2520distribution%26jtitle%3DPigm.%2520Cell%2520Melanoma%2520Res.%26date%3D2010%26volume%3D23%26spage%3De1%26epage%3De11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Boisgard, R.; Chezal, J. M.; Dollé, F.; Kuhnast, B.; Madelmont, J. C.; Maisonial, A.; Miot-Noirault, E.; Moins, N.; Papon, J.; Tavitian, B.</span><span> </span><span class="NLM_article-title">Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors</span>. World Patent WO2009095872,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Boisgard&author=J.+M.+Chezal&author=F.+Doll%C3%A9&author=B.+Kuhnast&author=J.+C.+Madelmont&author=A.+Maisonial&author=E.+Miot-Noirault&author=N.+Moins&author=J.+Papon&author=B.+Tavitian&title=Labelled+analogues+of+halobenzamides+as+multimodal+radiopharmaceuticals+and+their+precursors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoisgard%26aufirst%3DR.%26atitle%3DLabelled%2520analogues%2520of%2520halobenzamides%2520as%2520multimodal%2520radiopharmaceuticals%2520and%2520their%2520precursors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Auzeloux, P.; Billaud, E. M. F.; Chezal, J. M.; Madelmont, J. C.; Maisonial, A.; Miot-Noirault, E.; Papon, J.; Rbah-Vidal, L.; Vidal, A.</span><span> </span><span class="NLM_article-title">Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors</span>. PCT/IB2013/053106,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=P.+Auzeloux&author=E.+M.+F.+Billaud&author=J.+M.+Chezal&author=J.+C.+Madelmont&author=A.+Maisonial&author=E.+Miot-Noirault&author=J.+Papon&author=L.+Rbah-Vidal&author=A.+Vidal&title=Labelled+quinoxaline+derivatives+as+multimodal+radiopharmaceuticals+and+their+precursors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAuzeloux%26aufirst%3DP.%26atitle%3DLabelled%2520quinoxaline%2520derivatives%2520as%2520multimodal%2520radiopharmaceuticals%2520and%2520their%2520precursors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Maisonial, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhnast, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boisgard, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auzeloux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rbah, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet-Duquennoy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miot-Noirault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galmier, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Askienazy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dollé, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavitian, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madelmont, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moins, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chezal, J. M.</span><span> </span><span class="NLM_article-title">Single photon emission computed tomography/positron emission tomography imaging and targeted radionuclide therapy of melanoma: new multimodal fluorinated and iodinated radiotracers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2745</span><span class="NLM_x">–</span> <span class="NLM_lpage">2766</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101574q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2745-2766&author=A.+Maisonialauthor=B.+Kuhnastauthor=J.+Paponauthor=R.+Boisgardauthor=M.+Bayleauthor=A.+Vidalauthor=P.+Auzelouxauthor=L.+Rbahauthor=M.+Bonnet-Duquennoyauthor=E.+Miot-Noiraultauthor=M.+J.+Galmierauthor=M.+Borelauthor=S.+Askienazyauthor=F.+Doll%C3%A9author=B.+Tavitianauthor=J.+C.+Madelmontauthor=N.+Moinsauthor=J.+M.+Chezal&title=Single+photon+emission+computed+tomography%2Fpositron+emission+tomography+imaging+and+targeted+radionuclide+therapy+of+melanoma%3A+new+multimodal+fluorinated+and+iodinated+radiotracers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm101574q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101574q%26sid%3Dliteratum%253Aachs%26aulast%3DMaisonial%26aufirst%3DA.%26aulast%3DKuhnast%26aufirst%3DB.%26aulast%3DPapon%26aufirst%3DJ.%26aulast%3DBoisgard%26aufirst%3DR.%26aulast%3DBayle%26aufirst%3DM.%26aulast%3DVidal%26aufirst%3DA.%26aulast%3DAuzeloux%26aufirst%3DP.%26aulast%3DRbah%26aufirst%3DL.%26aulast%3DBonnet-Duquennoy%26aufirst%3DM.%26aulast%3DMiot-Noirault%26aufirst%3DE.%26aulast%3DGalmier%26aufirst%3DM.%2BJ.%26aulast%3DBorel%26aufirst%3DM.%26aulast%3DAskienazy%26aufirst%3DS.%26aulast%3DDoll%25C3%25A9%26aufirst%3DF.%26aulast%3DTavitian%26aufirst%3DB.%26aulast%3DMadelmont%26aufirst%3DJ.%2BC.%26aulast%3DMoins%26aufirst%3DN.%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26atitle%3DSingle%2520photon%2520emission%2520computed%2520tomography%252Fpositron%2520emission%2520tomography%2520imaging%2520and%2520targeted%2520radionuclide%2520therapy%2520of%2520melanoma%253A%2520new%2520multimodal%2520fluorinated%2520and%2520iodinated%2520radiotracers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2745%26epage%3D2766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Maisonial, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billaud, E. M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rbah-Vidal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galmier, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrit, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Askienazy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madelmont, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auzeloux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miot-Noirault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chezal, J. M.</span><span> </span><span class="NLM_article-title">Synthesis, radioiodination and <i>in vivo</i> screening of novel potent iodinated and fluorinated radiotracers as melanoma imaging and therapeutic probes</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">840</span><span class="NLM_x">–</span> <span class="NLM_lpage">853</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2013&pages=840-853&author=A.+Maisonialauthor=E.+M.+F.+Billaudauthor=S.+Besseauthor=L.+Rbah-Vidalauthor=J.+Paponauthor=L.+Audinauthor=M.+Bayleauthor=M.+J.+Galmierauthor=S.+Tarritauthor=M.+Borelauthor=S.+Askienazyauthor=J.+C.+Madelmontauthor=M.+Moinsauthor=P.+Auzelouxauthor=E.+Miot-Noiraultauthor=J.+M.+Chezal&title=Synthesis%2C+radioiodination+and+in+vivo+screening+of+novel+potent+iodinated+and+fluorinated+radiotracers+as+melanoma+imaging+and+therapeutic+probes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaisonial%26aufirst%3DA.%26aulast%3DBillaud%26aufirst%3DE.%2BM.%2BF.%26aulast%3DBesse%26aufirst%3DS.%26aulast%3DRbah-Vidal%26aufirst%3DL.%26aulast%3DPapon%26aufirst%3DJ.%26aulast%3DAudin%26aufirst%3DL.%26aulast%3DBayle%26aufirst%3DM.%26aulast%3DGalmier%26aufirst%3DM.%2BJ.%26aulast%3DTarrit%26aufirst%3DS.%26aulast%3DBorel%26aufirst%3DM.%26aulast%3DAskienazy%26aufirst%3DS.%26aulast%3DMadelmont%26aufirst%3DJ.%2BC.%26aulast%3DMoins%26aufirst%3DM.%26aulast%3DAuzeloux%26aufirst%3DP.%26aulast%3DMiot-Noirault%26aufirst%3DE.%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26atitle%3DSynthesis%252C%2520radioiodination%2520and%2520in%2520vivo%2520screening%2520of%2520novel%2520potent%2520iodinated%2520and%2520fluorinated%2520radiotracers%2520as%2520melanoma%2520imaging%2520and%2520therapeutic%2520probes%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D63%26spage%3D840%26epage%3D853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Cai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, D.</span><span> </span><span class="NLM_article-title">Sequential reaction process to assemble polysubstituted indolizidines, quinolizidines and quinolizidine analogues</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">5697</span><span class="NLM_x">–</span> <span class="NLM_lpage">5708</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=5697-5708&author=G.+Caiauthor=W.+Zhuauthor=D.+Ma&title=Sequential+reaction+process+to+assemble+polysubstituted+indolizidines%2C+quinolizidines+and+quinolizidine+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DD.%26atitle%3DSequential%2520reaction%2520process%2520to%2520assemble%2520polysubstituted%2520indolizidines%252C%2520quinolizidines%2520and%2520quinolizidine%2520analogues%26jtitle%3DTetrahedron%26date%3D2006%26volume%3D62%26spage%3D5697%26epage%3D5708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Jones, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holtz, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edward, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cragoe, E. J.,  Jr.</span><span> </span><span class="NLM_article-title">6-Substituted 5-chloro-1,3-dihydro-2H-imidazo[4,5-b]pyrazin-2-ones with hypotensive activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00263a029" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1973&pages=537-542&author=J.+H.+Jonesauthor=W.+J.+Holtzauthor=J.+Edwardauthor=E.+J.+Cragoe&title=6-Substituted+5-chloro-1%2C3-dihydro-2H-imidazo%5B4%2C5-b%5Dpyrazin-2-ones+with+hypotensive+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm00263a029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00263a029%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DJ.%2BH.%26aulast%3DHoltz%26aufirst%3DW.%2BJ.%26aulast%3DEdward%26aufirst%3DJ.%26aulast%3DCragoe%26aufirst%3DE.%2BJ.%26atitle%3D6-Substituted%25205-chloro-1%252C3-dihydro-2H-imidazo%255B4%252C5-b%255Dpyrazin-2-ones%2520with%2520hypotensive%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1973%26volume%3D16%26spage%3D537%26epage%3D542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Denoyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labarre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miot-Noirault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galmier, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madelmont, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chezal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moins, N.</span><span> </span><span class="NLM_article-title">Development of a high-performance liquid chromatographic method for the determination of a new potent radioiodinated melanoma imaging and therapeutic agent</span> <span class="citation_source-journal">J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">875</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">418</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1016%2Fj.jchromb.2008.09.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=18838313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlGhur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=875&publication_year=2008&pages=411-418&author=D.+Denoyerauthor=P.+Labarreauthor=J.+Paponauthor=E.+Miot-Noiraultauthor=M.+J.+Galmierauthor=J.+C.+Madelmontauthor=J.+M.+Chezalauthor=N.+Moins&title=Development+of+a+high-performance+liquid+chromatographic+method+for+the+determination+of+a+new+potent+radioiodinated+melanoma+imaging+and+therapeutic+agent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a high-performance liquid chromatographic method for the determination of a new potent radioiodinated melanoma imaging and therapeutic agent</span></div><div class="casAuthors">Denoyer, Delphine; Labarre, Pierre; Papon, Janine; Miot-Noirault, Elisabeth; Galmier, Marie-Josephe; Madelmont, Jean-Claude; Chezal, Jean-Michel; Moins, Nicole</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">875</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">411-418</span>CODEN:
                <span class="NLM_cas:coden">JCBAAI</span>;
        ISSN:<span class="NLM_cas:issn">1570-0232</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">N-(2-diethylaminoethyl)-6-iodoquinoxaline-2-carbamide (ICF 01012) is a new melanoma imaging agent showing promising properties for application in internal radionuclide therapy.  We developed an anal. protocol for detection of ICF 01012 in biol. samples using HPLC.  The proposed method was first validated using std. of ICF 01012 and four potent metabolites of this compd. and then applied to follow the metabolic fate of [125I]ICF 01012 after injection in melanoma-bearing mice.  The results demonstrate that this method exhibits a good linearity (r2 = 0.9947), specificity and acceptable accuracy.  This simple method appears convenient and sufficient for pharmacokinetic studies on [125I]ICF 01012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS4d_A7e4q77Vg90H21EOLACvtfcHk0lhYTbXtkCaWMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlGhur%252FI&md5=b5e2ee335742720ac4c02eefce938349</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.jchromb.2008.09.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchromb.2008.09.021%26sid%3Dliteratum%253Aachs%26aulast%3DDenoyer%26aufirst%3DD.%26aulast%3DLabarre%26aufirst%3DP.%26aulast%3DPapon%26aufirst%3DJ.%26aulast%3DMiot-Noirault%26aufirst%3DE.%26aulast%3DGalmier%26aufirst%3DM.%2BJ.%26aulast%3DMadelmont%26aufirst%3DJ.%2BC.%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26aulast%3DMoins%26aufirst%3DN.%26atitle%3DDevelopment%2520of%2520a%2520high-performance%2520liquid%2520chromatographic%2520method%2520for%2520the%2520determination%2520of%2520a%2520new%2520potent%2520radioiodinated%2520melanoma%2520imaging%2520and%2520therapeutic%2520agent%26jtitle%3DJ.%2520Chromatogr.%252C%2520B%253A%2520Anal.%2520Technol.%2520Biomed.%2520Life%2520Sci.%26date%3D2008%26volume%3D875%26spage%3D411%26epage%3D418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Trost, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, Z. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joege, T.</span><span> </span><span class="NLM_article-title">A chemoselective reduction of alkynes to (E)-alkenes</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">7922</span><span class="NLM_x">–</span> <span class="NLM_lpage">7923</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja026457l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BD38XksFahtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=7922-7923&author=B.+M.+Trostauthor=Z.+T.+Ballauthor=T.+Joege&title=A+chemoselective+reduction+of+alkynes+to+%28E%29-alkenes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A Chemoselective Reduction of Alkynes to (E)-Alkenes</span></div><div class="casAuthors">Trost, Barry M.; Ball, Zachary T.; Joege, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">7922-7923</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The trans redn. of all types of alkynes to give (E)-olefins is achieved through a two-stage trans hydrosilylation and protodesilylation.  Reaction of an alkyne and a silane with the ruthenium catalyst [Cp*Ru(MeCN)3]PF6 results in clean hydrosilylation to give only the (Z)-trans addn. product at ambient temp. with catalyst loadings of 1-5 mol %.  The crude vinylsilane products are then protodesilylated by the action of cuprous iodide and TBAF at room temp. to 35°.  The reaction is compatible with many sensitive functional groups and provides a general trans-alkyne redn. not possible by other means.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVUlhi2OJFc7Vg90H21EOLACvtfcHk0lgCXYytqRZZ6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksFahtbY%253D&md5=4579c102575fc24bd38d1f8242770f4a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fja026457l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja026457l%26sid%3Dliteratum%253Aachs%26aulast%3DTrost%26aufirst%3DB.%2BM.%26aulast%3DBall%26aufirst%3DZ.%2BT.%26aulast%3DJoege%26aufirst%3DT.%26atitle%3DA%2520chemoselective%2520reduction%2520of%2520alkynes%2520to%2520%2528E%2529-alkenes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D7922%26epage%3D7923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Fürstner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radkowski, K.</span><span> </span><span class="NLM_article-title">A chemo- and stereoselective reduction of cycloalkynes to (E)-cycloalkenes</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_fpage">2182</span><span class="NLM_x">–</span> <span class="NLM_lpage">2183</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=2182-2183&author=A.+F%C3%BCrstnerauthor=K.+Radkowski&title=A+chemo-+and+stereoselective+reduction+of+cycloalkynes+to+%28E%29-cycloalkenes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DF%25C3%25BCrstner%26aufirst%3DA.%26aulast%3DRadkowski%26aufirst%3DK.%26atitle%3DA%2520chemo-%2520and%2520stereoselective%2520reduction%2520of%2520cycloalkynes%2520to%2520%2528E%2529-cycloalkenes%26jtitle%3DChem.%2520Commun.%26date%3D2002%26spage%3D2182%26epage%3D2183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Hara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishi, H.</span><span> </span><span class="NLM_article-title">Development of <sup>18</sup>F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=187-199&author=T.+Haraauthor=N.+Kosakaauthor=H.+Kishi&title=Development+of+18F-fluoroethylcholine+for+cancer+imaging+with+PET%3A+synthesis%2C+biochemistry%2C+and+prostate+cancer+imaging"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHara%26aufirst%3DT.%26aulast%3DKosaka%26aufirst%3DN.%26aulast%3DKishi%26aufirst%3DH.%26atitle%3DDevelopment%2520of%252018F-fluoroethylcholine%2520for%2520cancer%2520imaging%2520with%2520PET%253A%2520synthesis%252C%2520biochemistry%252C%2520and%2520prostate%2520cancer%2520imaging%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2002%26volume%3D43%26spage%3D187%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Wester, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiss, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senekowitsch-Schmidtke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwaiger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stöcklin, G.</span><span> </span><span class="NLM_article-title">Synthesis and radiopharmacology of <i>O</i>-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine for tumour imaging</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1999&pages=205-212&author=H.+J.+Westerauthor=M.+Herzauthor=W.+Weberauthor=P.+Heissauthor=R.+Senekowitsch-Schmidtkeauthor=M.+Schwaigerauthor=G.+St%C3%B6cklin&title=Synthesis+and+radiopharmacology+of+O-%282-%5B18F%5Dfluoroethyl%29-L-tyrosine+for+tumour+imaging"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWester%26aufirst%3DH.%2BJ.%26aulast%3DHerz%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DW.%26aulast%3DHeiss%26aufirst%3DP.%26aulast%3DSenekowitsch-Schmidtke%26aufirst%3DR.%26aulast%3DSchwaiger%26aufirst%3DM.%26aulast%3DSt%25C3%25B6cklin%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520radiopharmacology%2520of%2520O-%25282-%255B18F%255Dfluoroethyl%2529-L-tyrosine%2520for%2520tumour%2520imaging%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D1999%26volume%3D40%26spage%3D205%26epage%3D212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Armarego, W. L. F.; Perrin, D. D.</span> <span class="citation_source-book">Purification of laboratory chemicals</span>, <span class="NLM_edition">4</span>th ed.; <span class="NLM_publisher-name">Butterworth-Heinemann Eds.; Redd Educational and Professional Publishing Ltd</span>: <span class="NLM_publisher-loc">Oxford</span>,<span class="NLM_x"> </span><span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=W.+L.+F.+Armarego&author=D.+D.+Perrin&title=Purification+of+laboratory+chemicals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DArmarego%26aufirst%3DW.%2BL.%2BF.%26btitle%3DPurification%2520of%2520laboratory%2520chemicals%26pub%3DButterworth-Heinemann%2520Eds.%253B%2520Redd%2520Educational%2520and%2520Professional%2520Publishing%2520Ltd%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Mock, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkle, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vavrek, M. T.</span><span> </span><span class="NLM_article-title">A color spot test for the detection of Kryptofix 2.2.2 in [<sup>18</sup>F]FDG preparations</span> <span class="citation_source-journal">Nucl. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1016%2FS0969-8051%2896%2900212-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=9089712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADyaK2sXitlOmu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1997&pages=193-195&author=B.+H.+Mockauthor=W.+Winkleauthor=M.+T.+Vavrek&title=A+color+spot+test+for+the+detection+of+Kryptofix+2.2.2+in+%5B18F%5DFDG+preparations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A color spot test for the detection of kryptofix 222 in [18F]FDG preparations</span></div><div class="casAuthors">Mock, Bruce H.; Winkle, Wendy; Vavrek, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">193-195</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0883-2897</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A color spot test is described that can confirm the absence of Kryptofix 2.2.2 in 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) in less than 5 min.  Pretreated strips of plastic-backed silica gel 60 thin-layer chromatog. medium, satd. with iodoplatinate reagent, are over-spotted with sep. droplets of final product [18F]FDG and Kryptofix std. solns.  A blue-black circular spot is clearly visible at Kryptofix concns. as low as 2 μg/mL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5OqWCUUb5C7Vg90H21EOLACvtfcHk0lgCXYytqRZZ6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXitlOmu7k%253D&md5=38f706f2485adda9884f329e9a7b09e5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0969-8051%2896%2900212-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-8051%252896%252900212-0%26sid%3Dliteratum%253Aachs%26aulast%3DMock%26aufirst%3DB.%2BH.%26aulast%3DWinkle%26aufirst%3DW.%26aulast%3DVavrek%26aufirst%3DM.%2BT.%26atitle%3DA%2520color%2520spot%2520test%2520for%2520the%2520detection%2520of%2520Kryptofix%25202.2.2%2520in%2520%255B18F%255DFDG%2520preparations%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D1997%26volume%3D24%26spage%3D193%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, B. M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaquero, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pomper, M. G.</span><span> </span><span class="NLM_article-title">Performance evaluation of GE healthcare eXplore VISTA dual-ring small-animal PET scanner</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1891</span><span class="NLM_x">–</span> <span class="NLM_lpage">1900</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=1891-1900&author=Y.+Wangauthor=J.+Seidelauthor=B.+M.+W.+Tsuiauthor=J.+J.+Vaqueroauthor=M.+G.+Pomper&title=Performance+evaluation+of+GE+healthcare+eXplore+VISTA+dual-ring+small-animal+PET+scanner"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSeidel%26aufirst%3DJ.%26aulast%3DTsui%26aufirst%3DB.%2BM.%2BW.%26aulast%3DVaquero%26aufirst%3DJ.%2BJ.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26atitle%3DPerformance%2520evaluation%2520of%2520GE%2520healthcare%2520eXplore%2520VISTA%2520dual-ring%2520small-animal%2520PET%2520scanner%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2006%26volume%3D47%26spage%3D1891%26epage%3D1900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 18 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Xu</span>, <span class="hlFld-ContribAuthor ">Lujie  Yuan</span>, <span class="hlFld-ContribAuthor ">Lianglan  Yin</span>, <span class="hlFld-ContribAuthor ">Yaqun  Jiang</span>, <span class="hlFld-ContribAuthor ">Yongkang  Gai</span>, <span class="hlFld-ContribAuthor ">Qingyao  Liu</span>, <span class="hlFld-ContribAuthor ">Yichun  Wang</span>, <span class="hlFld-ContribAuthor ">Yongxue  Zhang</span>, and <span class="hlFld-ContribAuthor ">Xiaoli  Lan</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and Preclinical Evaluation of 18F-PEG3-FPN for the Detection of Metastatic Pigmented Melanoma. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2017,</strong> <em>14 </em>
                                    (11)
                                     , 3896-3905. <a href="https://doi.org/10.1021/acs.molpharmaceut.7b00607" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.7b00607</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.7b00607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.7b00607%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DSynthesis%252Band%252BPreclinical%252BEvaluation%252Bof%252B18F-PEG3-FPN%252Bfor%252Bthe%252BDetection%252Bof%252BMetastatic%252BPigmented%252BMelanoma%26aulast%3DXu%26aufirst%3DXiaodong%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D15072017%26date%3D16102017%26date%3D20092017%26date%3D27102017%26date%3D06112017%26date%3D16102017%26volume%3D14%26issue%3D11%26spage%3D3896%26epage%3D3905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maxine P.  Roberts</span>, <span class="hlFld-ContribAuthor ">Vu  Nguyen</span>, <span class="hlFld-ContribAuthor ">Mark E.  Ashford</span>, <span class="hlFld-ContribAuthor ">Paula  Berghofer</span>, <span class="hlFld-ContribAuthor ">Naomi A.  Wyatt</span>, <span class="hlFld-ContribAuthor ">Anwen M.  Krause-Heuer</span>, <span class="hlFld-ContribAuthor ">Tien Q.  Pham</span>, <span class="hlFld-ContribAuthor ">Stephen R.  Taylor</span>, <span class="hlFld-ContribAuthor ">Leena  Hogan</span>, <span class="hlFld-ContribAuthor ">Cathy D.  Jiang</span>, <span class="hlFld-ContribAuthor ">Benjamin H.  Fraser</span>, <span class="hlFld-ContribAuthor ">Nigel A.  Lengkeek</span>, <span class="hlFld-ContribAuthor ">Lidia  Matesic</span>, <span class="hlFld-ContribAuthor ">Marie-Claude  Gregoire</span>, <span class="hlFld-ContribAuthor ">Delphine  Denoyer</span>, <span class="hlFld-ContribAuthor ">Rodney J.  Hicks</span>, <span class="hlFld-ContribAuthor ">Andrew  Katsifis</span>, and <span class="hlFld-ContribAuthor ">Ivan  Greguric</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and in Vivo Evaluation of [123I]Melanin-Targeted Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (15)
                                     , 6214-6224. <a href="https://doi.org/10.1021/acs.jmedchem.5b00777" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00777</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00777%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bin%252BVivo%252BEvaluation%252Bof%252B%25255B123I%25255DMelanin-Targeted%252BAgents%26aulast%3DRoberts%26aufirst%3DMaxine%2BP.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D21052015%26date%3D29072015%26date%3D13082015%26date%3D15072015%26volume%3D58%26issue%3D15%26spage%3D6214%26epage%3D6224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emilie M. F.  Billaud</span>, <span class="hlFld-ContribAuthor ">Aurélien  Vidal</span>, <span class="hlFld-ContribAuthor ">Amélie  Vincenot</span>, <span class="hlFld-ContribAuthor ">Sophie  Besse</span>, <span class="hlFld-ContribAuthor ">Bernadette  Bouchon</span>, <span class="hlFld-ContribAuthor ">Eric  Debiton</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Miot-Noirault</span>, <span class="hlFld-ContribAuthor ">Imen  Miladi</span>, <span class="hlFld-ContribAuthor ">Latifa  Rbah-Vidal</span>, <span class="hlFld-ContribAuthor ">Philippe  Auzeloux</span>, and <span class="hlFld-ContribAuthor ">Jean-Michel  Chezal</span>  . </span><span class="cited-content_cbyCitation_article-title">Development and Preliminary Evaluation of TFIB, a New Bimodal Prosthetic Group for Bioactive Molecule Labeling. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (2)
                                     , 168-172. <a href="https://doi.org/10.1021/ml500423v" title="DOI URL">https://doi.org/10.1021/ml500423v</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml500423v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml500423v%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDevelopment%252Band%252BPreliminary%252BEvaluation%252Bof%252BTFIB%25252C%252Ba%252BNew%252BBimodal%252BProsthetic%252BGroup%252Bfor%252BBioactive%252BMolecule%252BLabeling%26aulast%3DBillaud%26aufirst%3DEmilie%2BM.%2BF.%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D18102014%26date%3D24112014%26date%3D01122014%26date%3D12022015%26date%3D24112014%26volume%3D6%26issue%3D2%26spage%3D168%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Radhia  El Aissi</span>, <span class="hlFld-ContribAuthor ">Jianrong  Liu</span>, <span class="hlFld-ContribAuthor ">Sophie  Besse</span>, <span class="hlFld-ContribAuthor ">Damien  Canitrot</span>, <span class="hlFld-ContribAuthor ">Olivier  Chavignon</span>, <span class="hlFld-ContribAuthor ">Jean-Michel  Chezal</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Miot-Noirault</span>, and <span class="hlFld-ContribAuthor ">Emmanuel  Moreau</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of New Quinoxaline Derivatives of ICF01012 as Melanoma-Targeting Probes. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>5 </em>
                                    (5)
                                     , 468-473. <a href="https://doi.org/10.1021/ml400468x" title="DOI URL">https://doi.org/10.1021/ml400468x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml400468x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml400468x%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNew%252BQuinoxaline%252BDerivatives%252Bof%252BICF01012%252Bas%252BMelanoma-Targeting%252BProbes%26aulast%3DEl%2BAissi%26aufirst%3DRadhia%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D15112013%26date%3D20022014%26date%3D24022014%26date%3D08052014%26date%3D20022014%26volume%3D5%26issue%3D5%26spage%3D468%26epage%3D473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thangavel  Selvi</span> and <span class="hlFld-ContribAuthor ">Kannupal  Srinivasan</span>  . </span><span class="cited-content_cbyCitation_article-title">Boron Trifluoride Mediated Ring-Opening Reactions of trans-2-Aryl-3-nitro-cyclopropane-1,1-dicarboxylates. Synthesis of Aroylmethylidene Malonates as Potential Building Blocks for Heterocycles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2014,</strong> <em>79 </em>
                                    (8)
                                     , 3653-3658. <a href="https://doi.org/10.1021/jo402848v" title="DOI URL">https://doi.org/10.1021/jo402848v</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jo402848v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjo402848v%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DBoron%252BTrifluoride%252BMediated%252BRing-Opening%252BReactions%252Bof%252Btrans-2-Aryl-3-nitro-cyclopropane-1%25252C1-dicarboxylates.%252BSynthesis%252Bof%252BAroylmethylidene%252BMalonates%252Bas%252BPotential%252BBuilding%252BBlocks%252Bfor%252BHeterocycles%26aulast%3DSelvi%26aufirst%3DThangavel%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D23122013%26date%3D10042014%26date%3D18042014%26date%3D01042014%26volume%3D79%26issue%3D8%26spage%3D3653%26epage%3D3658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacques  Rouanet</span>, <span class="hlFld-ContribAuthor ">Mercedes  Quintana</span>, <span class="hlFld-ContribAuthor ">Philippe  Auzeloux</span>, <span class="hlFld-ContribAuthor ">Florent  Cachin</span>, <span class="hlFld-ContribAuthor ">Françoise  Degoul</span>. </span><span class="cited-content_cbyCitation_article-title">Benzamide derivative radiotracers targeting melanin for melanoma imaging and therapy: Preclinical/clinical development and combination with other treatments. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2021,</strong> <em>224 </em>, 107829. <a href="https://doi.org/10.1016/j.pharmthera.2021.107829" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2021.107829</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2021.107829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2021.107829%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DBenzamide%252Bderivative%252Bradiotracers%252Btargeting%252Bmelanin%252Bfor%252Bmelanoma%252Bimaging%252Band%252Btherapy%25253A%252BPreclinical%25252Fclinical%252Bdevelopment%252Band%252Bcombination%252Bwith%252Bother%252Btreatments%26aulast%3DRouanet%26aufirst%3DJacques%26date%3D2021%26volume%3D224%26spage%3D107829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kohei  Umedera</span>, <span class="hlFld-ContribAuthor ">Taiki  Morita</span>, <span class="hlFld-ContribAuthor ">Atsushi  Yoshimori</span>, <span class="hlFld-ContribAuthor ">Kentaro  Yamada</span>, <span class="hlFld-ContribAuthor ">Akira  Katoh</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Kouji</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Nakamura</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Three‐Dimensional (Di)Azatricyclododecene Scaffold and Its Application to Peptidomimetics. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2021,</strong> <em>61 </em><a href="https://doi.org/10.1002/chem.202101440" title="DOI URL">https://doi.org/10.1002/chem.202101440</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202101440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202101440%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DSynthesis%252Bof%252BThree%2525E2%252580%252590Dimensional%252B%252528Di%252529Azatricyclododecene%252BScaffold%252Band%252BIts%252BApplication%252Bto%252BPeptidomimetics%26aulast%3DUmedera%26aufirst%3DKohei%26date%3D2021%26date%3D2021%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weijun  Wei</span>, <span class="hlFld-ContribAuthor ">Emily B.  Ehlerding</span>, <span class="hlFld-ContribAuthor ">Xiaoli  Lan</span>, <span class="hlFld-ContribAuthor ">Quanyong  Luo</span>, <span class="hlFld-ContribAuthor ">Weibo  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">PET and SPECT imaging of melanoma: the state of the art. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Nuclear Medicine and Molecular Imaging</span><span> <strong>2018,</strong> <em>45 </em>
                                    (1)
                                     , 132-150. <a href="https://doi.org/10.1007/s00259-017-3839-5" title="DOI URL">https://doi.org/10.1007/s00259-017-3839-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00259-017-3839-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00259-017-3839-5%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Nuclear%2520Medicine%2520and%2520Molecular%2520Imaging%26atitle%3DPET%252Band%252BSPECT%252Bimaging%252Bof%252Bmelanoma%25253A%252Bthe%252Bstate%252Bof%252Bthe%252Bart%26aulast%3DWei%26aufirst%3DWeijun%26date%3D2018%26date%3D2017%26volume%3D45%26issue%3D1%26spage%3D132%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pradeep K.  Garg</span>, <span class="hlFld-ContribAuthor ">Rachid  Nazih</span>, <span class="hlFld-ContribAuthor ">Yanjun  Wu</span>, <span class="hlFld-ContribAuthor ">Vladimir P.  Grinevich</span>, <span class="hlFld-ContribAuthor ">Sudha  Garg</span>. </span><span class="cited-content_cbyCitation_article-title">Selective targeting of melanoma using N-(2-diethylaminoethyl) 4-[18F]fluoroethoxy benzamide (4-[18F]FEBZA): a novel PET imaging probe. </span><span class="cited-content_cbyCitation_journal-name">EJNMMI Research</span><span> <strong>2017,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13550-017-0311-2" title="DOI URL">https://doi.org/10.1186/s13550-017-0311-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13550-017-0311-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13550-017-0311-2%26sid%3Dliteratum%253Aachs%26jtitle%3DEJNMMI%2520Research%26atitle%3DSelective%252Btargeting%252Bof%252Bmelanoma%252Busing%252BN-%2525282-diethylaminoethyl%252529%252B4-%25255B18F%25255Dfluoroethoxy%252Bbenzamide%252B%2525284-%25255B18F%25255DFEBZA%252529%25253A%252Ba%252Bnovel%252BPET%252Bimaging%252Bprobe%26aulast%3DGarg%26aufirst%3DPradeep%2BK.%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Imen  Miladi</span>, <span class="hlFld-ContribAuthor ">Magali  Vivier</span>, <span class="hlFld-ContribAuthor ">Marie-Mélanie  Dauplat</span>, <span class="hlFld-ContribAuthor ">Morgane  Chatard</span>, <span class="hlFld-ContribAuthor ">Sophie  Besse</span>, <span class="hlFld-ContribAuthor ">Aurélien  Vidal</span>, <span class="hlFld-ContribAuthor ">Karine  Chassain</span>, <span class="hlFld-ContribAuthor ">Betty  Jean</span>, <span class="hlFld-ContribAuthor ">Christiane  Forestier</span>, <span class="hlFld-ContribAuthor ">Jean-Michel  Chezal</span>, <span class="hlFld-ContribAuthor ">Francoise  Rédini</span>, <span class="hlFld-ContribAuthor ">Francoise  Degoul</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Miot-Noirault</span>. </span><span class="cited-content_cbyCitation_article-title">Doxycycline and its quaternary ammonium derivative for adjuvant therapies of chondrosarcoma. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2017,</strong> <em>80 </em>
                                    (3)
                                     , 517-526. <a href="https://doi.org/10.1007/s00280-017-3377-7" title="DOI URL">https://doi.org/10.1007/s00280-017-3377-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-017-3377-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-017-3377-7%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3DDoxycycline%252Band%252Bits%252Bquaternary%252Bammonium%252Bderivative%252Bfor%252Badjuvant%252Btherapies%252Bof%252Bchondrosarcoma%26aulast%3DMiladi%26aufirst%3DImen%26date%3D2017%26date%3D2017%26volume%3D80%26issue%3D3%26spage%3D517%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Latifa  Rbah-Vidal</span>, <span class="hlFld-ContribAuthor ">Aurélien  Vidal</span>, <span class="hlFld-ContribAuthor ">Emilie M.F.  Billaud</span>, <span class="hlFld-ContribAuthor ">Sophie  Besse</span>, <span class="hlFld-ContribAuthor ">Isabelle  Ranchon-Cole</span>, <span class="hlFld-ContribAuthor ">Florence  Mishellany</span>, <span class="hlFld-ContribAuthor ">Yann  Perrot</span>, <span class="hlFld-ContribAuthor ">Lydia  Maigne</span>, <span class="hlFld-ContribAuthor ">Nicole  Moins</span>, <span class="hlFld-ContribAuthor ">Jean-Luc  Guerquin-Kern</span>, <span class="hlFld-ContribAuthor ">Françoise  Degoul</span>, <span class="hlFld-ContribAuthor ">Jean-Michel  Chezal</span>, <span class="hlFld-ContribAuthor ">Philippe  Auzeloux</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Miot-Noirault</span>. </span><span class="cited-content_cbyCitation_article-title">Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy. </span><span class="cited-content_cbyCitation_journal-name">Neoplasia</span><span> <strong>2017,</strong> <em>19 </em>
                                    (1)
                                     , 17-27. <a href="https://doi.org/10.1016/j.neo.2016.11.001" title="DOI URL">https://doi.org/10.1016/j.neo.2016.11.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neo.2016.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neo.2016.11.001%26sid%3Dliteratum%253Aachs%26jtitle%3DNeoplasia%26atitle%3DTheranostic%252BApproach%252Bfor%252BMetastatic%252BPigmented%252BMelanoma%252BUsing%252BICF15002%25252C%252Ba%252BMultimodal%252BRadiotracer%252Bfor%252BBoth%252BPET%252BImaging%252Band%252BTargeted%252BRadionuclide%252BTherapy%26aulast%3DRbah-Vidal%26aufirst%3DLatifa%26date%3D2017%26volume%3D19%26issue%3D1%26spage%3D17%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dion  van der Born</span>, <span class="hlFld-ContribAuthor ">Anna  Pees</span>, <span class="hlFld-ContribAuthor ">Alex J.  Poot</span>, <span class="hlFld-ContribAuthor ">Romano V. A.  Orru</span>, <span class="hlFld-ContribAuthor ">Albert D.  Windhorst</span>, <span class="hlFld-ContribAuthor ">Danielle J.  Vugts</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine-18 labelled building blocks for PET tracer synthesis. </span><span class="cited-content_cbyCitation_journal-name">Chem. Soc. Rev.</span><span> <strong>2017,</strong> <em>46 </em>
                                    (15)
                                     , 4709-4773. <a href="https://doi.org/10.1039/C6CS00492J" title="DOI URL">https://doi.org/10.1039/C6CS00492J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6CS00492J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6CS00492J%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Soc.%2520Rev.%26atitle%3DFluorine-18%252Blabelled%252Bbuilding%252Bblocks%252Bfor%252BPET%252Btracer%252Bsynthesis%26aulast%3Dvan%2Bder%2BBorn%26aufirst%3DDion%26date%3D2017%26date%3D2017%26volume%3D46%26issue%3D15%26spage%3D4709%26epage%3D4773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nathalie  Rizzo-Padoin</span>, <span class="hlFld-ContribAuthor ">Michael  Chaussard</span>, <span class="hlFld-ContribAuthor ">Nicolas  Vignal</span>, <span class="hlFld-ContribAuthor ">Ewa  Kotula</span>, <span class="hlFld-ContribAuthor ">Vadim  Tsoupko-Sitnikov</span>, <span class="hlFld-ContribAuthor ">Sofia  Vaz</span>, <span class="hlFld-ContribAuthor ">Fortune  Hontonnou</span>, <span class="hlFld-ContribAuthor ">Wang-Qing  Liu</span>, <span class="hlFld-ContribAuthor ">Jean-Luc  Poyet</span>, <span class="hlFld-ContribAuthor ">Michel  Vidal</span>, <span class="hlFld-ContribAuthor ">Pascal  Merlet</span>, <span class="hlFld-ContribAuthor ">Benoit  Hosten</span>, <span class="hlFld-ContribAuthor ">Laure  Sarda-Mantel</span>. </span><span class="cited-content_cbyCitation_article-title">[ 18 F]MEL050 as a melanin-targeted PET tracer: Fully automated radiosynthesis and comparison to  18 F-FDG for the detection of pigmented melanoma in mice primary subcutaneous tumors and pulmonary metastases. </span><span class="cited-content_cbyCitation_journal-name">Nuclear Medicine and Biology</span><span> <strong>2016,</strong> <em>43 </em>
                                    (12)
                                     , 773-780. <a href="https://doi.org/10.1016/j.nucmedbio.2016.08.010" title="DOI URL">https://doi.org/10.1016/j.nucmedbio.2016.08.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nucmedbio.2016.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nucmedbio.2016.08.010%26sid%3Dliteratum%253Aachs%26jtitle%3DNuclear%2520Medicine%2520and%2520Biology%26atitle%3D%25255B%252B18%252BF%25255DMEL050%252Bas%252Ba%252Bmelanin-targeted%252BPET%252Btracer%25253A%252BFully%252Bautomated%252Bradiosynthesis%252Band%252Bcomparison%252Bto%252B18%252BF-FDG%252Bfor%252Bthe%252Bdetection%252Bof%252Bpigmented%252Bmelanoma%252Bin%252Bmice%252Bprimary%252Bsubcutaneous%252Btumors%252Band%252Bpulmonary%252Bmetastases%26aulast%3DRizzo-Padoin%26aufirst%3DNathalie%26date%3D2016%26volume%3D43%26issue%3D12%26spage%3D773%26epage%3D780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Allen F  Brooks</span>, <span class="hlFld-ContribAuthor ">Lindsey R  Drake</span>, <span class="hlFld-ContribAuthor ">Megan N  Stewart</span>, <span class="hlFld-ContribAuthor ">Brian P  Cary</span>, <span class="hlFld-ContribAuthor ">Isaac M  Jackson</span>, <span class="hlFld-ContribAuthor ">Dale  Mallette</span>, <span class="hlFld-ContribAuthor ">Andrew V  Mossine</span>, <span class="hlFld-ContribAuthor ">Peter JH  Scott</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine-18 patents (2009–2015). Part 1: novel radiotracers. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Patent Analyst</span><span> <strong>2016,</strong> <em>5 </em>
                                    (1)
                                     , 17-47. <a href="https://doi.org/10.4155/ppa.15.36" title="DOI URL">https://doi.org/10.4155/ppa.15.36</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/ppa.15.36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fppa.15.36%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Patent%2520Analyst%26atitle%3DFluorine-18%252Bpatents%252B%2525282009%2525E2%252580%2525932015%252529.%252BPart%252B1%25253A%252Bnovel%252Bradiotracers%26aulast%3DBrooks%26aufirst%3DAllen%2BF%26date%3D2016%26volume%3D5%26issue%3D1%26spage%3D17%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Radhia  El Aissi</span>, <span class="hlFld-ContribAuthor ">Jean-Michel  Chezal</span>, <span class="hlFld-ContribAuthor ">Sébastien  Tarrit</span>, <span class="hlFld-ContribAuthor ">Olivier  Chavignon</span>, <span class="hlFld-ContribAuthor ">Emmanuel  Moreau</span>. </span><span class="cited-content_cbyCitation_article-title">Melanoma-targeted delivery system (part 1): Design, synthesis and evaluation of releasable disulfide drug by glutathione. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>101 </em>, 668-680. <a href="https://doi.org/10.1016/j.ejmech.2015.06.055" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.06.055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.06.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.06.055%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMelanoma-targeted%252Bdelivery%252Bsystem%252B%252528part%252B1%252529%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Breleasable%252Bdisulfide%252Bdrug%252Bby%252Bglutathione%26aulast%3DEl%2BAissi%26aufirst%3DRadhia%26date%3D2015%26volume%3D101%26spage%3D668%26epage%3D680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Torsten  Kniess</span>, <span class="hlFld-ContribAuthor ">Markus  Laube</span>, <span class="hlFld-ContribAuthor ">Peter  Brust</span>, <span class="hlFld-ContribAuthor ">Jörg  Steinbach</span>. </span><span class="cited-content_cbyCitation_article-title">2-[
              18
              F]Fluoroethyl tosylate – a versatile tool for building
              18
              F-based radiotracers for positron emission tomography. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2015,</strong> <em>6 </em>
                                    (10)
                                     , 1714-1754. <a href="https://doi.org/10.1039/C5MD00303B" title="DOI URL">https://doi.org/10.1039/C5MD00303B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5MD00303B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5MD00303B%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3D2-%25255B%252B18%252BF%25255DFluoroethyl%252Btosylate%252B%2525E2%252580%252593%252Ba%252Bversatile%252Btool%252Bfor%252Bbuilding%252B18%252BF-based%252Bradiotracers%252Bfor%252Bpositron%252Bemission%252Btomography%26aulast%3DKniess%26aufirst%3DTorsten%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D10%26spage%3D1714%26epage%3D1754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L.  Vercellino</span>, <span class="hlFld-ContribAuthor ">P.  Schneider</span>, <span class="hlFld-ContribAuthor ">P.  Merlet</span>. </span><span class="cited-content_cbyCitation_article-title">Rôle de la TEP/TDM dans la prise en charge du mélanome. </span><span class="cited-content_cbyCitation_journal-name">Médecine Nucléaire</span><span> <strong>2014,</strong> <em>38 </em>
                                    (3)
                                     , 216-220. <a href="https://doi.org/10.1016/j.mednuc.2014.03.001" title="DOI URL">https://doi.org/10.1016/j.mednuc.2014.03.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mednuc.2014.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mednuc.2014.03.001%26sid%3Dliteratum%253Aachs%26jtitle%3DM%25C3%25A9decine%2520Nucl%25C3%25A9aire%26atitle%3DR%2525C3%2525B4le%252Bde%252Bla%252BTEP%25252FTDM%252Bdans%252Bla%252Bprise%252Ben%252Bcharge%252Bdu%252Bm%2525C3%2525A9lanome%26aulast%3DVercellino%26aufirst%3DL.%26date%3D2014%26volume%3D38%26issue%3D3%26spage%3D216%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Johannes  Ermert</span>. </span><span class="cited-content_cbyCitation_article-title">18
              F-Labelled Intermediates for Radiosynthesis by Modular Build-Up Reactions: Newer Developments. </span><span class="cited-content_cbyCitation_journal-name">BioMed Research International</span><span> <strong>2014,</strong> <em>2014 </em>, 1-15. <a href="https://doi.org/10.1155/2014/812973" title="DOI URL">https://doi.org/10.1155/2014/812973</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2014/812973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2014%2F812973%26sid%3Dliteratum%253Aachs%26jtitle%3DBioMed%2520Research%2520International%26atitle%3D18%252BF-Labelled%252BIntermediates%252Bfor%252BRadiosynthesis%252Bby%252BModular%252BBuild-Up%252BReactions%25253A%252BNewer%252BDevelopments%26aulast%3DErmert%26aufirst%3DJohannes%26date%3D2014%26volume%3D2014%26spage%3D1%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/medium/jm-2013-00877v_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400877v&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/medium/jm-2013-00877v_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of <b>1</b> (ICF01006),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a><b>2</b> (ICF01012),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and <b>3</b>,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> three examples of arylcarboxamides with high affinity for melanin-containing cells, evaluated in clinical or preclinical studies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400877v&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/medium/jm-2013-00877v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of the six iodinated and fluorinated 6-iodoquinoxaline-2-carboxamide derivatives investigated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400877v&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/medium/jm-2013-00877v_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Alcohols <b>21</b> and <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400877v&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) imidazole, TBDMSCl, DMF, rt, 24 h; (ii) imidazole, PPh<sub>3</sub>, I<sub>2</sub>, DCM, 0 °C, 30 min, then rt, 1 h; (iii) K<sub>2</sub>CO<sub>3</sub>, MeCN, rt, 72 h; (iv) NH<sub>2</sub>NH<sub>2</sub>, H<sub>2</sub>O, EtOH, rt, 17 h; (v) THF, rt, 18 h; (vi) TBAF 1 M, THF, rt, 2 h; (vii) (EtO)<sub>3</sub>SiH, [Cp*Ru(MeCN)<sub>3</sub>]PF<sub>6</sub>, DCM, 0 °C, 10 min, then rt, 2 h; (viii) AgF 1 M in MeOH, THF, rt in darkness, 2.5 h.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/medium/jm-2013-00877v_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of Mesylate Precursors <b>22</b>, <b>25</b>, <b>28</b>, <b>29</b>, and <b>31</b> Required for Radiofluorination<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400877v&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) MsCl, NEt<sub>3</sub>, DMAP, DCM, rt, 30–120 min.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/medium/jm-2013-00877v_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Radiosyntheses of [<sup>18</sup>F]<b>4</b>–<b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400877v&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) [<sup>18</sup>F]KF,K<sub>222</sub> complex, MeCN, 70 °C, 10 min, then 110 °C, 10 min; (ii) [<sup>18</sup>F]KF,K<sub>222</sub> complex, MeCN, 90 °C, 10 min.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/medium/jm-2013-00877v_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <i>In vivo</i> PET imaging biodistribution of radioactivity in B16Bl6 primary melanoma-bearing C57BL/6J mice 1 h after injection of [<sup>18</sup>F]<b>4</b> (A), [<sup>18</sup>F]<b>5</b> (B), [<sup>18</sup>F]<b>6</b> (C), [<sup>18</sup>F]<b>7</b> (D), [<sup>18</sup>F]<b>8</b> (E), and [<sup>18</sup>F]<b>9</b> (F) (8–12 MBq, iv). Coronal images represent maximum intensity projections. Tumors are indicated by arrows.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-21/jm400877v/production/images/large/jm-2013-00877v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400877v&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i62">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26253" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26253" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 48 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peris, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saiag, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spatz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malvehy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton-Bishop, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratigos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pehamberger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A.</span><span> </span><span class="NLM_article-title">Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=270-283&author=C.+Garbeauthor=K.+Perisauthor=A.+Hauschildauthor=P.+Saiagauthor=M.+Middletonauthor=A.+Spatzauthor=J.+J.+Grobauthor=J.+Malvehyauthor=J.+Newton-Bishopauthor=A.+Stratigosauthor=H.+Pehambergerauthor=A.+Eggermont&title=Diagnosis+and+treatment+of+melanoma%3A+European+consensus-based+interdisciplinary+guideline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DPeris%26aufirst%3DK.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DSaiag%26aufirst%3DP.%26aulast%3DMiddleton%26aufirst%3DM.%26aulast%3DSpatz%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DMalvehy%26aufirst%3DJ.%26aulast%3DNewton-Bishop%26aufirst%3DJ.%26aulast%3DStratigos%26aufirst%3DA.%26aulast%3DPehamberger%26aufirst%3DH.%26aulast%3DEggermont%26aufirst%3DA.%26atitle%3DDiagnosis%2520and%2520treatment%2520of%2520melanoma%253A%2520European%2520consensus-based%2520interdisciplinary%2520guideline%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2010%26volume%3D46%26spage%3D270%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiter, U.</span><span> </span><span class="NLM_article-title">Melanoma epidemiology and trends</span> <span class="citation_source-journal">Clin. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1016%2Fj.clindermatol.2008.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=19095149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FktVKjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=3-9&author=C.+Garbeauthor=U.+Leiter&title=Melanoma+epidemiology+and+trends"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Melanoma epidemiology and trends</span></div><div class="casAuthors">Garbe Claus; Leiter Ulrike</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in dermatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Rising incidence rates of cutaneous melanoma have been observed during the last four decades in white populations worldwide.  The cancer statistics in the United States have revealed 6 cases per 100,000 and year at the beginning of the 1970s and 18 cases per 100,000 inhabitants and year at the beginning of 2000, demonstrating a threefold increase in incidence rates.  Incidence rates in central Europe increased in the same time period from 3 to 4 cases to 10 to 15 cases per 100,000 inhabitants and year, which is very similar to the increase in the United States.  Cohort studies from several countries indicate that the trend of increasing incidence rates will continue in the future for at least the next 2 decades; thus, an additional doubling of incidence rates is expected.  The highest incidence rates have been reported from Australia and New Zealand, from 40 to 60 cases per 100,000 inhabitants and year.  Mortality rates likewise slightly increased in the United States and in Europe during the 1970s and 1980s.  In the 1990 s, however, a leveling off of mortality rates was observed in many countries.  Simultaneously, a clear decrease of Breslow tumor thickness was reported in the United States and European countries.  This development indicates improved early recognition of cutaneous melanoma, which is presently the main factor for a more favorable prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPuKSLi1S0zYHWj6b1v8uTfW6udTcc2eY5D3aSDsfq7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FktVKjug%253D%253D&md5=e740ba030ce6a0e2a9135db1a1e7f752</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.clindermatol.2008.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clindermatol.2008.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DLeiter%26aufirst%3DU.%26atitle%3DMelanoma%2520epidemiology%2520and%2520trends%26jtitle%3DClin.%2520Dermatol.%26date%3D2009%26volume%3D27%26spage%3D3%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Jennings, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, G. M.</span><span> </span><span class="NLM_article-title">Predicting outcome in melanoma: Where are we now?</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">496</span><span class="NLM_x">–</span> <span class="NLM_lpage">503</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1111%2Fj.1365-2133.2009.09324.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=496-503&author=L.+Jenningsauthor=G.+M.+Murphy&title=Predicting+outcome+in+melanoma%3A+Where+are+we+now%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2009.09324.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2009.09324.x%26sid%3Dliteratum%253Aachs%26aulast%3DJennings%26aufirst%3DL.%26aulast%3DMurphy%26aufirst%3DG.%2BM.%26atitle%3DPredicting%2520outcome%2520in%2520melanoma%253A%2520Where%2520are%2520we%2520now%253F%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2009%26volume%3D16%26spage%3D496%26epage%3D503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Balch, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gershenwald, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soong, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzaid, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochran, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coit, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimotty, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMasters, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihm, M. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sober, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondak, V. K.</span><span> </span><span class="NLM_article-title">Final version of 2009 AJCC melanoma staging and classification</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">6199</span><span class="NLM_x">–</span> <span class="NLM_lpage">6206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1200%2FJCO.2009.23.4799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=19917835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BD1MfivFaquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=6199-6206&author=C.+M.+Balchauthor=J.+E.+Gershenwaldauthor=S.+J.+Soongauthor=J.+F.+Thompsonauthor=M.+B.+Atkinsauthor=D.+R.+Byrdauthor=A.+C.+Buzaidauthor=A.+J.+Cochranauthor=D.+G.+Coitauthor=S.+Dingauthor=A.+M.+Eggermontauthor=K.+T.+Flahertyauthor=P.+A.+Gimottyauthor=J.+M.+Kirkwoodauthor=K.+M.+McMastersauthor=M.+C.+Mihmauthor=D.+L.+Mortonauthor=M.+I.+Rossauthor=A.+J.+Soberauthor=V.+K.+Sondak&title=Final+version+of+2009+AJCC+melanoma+staging+and+classification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Final version of 2009 AJCC melanoma staging and classification</span></div><div class="casAuthors">Balch Charles M; Gershenwald Jeffrey E; Soong Seng-Jaw; Thompson John F; Atkins Michael B; Byrd David R; Buzaid Antonio C; Cochran Alistair J; Coit Daniel G; Ding Shouluan; Eggermont Alexander M; Flaherty Keith T; Gimotty Phyllis A; Kirkwood John M; McMasters Kelly M; Mihm Martin C Jr; Morton Donald L; Ross Merrick I; Sober Arthur J; Sondak Vernon K</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">6199-206</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To revise the staging system for cutaneous melanoma on the basis of data from an expanded American Joint Committee on Cancer (AJCC) Melanoma Staging Database.  METHODS:  The melanoma staging recommendations were made on the basis of a multivariate analysis of 30,946 patients with stages I, II, and III melanoma and 7,972 patients with stage IV melanoma to revise and clarify TNM classifications and stage grouping criteria.  RESULTS:  Findings and new definitions include the following: (1) in patients with localized melanoma, tumor thickness, mitotic rate (histologically defined as mitoses/mm(2)), and ulceration were the most dominant prognostic factors. (2) Mitotic rate replaces level of invasion as a primary criterion for defining T1b melanomas. (3) Among the 3,307 patients with regional metastases, components that defined the N category were the number of metastatic nodes, tumor burden, and ulceration of the primary melanoma. (4) For staging purposes, all patients with microscopic nodal metastases, regardless of extent of tumor burden, are classified as stage III.  Micrometastases detected by immunohistochemistry are specifically included. (5) On the basis of a multivariate analysis of patients with distant metastases, the two dominant components in defining the M category continue to be the site of distant metastases (nonvisceral v lung v all other visceral metastatic sites) and an elevated serum lactate dehydrogenase level.  CONCLUSION:  Using an evidence-based approach, revisions to the AJCC melanoma staging system have been made that reflect our improved understanding of this disease.  These revisions will be formally incorporated into the seventh edition (2009) of the AJCC Cancer Staging Manual and implemented by early 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQegqsO8SNrUbxh97K6Vt6fW6udTcc2eZoGG0b9OU_Obntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MfivFaquw%253D%253D&md5=c4e7e8e046660cd903056a12cc8949f7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.23.4799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.23.4799%26sid%3Dliteratum%253Aachs%26aulast%3DBalch%26aufirst%3DC.%2BM.%26aulast%3DGershenwald%26aufirst%3DJ.%2BE.%26aulast%3DSoong%26aufirst%3DS.%2BJ.%26aulast%3DThompson%26aufirst%3DJ.%2BF.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26aulast%3DByrd%26aufirst%3DD.%2BR.%26aulast%3DBuzaid%26aufirst%3DA.%2BC.%26aulast%3DCochran%26aufirst%3DA.%2BJ.%26aulast%3DCoit%26aufirst%3DD.%2BG.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DGimotty%26aufirst%3DP.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DMcMasters%26aufirst%3DK.%2BM.%26aulast%3DMihm%26aufirst%3DM.%2BC.%26aulast%3DMorton%26aufirst%3DD.%2BL.%26aulast%3DRoss%26aufirst%3DM.%2BI.%26aulast%3DSober%26aufirst%3DA.%2BJ.%26aulast%3DSondak%26aufirst%3DV.%2BK.%26atitle%3DFinal%2520version%2520of%25202009%2520AJCC%2520melanoma%2520staging%2520and%2520classification%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D6199%26epage%3D6206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Scott, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinley, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trocha, S. D.</span><span> </span><span class="NLM_article-title">Treatment and outcomes of melanoma with a Breslow’s depth greater than or equal to one millimeter in a regional teaching hospital</span> <span class="citation_source-journal">Am. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=15869131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BD2M3jsVGmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2005&pages=198-201&author=J.+D.+Scottauthor=B.+P.+McKinleyauthor=A.+Bishopauthor=S.+D.+Trocha&title=Treatment+and+outcomes+of+melanoma+with+a+Breslow%E2%80%99s+depth+greater+than+or+equal+to+one+millimeter+in+a+regional+teaching+hospital"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment and outcomes of melanoma with a Breslow's depth greater than or equal to one millimeter in a regional teaching hospital</span></div><div class="casAuthors">Scott John D; McKinley Brian P; Bishop Aundie; Trocha Steven D</div><div class="citationInfo"><span class="NLM_cas:title">The American surgeon</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">198-201</span>
        ISSN:<span class="NLM_cas:issn">0003-1348</span>.
    </div><div class="casAbstract">Local control and regional lymph node evaluation are the primary treatment goals for cutaneous primary melanoma.  Historically, primary lesions were excised with large 3- to 5-cm radial margins.  Recent clinical trials have suggested that similar survival and recurrence rates can be achieved with smaller margins of excision.  In addition to excision of the primary lesion, the presence or absence of nodal metastasis is the single most powerful predictor of survival in patients with melanoma.  Based on the available trials, the standard of care for a melanoma 1 mm or greater in depth is a wide local excision with a 2-cm margin and a sentinel lymph node biopsy (SLNB).  The application of this standard in regional teaching hospitals is unknown.  We performed a retrospective review of a cancer registry at a teaching hospital in South Carolina.  This analysis included all patients who underwent surgery for melanoma at our institution between July 1997 and March 2003.  Our single inclusion criterion was that the primary melanoma had to be 1 mm or greater in depth.  Only 42 per cent of the patients underwent excision with a radial margin >2 cm, and only 60 per cent of the patients underwent SLNB.  As time progressed, the use of SLNB at our institution increased; but, even as late as 2003, some patients did not receive SLNB.  Adherence to standards did not appear to have an effect on overall survival.  In conclusion, the current standard for the treatment of invasive melanoma greater than or equal to 1 mm in thickness is a 2-cm margin of excision and a SLNB.  In this regional teaching hospital, surgical treatment and staging of melanoma did not strictly adhere to the standard.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdwdDDqecAz3O4gDb7JggCfW6udTcc2eZoGG0b9OU_Obntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3jsVGmtw%253D%253D&md5=4eb1b8868385e667c5a82b62c761b837</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DMcKinley%26aufirst%3DB.%2BP.%26aulast%3DBishop%26aufirst%3DA.%26aulast%3DTrocha%26aufirst%3DS.%2BD.%26atitle%3DTreatment%2520and%2520outcomes%2520of%2520melanoma%2520with%2520a%2520Breslow%25E2%2580%2599s%2520depth%2520greater%2520than%2520or%2520equal%2520to%2520one%2520millimeter%2520in%2520a%2520regional%2520teaching%2520hospital%26jtitle%3DAm.%2520Surg.%26date%3D2005%26volume%3D71%26spage%3D198%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Phan, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messina, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondak, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zager, J. S.</span><span> </span><span class="NLM_article-title">Sentinel lymph node biopsy for melanoma: Indications and rationale</span> <span class="citation_source-journal">Cancer Control.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">234</span><span class="NLM_x">–</span> <span class="NLM_lpage">239</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=234-239&author=G.+Q.+Phanauthor=J.+L.+Messinaauthor=V.+K.+Sondakauthor=J.+S.+Zager&title=Sentinel+lymph+node+biopsy+for+melanoma%3A+Indications+and+rationale"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPhan%26aufirst%3DG.%2BQ.%26aulast%3DMessina%26aufirst%3DJ.%2BL.%26aulast%3DSondak%26aufirst%3DV.%2BK.%26aulast%3DZager%26aufirst%3DJ.%2BS.%26atitle%3DSentinel%2520lymph%2520node%2520biopsy%2520for%2520melanoma%253A%2520Indications%2520and%2520rationale%26jtitle%3DCancer%2520Control.%26date%3D2009%26volume%3D16%26spage%3D234%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigentler, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilholz, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span> </span><span class="NLM_article-title">Systematic review of medical treatment in melanoma: Current status and future prospects</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=5-24&author=C.+Garbeauthor=T.+K.+Eigentlerauthor=U.+Keilholzauthor=A.+Hauschildauthor=J.+M.+Kirkwood&title=Systematic+review+of+medical+treatment+in+melanoma%3A+Current+status+and+future+prospects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DEigentler%26aufirst%3DT.%2BK.%26aulast%3DKeilholz%26aufirst%3DU.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26atitle%3DSystematic%2520review%2520of%2520medical%2520treatment%2520in%2520melanoma%253A%2520Current%2520status%2520and%2520future%2520prospects%26jtitle%3DOncologist%26date%3D2011%26volume%3D16%26spage%3D5%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Tarhini, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwala, S. S.</span><span> </span><span class="NLM_article-title">Cutaneous melanoma: Available therapy for metastatic disease</span> <span class="citation_source-journal">Dermatol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1111%2Fj.1529-8019.2005.00052.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=16405566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FhvF2qsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=19-25&author=A.+A.+Tarhiniauthor=S.+S.+Agarwala&title=Cutaneous+melanoma%3A+Available+therapy+for+metastatic+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cutaneous melanoma: available therapy for metastatic disease</span></div><div class="casAuthors">Tarhini Ahmad A; Agarwala Sanjiv S</div><div class="citationInfo"><span class="NLM_cas:title">Dermatologic therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-25</span>
        ISSN:<span class="NLM_cas:issn">1396-0296</span>.
    </div><div class="casAbstract">Survival of melanoma varies widely by stage, from a potentially highly curable disease when detected in early stages, to a disease with dismal prognosis when it reaches advanced inoperable stages.  Stage IV melanoma defines distant metastasis and continues to comprise an ominous prognosis, with a median survival of 6-9 months.  Currently, there is no therapeutic agent known to prolong survival in patients with metastatic melanoma.  Therapeutic approaches studied in metastatic melanoma include chemotherapy, biochemotherapy, nonspecific immune adjuvants, cancer-specific vaccines, cytokines, monoclonal antibodies, and specific immunostimulants.  Chemotherapy with single-agent dacarbazine is the only United States Food and Drug Administration (US-FDA)-approved chemotherapy agent for metastatic melanoma.  Immunological approaches have yielded the only newly US-FDA-approved agent for metastatic disease in 30 years, high-dose bolus IL-2, based on durable responses in some patients with metastatic melanoma, but with associated high toxicity rate and cost.  A number of novel therapeutic agents are undergoing active clinical investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROWnqd8D7PepI8NvIb08rbfW6udTcc2eZcJqw4hxklL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FhvF2qsA%253D%253D&md5=7fe340f6a6a28d6e7d2007467658be90</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1529-8019.2005.00052.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1529-8019.2005.00052.x%26sid%3Dliteratum%253Aachs%26aulast%3DTarhini%26aufirst%3DA.%2BA.%26aulast%3DAgarwala%26aufirst%3DS.%2BS.%26atitle%3DCutaneous%2520melanoma%253A%2520Available%2520therapy%2520for%2520metastatic%2520disease%26jtitle%3DDermatol.%2520Ther.%26date%3D2006%26volume%3D19%26spage%3D19%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigentler, T. K.</span><span> </span><span class="NLM_article-title">Diagnosis and treatment of cutaneous melanoma: State of the art 2006</span> <span class="citation_source-journal">Melanoma Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1097%2FCMR.0b013e328042bb36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=17496787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BD2s3pt12rtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=117-127&author=C.+Garbeauthor=T.+K.+Eigentler&title=Diagnosis+and+treatment+of+cutaneous+melanoma%3A+State+of+the+art+2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosis and treatment of cutaneous melanoma: state of the art 2006</span></div><div class="casAuthors">Garbe Claus; Eigentler Thomas K</div><div class="citationInfo"><span class="NLM_cas:title">Melanoma research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-27</span>
        ISSN:<span class="NLM_cas:issn">0960-8931</span>.
    </div><div class="casAbstract">Although the incidence of melanoma is still rising in Caucasian populations, the increase in mortality has leveled off.  Improvements in early diagnosis, with more frequent diagnosis of low-risk patients (i.e. those with <1 mm of tumor thickness), is the main reason for these divergent developments.  Primary prevention has not yet been successful and recent studies have demonstrated the lack of effectiveness of sunscreen in preventing nevi in children.  Progress was made in early melanoma diagnosis when dermoscopy and digital dermoscopy were introduced, and computer algorithms have proved to be highly efficacious for automated melanoma diagnosis.  Primary melanomas are now excised with narrower surgical margins of 1-2 cm.  Sentinel-node biopsy is recommended as a nodal staging procedure in patients with tumor thickness of 1 mm and more, but the prognostic impact of this procedure has not yet been demonstrated.  New imaging techniques, e.g. whole-body MRI and PET-CT, provide more accurate staging, particularly in patients with apparent metastasis, and facilitate decisions on surgical treatment strategies.  Staging is now based on the 2001 TNM classification including tumor thickness and histopathologic ulceration in stages I and II and lymph node micro and macro-metastasis in stage III.  A stage- and risk-adopted follow-up schedule is proposed for melanoma surveillance.  Adjuvant therapy with interferon-alpha in high-risk patients offers a small benefit in terms of recurrence-free and overall survival; the optimal dosage and duration of this treatment are still to be defined.  Almost no progress has been made in the medical treatment of disseminated metastasis of melanoma.  Therapy with dacarbazine and a few other single agents remains the first-line treatment approach of choice.  A number of new treatment modalities, including targeted molecules and immunologic approaches with monoclonal antibodies, are under development; hopefully, new treatment modalities will be available in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3xPhuLOo0mgpJitSxOdIlfW6udTcc2eZcJqw4hxklL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3pt12rtw%253D%253D&md5=84dc2d5b958d4a888152168370f4b44d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1097%2FCMR.0b013e328042bb36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCMR.0b013e328042bb36%26sid%3Dliteratum%253Aachs%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DEigentler%26aufirst%3DT.%2BK.%26atitle%3DDiagnosis%2520and%2520treatment%2520of%2520cutaneous%2520melanoma%253A%2520State%2520of%2520the%2520art%25202006%26jtitle%3DMelanoma%2520Res.%26date%3D2007%26volume%3D17%26spage%3D117%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Punt, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suciu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruit, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lienard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilholz, U.</span><span> </span><span class="NLM_article-title">Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">2991</span><span class="NLM_x">–</span> <span class="NLM_lpage">2995</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=2991-2995&author=C.+J.+Puntauthor=S.+Suciuauthor=M.+A.+Goreauthor=J.+Kollerauthor=W.+H.+Kruitauthor=J.+Thomasauthor=P.+Patelauthor=D.+Lienardauthor=A.+M.+Eggermontauthor=U.+Keilholz&title=Chemoimmunotherapy+with+dacarbazine%2C+cisplatin%2C+interferon-alpha2b+and+interleukin-2+versus+two+cycles+of+dacarbazine+followed+by+chemoimmunotherapy+in+patients+with+metastatic+melanoma%3A+A+randomised+phase+II+study+of+the+European+Organization+for+Research+and+Treatment+of+Cancer+Melanoma+Group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPunt%26aufirst%3DC.%2BJ.%26aulast%3DSuciu%26aufirst%3DS.%26aulast%3DGore%26aufirst%3DM.%2BA.%26aulast%3DKoller%26aufirst%3DJ.%26aulast%3DKruit%26aufirst%3DW.%2BH.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DLienard%26aufirst%3DD.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DKeilholz%26aufirst%3DU.%26atitle%3DChemoimmunotherapy%2520with%2520dacarbazine%252C%2520cisplatin%252C%2520interferon-alpha2b%2520and%2520interleukin-2%2520versus%2520two%2520cycles%2520of%2520dacarbazine%2520followed%2520by%2520chemoimmunotherapy%2520in%2520patients%2520with%2520metastatic%2520melanoma%253A%2520A%2520randomised%2520phase%2520II%2520study%2520of%2520the%2520European%2520Organization%2520for%2520Research%2520and%2520Treatment%2520of%2520Cancer%2520Melanoma%2520Group%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26spage%3D2991%26epage%3D2995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">O’Day, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loquai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutzmer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trefzer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottensmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Boer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hait, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P.</span><span> </span><span class="NLM_article-title">A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1038%2Fbjc.2011.183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=21750555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlOru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=346-352&author=S.+O%E2%80%99Dayauthor=A.+Pavlickauthor=C.+Loquaiauthor=D.+Lawsonauthor=R.+Gutzmerauthor=J.+Richardsauthor=D.+Schadendorfauthor=J.+A.+Thompsonauthor=R.+Gonzalezauthor=U.+Trefzerauthor=P.+Mohrauthor=C.+Ottensmeierauthor=D.+Chaoauthor=B.+Zhongauthor=C.+J.+de+Boerauthor=C.+Uhlarauthor=D.+Marshallauthor=M.+E.+Goreauthor=Z.+Langauthor=W.+Haitauthor=P.+Ho&title=A+randomised%2C+phase+II+study+of+intetumumab%2C+an+anti-%CE%B1v-integrin+mAb%2C+alone+and+with+dacarbazine+in+stage+IV+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma</span></div><div class="casAuthors">O'Day, S.; Pavlick, A.; Loquai, C.; Lawson, D.; Gutzmer, R.; Richards, J.; Schadendorf, D.; Thompson, J. A.; Gonzalez, R.; Trefzer, U.; Mohr, P.; Ottensmeier, C.; Chao, D.; Zhong, B.; de Boer, C. J.; Uhlar, C.; Marshall, D.; Gore, M. E.; Lang, Z.; Hait, W.; Ho, P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">346-352</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: αv integrins are involved in angiogenesis and melanoma tumorigenesis.  Intetumumab (CNTO 95) is a fully human anti-αv-integrin monoclonal antibody.  Methods: In a multicentre, randomized, phase II study, stage IV melanoma patients were randomized 1:1:1:1 to 1000 mg m-2 dacarbazine+placebo (n=32), 1000 mg m-2 dacarbazine+10 mg kg-1 intetumumab (n=32), 10 mg kg-1 intetumumab (n=33), or 5 mg kg-1 intetumumab (n=32) q3w.  The primary endpoint was progression-free survival (PFS).  Secondary endpoints included overall survival (OS), objective response rate (ORR), adverse events, and pharmacokinetics.  Results: No statistically significant differences in efficacy were obsd. between groups.  In the dacarbazine+placebo, dacarbazine+intetumumab, 10 mg kg-1 intetumumab, and 5 mg kg-1 intetumumab groups, median PFS was 1.8, 2.5, 1.4, and 1.4 mo; median OS was 8, 11, 15, and 9.8 mo; and ORR of complete+partial response was 10, 3, 6, and 0%.  Nonlinear intetumumab pharmacokinetics and potential intetumumab-dacarbazine interactions were obsd.  Transient, asymptomatic, nonrecurring, grade 1-2, uveitic reactions that resolved spontaneously or with topical steroids were seen in 22-30% of intetumumab-treated patients.  Low-grade infusion-reaction symptoms (headache, fatigue, nausea, vomiting, fever, chills) were obsd., as expected, in 16-73% of dacarbazine-treated patients.  No intetumumab-related myelosuppression, lab./ECG abnormalities, or deaths occurred.  Conclusion: With its favorable safety profile and a nonsignificant trend towards improved OS, intetumumab merits further investigation in advanced melanoma.  British Journal of Cancer (2011) 105, 346-352; doi:10.1038/bjc.2011.183 www.bjcancer.com Published online 12 July 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH1_VG9tlMO7Vg90H21EOLACvtfcHk0ljueyVxBuLQ_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlOru78%253D&md5=a5f2ce3b20b110d5b0b8a115b7878ccb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.183%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%26aulast%3DPavlick%26aufirst%3DA.%26aulast%3DLoquai%26aufirst%3DC.%26aulast%3DLawson%26aufirst%3DD.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DRichards%26aufirst%3DJ.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DTrefzer%26aufirst%3DU.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DOttensmeier%26aufirst%3DC.%26aulast%3DChao%26aufirst%3DD.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3Dde%2BBoer%26aufirst%3DC.%2BJ.%26aulast%3DUhlar%26aufirst%3DC.%26aulast%3DMarshall%26aufirst%3DD.%26aulast%3DGore%26aufirst%3DM.%2BE.%26aulast%3DLang%26aufirst%3DZ.%26aulast%3DHait%26aufirst%3DW.%26aulast%3DHo%26aufirst%3DP.%26atitle%3DA%2520randomised%252C%2520phase%2520II%2520study%2520of%2520intetumumab%252C%2520an%2520anti-%25CE%25B1v-integrin%2520mAb%252C%2520alone%2520and%2520with%2520dacarbazine%2520in%2520stage%2520IV%2520melanoma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2011%26volume%3D105%26spage%3D346%26epage%3D352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Attia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phan, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maker, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quezado, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherry, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topalian, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kammula, U. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royal, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Restifo, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haworth, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mavroukakis, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichol, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yellin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. A.</span><span> </span><span class="NLM_article-title">Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-CTLA4</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">6043</span><span class="NLM_x">–</span> <span class="NLM_lpage">6053</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1200%2FJCO.2005.06.205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=16087944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKgtb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=6043-6053&author=P.+Attiaauthor=G.+Q.+Phanauthor=A.+V.+Makerauthor=M.+R.+Robinsonauthor=M.+M.+Quezadoauthor=J.+C.+Yangauthor=R.+M.+Sherryauthor=S.+L.+Topalianauthor=U.+S.+Kammulaauthor=R.+E.+Royalauthor=N.+P.+Restifoauthor=L.+R.+Haworthauthor=C.+Levyauthor=S.+A.+Mavroukakisauthor=G.+Nicholauthor=M.+J.+Yellinauthor=S.+A.+Rosenberg&title=Autoimmunity+correlates+with+tumor+regression+in+patients+with+metastatic+melanoma+treated+with+anti-CTLA4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4</span></div><div class="casAuthors">Attia, Peter; Phan, Giao Q.; Maker, Ajay V.; Robinson, Michael R.; Quezado, Martha M.; Yang, James C.; Sherry, Richard M.; Topalian, Suzanne L.; Kammula, Udai S.; Royal, Richard E.; Restifo, Nicholas P.; Haworth, Leah R.; Levy, Catherine; Mavroukakis, Sharon A.; Nichol, Geoff; Yellin, Michael J.; Rosenberg, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6043-6053</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Previously, we reported our experience treating 14 patients with metastatic melanoma using a fully human antibody to cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) in conjunction with peptide vaccination.  We have now treated 56 patients to evaluate two different dose schedules of anti-CTLA-4 and to explore the relationship between autoimmunity and tumor regression.  Patients and Methods: A total of 56 patients with progressive stage IV melanoma were enrolled onto the study.  All had Karnofsky performance status ≥ 60% with no prior history of autoimmunity.  Twenty-nine patients received 3 mg/kg anti-CTLA-4 every 3 wk, whereas 27 received 3 mg/kg as their initial dose with subsequent doses reduced to 1 mg/kg every 3 wk.  In both cohorts patients received concomitant vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-assocd. antigen, gp100:209-217(210M) and gp100:280-288(288V).  Results: Two patients achieved a complete response (ongoing at 30 and 31 mo, resp.) and five patients achieved a partial response (durations of 4, 6, 25+, 26+, and 34+ months, resp.), for an overall objective response rate of 13%.  Tumor regression was seen in lung, liver, brain, lymph nodes, and s.c. sites.  Of 14 patients with grade 3/4 autoimmune toxicity, five (36%) experienced a clin. response compared with only two responses in the 42 patients (5%) with no autoimmune toxicity (P = .008).  There were no significant differences in response rate or toxicity between the two dose schedules.  Conclusion: Administration of anti-CTLA-4 monoclonal antibody plus peptide vaccination can cause durable objective responses, which correlate with the induction of autoimmunity, in patients with metastatic melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxb94fysv4CbVg90H21EOLACvtfcHk0ljueyVxBuLQ_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKgtb3L&md5=7daaac6d96ba23e275e9538f1210bcb3</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.06.205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.06.205%26sid%3Dliteratum%253Aachs%26aulast%3DAttia%26aufirst%3DP.%26aulast%3DPhan%26aufirst%3DG.%2BQ.%26aulast%3DMaker%26aufirst%3DA.%2BV.%26aulast%3DRobinson%26aufirst%3DM.%2BR.%26aulast%3DQuezado%26aufirst%3DM.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DSherry%26aufirst%3DR.%2BM.%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DKammula%26aufirst%3DU.%2BS.%26aulast%3DRoyal%26aufirst%3DR.%2BE.%26aulast%3DRestifo%26aufirst%3DN.%2BP.%26aulast%3DHaworth%26aufirst%3DL.%2BR.%26aulast%3DLevy%26aufirst%3DC.%26aulast%3DMavroukakis%26aufirst%3DS.%2BA.%26aulast%3DNichol%26aufirst%3DG.%26aulast%3DYellin%26aufirst%3DM.%2BJ.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26atitle%3DAutoimmunity%2520correlates%2520with%2520tumor%2520regression%2520in%2520patients%2520with%2520metastatic%2520melanoma%2520treated%2520with%2520anti-CTLA4%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D6043%26epage%3D6053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0liyw646IyKRiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Xing, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cromwell, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cormier, J. N.</span><span> </span><span class="NLM_article-title">Review of diagnostic imaging modalities for the surveillance of melanoma patients</span> <span class="citation_source-journal">Dermatol. Res. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span><span class="NLM_elocation-id">941921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BC3MjpslKnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=Y.+Xingauthor=K.+D.+Cromwellauthor=J.+N.+Cormier&title=Review+of+diagnostic+imaging+modalities+for+the+surveillance+of+melanoma+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Review of diagnostic imaging modalities for the surveillance of melanoma patients</span></div><div class="casAuthors">Xing Yan; Cromwell Kate D; Cormier Janice N</div><div class="citationInfo"><span class="NLM_cas:title">Dermatology research and practice</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">941921</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As melanoma survival rates continue to increase, optimal surveillance strategies for recurrences are needed, as are effective imaging modalities.  Therefore, we performed a meta-analysis to evaluate the current state of imaging modalities for surveillance of melanoma in the published medical literature to determine the sensitivity, specificity, and positive predictive values of ultrasonography, computed tomography (CT), positron emission tomography (PET), and CT-PET combined.  Ultrasonography was found to be the most sensitive and specific for detecting lymph node metastases, and PET-CT was the most sensitive and specific for detecting distant metastases.  In addition to identifying appropriate surveillance methods, future studies should focus on the most effective and cost-effective intervals for performing these tests.  In addition, the results from the meta-analysis related to sensitivity and specificity of the tests should be made available to doctors in community practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1jHmAg29Abi-bLEOO4dYpfW6udTcc2eaoG8Bt0xydfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjpslKnsA%253D%253D&md5=60ae36a57f98a807bf5f402f5d452cd8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DY.%26aulast%3DCromwell%26aufirst%3DK.%2BD.%26aulast%3DCormier%26aufirst%3DJ.%2BN.%26atitle%3DReview%2520of%2520diagnostic%2520imaging%2520modalities%2520for%2520the%2520surveillance%2520of%2520melanoma%2520patients%26jtitle%3DDermatol.%2520Res.%2520Pract.%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Krug, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonneux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baurain, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vander Borght, T.</span><span> </span><span class="NLM_article-title">Role of PET in the initial staging of cutaneous malignant melanoma: Systematic review</span> <span class="citation_source-journal">Radiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">249</span><span class="NLM_x">, </span> <span class="NLM_fpage">836</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=249&publication_year=2008&pages=836-844&author=B.+Krugauthor=R.+Crottauthor=M.+Lonneuxauthor=J.+F.+Baurainauthor=A.+S.+Pirsonauthor=T.+Vander+Borght&title=Role+of+PET+in+the+initial+staging+of+cutaneous+malignant+melanoma%3A+Systematic+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrug%26aufirst%3DB.%26aulast%3DCrott%26aufirst%3DR.%26aulast%3DLonneux%26aufirst%3DM.%26aulast%3DBaurain%26aufirst%3DJ.%2BF.%26aulast%3DPirson%26aufirst%3DA.%2BS.%26aulast%3DVander%2BBorght%26aufirst%3DT.%26atitle%3DRole%2520of%2520PET%2520in%2520the%2520initial%2520staging%2520of%2520cutaneous%2520malignant%2520melanoma%253A%2520Systematic%2520review%26jtitle%3DRadiology%26date%3D2008%26volume%3D249%26spage%3D836%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Veit-Haibach, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogt, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jablonka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuehl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bockisch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahmen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoch, G.</span><span> </span><span class="NLM_article-title">Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma</span> <span class="citation_source-journal">Eur. J. Nucl. Med. Mol. Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">910</span><span class="NLM_x">–</span> <span class="NLM_lpage">918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1007%2Fs00259-008-1049-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=19156409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BD1MzjtValtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=910-918&author=P.+Veit-Haibachauthor=F.+M.+Vogtauthor=R.+Jablonkaauthor=H.+Kuehlauthor=A.+Bockischauthor=T.+Beyerauthor=G.+Dahmenauthor=S.+Rosenbaumauthor=G.+Antoch&title=Diagnostic+accuracy+of+contrast-enhanced+FDG-PET%2FCT+in+primary+staging+of+cutaneous+malignant+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma</span></div><div class="casAuthors">Veit-Haibach Patrick; Vogt Florian M; Jablonka Robert; Kuehl Hilmar; Bockisch Andreas; Beyer Thomas; Dahmen Gerlinde; Rosenbaum Sandra; Antoch Gerald</div><div class="citationInfo"><span class="NLM_cas:title">European journal of nuclear medicine and molecular imaging</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">910-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To evaluate the diagnostic accuracy of contrast-enhanced FDG-PET/CT (ce-PET/CT), PET-only, and CT-only in patients with newly diagnosed and resected cutaneous malignant melanoma.  METHODS:  A final group of 56 patients (mean age 62 years, range 23-86 years; 29 women, 27 men) were staged with ce-PET/CT after resection of the primary tumour.  Histopathology as well as clinical follow-up (mean 780 days, range 102-1,390 days) served as the standards of reference.  Differences between the staging modalities were tested for statistical significance with McNemar's test.  RESULTS:  All imaging procedures provided low sensitivities in the detection of lymph nodes (sensitivity N-stage: PET/CT and PET-only 38.5%; CT-only 23.1%) and distant metastases (sensitivity M-stage: PET/CT 41.7%, PET-only 33.3%, CT-only 25.0%) in initial staging after resection of the primary tumour.  No statistically significant differences were detected between the imaging procedures (p > 0.05).  PET/CT resulted in an alteration in further treatment in two patients compared to PET-only and in four patients compared to CT-only.  CONCLUSION:  All imaging modalities had a low sensitivity on initial staging of patients with malignant melanoma.  Thus, close patient follow-up must be considered mandatory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkiCuZ-WEFgySm0e6ZOaemfW6udTcc2eZBqxMGspqpbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzjtValtw%253D%253D&md5=8453d33e91dd9a35a0c26254d0e3bf4b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs00259-008-1049-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-008-1049-x%26sid%3Dliteratum%253Aachs%26aulast%3DVeit-Haibach%26aufirst%3DP.%26aulast%3DVogt%26aufirst%3DF.%2BM.%26aulast%3DJablonka%26aufirst%3DR.%26aulast%3DKuehl%26aufirst%3DH.%26aulast%3DBockisch%26aufirst%3DA.%26aulast%3DBeyer%26aufirst%3DT.%26aulast%3DDahmen%26aufirst%3DG.%26aulast%3DRosenbaum%26aufirst%3DS.%26aulast%3DAntoch%26aufirst%3DG.%26atitle%3DDiagnostic%2520accuracy%2520of%2520contrast-enhanced%2520FDG-PET%252FCT%2520in%2520primary%2520staging%2520of%2520cutaneous%2520malignant%2520melanoma%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2009%26volume%3D36%26spage%3D910%26epage%3D918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Mirk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treglia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salsano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basile, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonomo, L.</span><span> </span><span class="NLM_article-title">Comparison between <sup>18</sup>F-Fluorodeoxyglucose positron emission tomography and sentinel lymph node biopsy for regional lymph nodal staging in patients with melanoma: A review of the literature</span> <span class="citation_source-journal">Radiol. Res. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span><span class="NLM_elocation-id">912504</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BC387kt1artQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=P.+Mirkauthor=G.+Tregliaauthor=M.+Salsanoauthor=P.+Basileauthor=A.+Giordanoauthor=L.+Bonomo&title=Comparison+between+18F-Fluorodeoxyglucose+positron+emission+tomography+and+sentinel+lymph+node+biopsy+for+regional+lymph+nodal+staging+in+patients+with+melanoma%3A+A+review+of+the+literature"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison between F-Fluorodeoxyglucose Positron Emission Tomography and Sentinel Lymph Node Biopsy for Regional Lymph Nodal Staging in Patients with Melanoma: A Review of the Literature</span></div><div class="casAuthors">Mirk Paoletta; Treglia Giorgio; Salsano Marco; Basile Pietro; Giordano Alessandro; Bonomo Lorenzo</div><div class="citationInfo"><span class="NLM_cas:title">Radiology research and practice</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">912504</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aim. to compare (18)F-Fluorodeoxyglucose positron emission tomography (FDG-PET) to sentinel lymph node biopsy (SLNB) for regional lymph nodal staging in patients with melanoma.  Methods.  We performed a literature review discussing original articles which compared FDG-PET to SLNB for regional lymph nodal staging in patients with melanoma.  Results and Conclusions.  There is consensus in the literature that FDG-PET cannot replace SLNB for regional lymph nodal staging in patients with melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqkqTRv89izn6oPH0mYWL1fW6udTcc2eZBqxMGspqpbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387kt1artQ%253D%253D&md5=f4ccde3a2a8e0da686c87de708200c14</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMirk%26aufirst%3DP.%26aulast%3DTreglia%26aufirst%3DG.%26aulast%3DSalsano%26aufirst%3DM.%26aulast%3DBasile%26aufirst%3DP.%26aulast%3DGiordano%26aufirst%3DA.%26aulast%3DBonomo%26aufirst%3DL.%26atitle%3DComparison%2520between%252018F-Fluorodeoxyglucose%2520positron%2520emission%2520tomography%2520and%2520sentinel%2520lymph%2520node%2520biopsy%2520for%2520regional%2520lymph%2520nodal%2520staging%2520in%2520patients%2520with%2520melanoma%253A%2520A%2520review%2520of%2520the%2520literature%26jtitle%3DRadiol.%2520Res.%2520Pract.%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Jiménez-Requena, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delgado-Bolton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Pérez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambhir, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwimmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Vasquez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreras-Delgado, J. L.</span><span> </span><span class="NLM_article-title">Meta-analysis of the performance of <sup>18</sup>F-FDG PET in cutaneous melanoma</span> <span class="citation_source-journal">Eur. J. Nucl. Med. Mol. Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1007%2Fs00259-009-1224-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=19727717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FotFCqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=284-300&author=F.+Jim%C3%A9nez-Requenaauthor=R.+C.+Delgado-Boltonauthor=C.+Fernandez-P%C3%A9rezauthor=S.+S.+Gambhirauthor=J.+Schwimmerauthor=J.+M.+P%C3%A9rez-Vasquezauthor=J.+L.+Carreras-Delgado&title=Meta-analysis+of+the+performance+of+18F-FDG+PET+in+cutaneous+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma</span></div><div class="casAuthors">Jimenez-Requena Felisa; Delgado-Bolton Roberto C; Fernandez-Perez Cristina; Gambhir Sanjiv S; Schwimmer Judy; Perez-Vazquez Jose M; Carreras-Delgado Jose L</div><div class="citationInfo"><span class="NLM_cas:title">European journal of nuclear medicine and molecular imaging</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">284-300</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  The aim of this study was to perform a systematic review of the literature to evaluate the accuracy of FDG-PET in staging and restaging of cutaneous melanoma.  METHODS:  Systematic methods were used to identify, select, and evaluate the methodologic quality of the studies as well as to summarize the overall findings of sensitivity and specificity.  The search strategy consisted of identifying studies published between 2000 and 2006.  Inclusion criteria were studies that evaluated the diagnostic performance of FDG-PET in staging/restaging of cutaneous melanoma.  The results were compared and pooled with a meta-analysis published previously that included studies published until 1999.  The meta-analysis included 95% confidence intervals (CI) of sensitivity, specificity, likelihood-ratio (LR), and diagnostic-odds-ratio (DOR).  RESULTS:  The quantitative meta-analysis included 24 studies that were analysed in two groups: eight studies were included only in the regional staging analysis (group I), 13 studies were included only in the detection of distant metastases analysis (group II), and three studies were included in both analyses.  Compliance with the methodologic-quality criteria was acceptable.  We analysed the results of data presented in patients, lesions, basins, lymph-nodes, areas, and scans.  Regarding the performance of FDG-PET in the detection of metastases, the pooled studies presented homogeneity for the negative-LR (0.15; 95% CI, 0.10-0.22) when analyzing lesions.  When analyzing scans, there was global homogeneity for specificity (0.86; 95% CI, 0.77-0.92), positive-LR (5.86; 95% CI, 3.64-9.43), and DOR (37.89; 95% CI, 15.80-90.86).  The pooled studies presented heterogeneity for the other items analysed.  Regarding the detection of regional metastases, when analyzing lymph-nodes there was global homogeneity for specificity (0.99; 95% CI, 0.97-0.99; P = 0.101).  The meta-regression evidenced that the variable that most influenced the DOR of the different studies and that can explain the heterogeneity was the year of publication; this may be related to the evolution of PET technology and an improvement of sensitivity/specificity.  CONCLUSION:  FDG-PET is not useful in the evaluation of regional metastases, as it does not detect microscopic disease.  However, FDG-PET could be useful in the detection of distant metastases, and could suggest its utility in the management of patients with cutaneous melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8sCIMQI56vkH3Rlp_k91zfW6udTcc2eZBqxMGspqpbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FotFCqsg%253D%253D&md5=d7b0a340299feaa670b0dfc4d979f173</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs00259-009-1224-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-009-1224-8%26sid%3Dliteratum%253Aachs%26aulast%3DJim%25C3%25A9nez-Requena%26aufirst%3DF.%26aulast%3DDelgado-Bolton%26aufirst%3DR.%2BC.%26aulast%3DFernandez-P%25C3%25A9rez%26aufirst%3DC.%26aulast%3DGambhir%26aufirst%3DS.%2BS.%26aulast%3DSchwimmer%26aufirst%3DJ.%26aulast%3DP%25C3%25A9rez-Vasquez%26aufirst%3DJ.%2BM.%26aulast%3DCarreras-Delgado%26aufirst%3DJ.%2BL.%26atitle%3DMeta-analysis%2520of%2520the%2520performance%2520of%252018F-FDG%2520PET%2520in%2520cutaneous%2520melanoma%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2010%26volume%3D37%26spage%3D284%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Wagner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerdoud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Julian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevreau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payoux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courbon, F.</span><span> </span><span class="NLM_article-title">Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">1235</span><span class="NLM_x">–</span> <span class="NLM_lpage">1240</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1111%2Fj.1365-2133.2011.10247.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=21332457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A280%3ADC%252BC3Mrlt1CqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=1235-1240&author=T.+Wagnerauthor=N.+Meyerauthor=S.+Zerdoudauthor=A.+Julianauthor=C.+Chevreauauthor=P.+Payouxauthor=F.+Courbon&title=Fluorodeoxyglucose+positron+emission+tomography+fails+to+detect+distant+metastases+at+initial+staging+of+melanoma+patients+with+metastatic+involvement+of+sentinel+lymph+node"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node</span></div><div class="casAuthors">Wagner T; Meyer N; Zerdoud S; Julian A; Chevreau C; Payoux P; Courbon F</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of dermatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1235-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Positron emission tomography (PET) using fluorodeoxyglucose (FDG) has proven to be more sensitive and accurate than other imaging modalities for the detection of distant metastases in patients with melanoma.  Sentinel lymph node (SLN) status is the most important prognostic factor in melanoma patients with no evidence of distant metastasis.  OBJECTIVES:  To assess the rate of distant metastases in patients with a positive SLN biopsy (SLNB).  METHODS:  Forty-six consecutive patients with a positive SLNB underwent PET or PET-computed tomography within 6 weeks of the SLNB procedure.  The patients did not present any clinical sign of nodal involvement or of distant metastasis.  PET findings were classified as positive, negative or nonconclusive.  RESULTS:  No patient had a positive PET scan for distant metastasis.  Six patients (13%) had a nonconclusive PET scan; none of them presented distant metastasis within 12 months.  Forty patients (87%) had a negative PET scan; among them five (12%) presented with distant metastasis within 12 months.  CONCLUSIONS:  Fluorodeoxyglucose positron emission tomography failed to detect distant metastases at initial staging in patients with a positive SLNB, even in patients who presented with distant metastases within 12 months after the FDG PET scan.  These results could be explained by the low prevalence of macroscopic metastatic disease at this stage and by the important delay between the onset of the spread of microscopic metastatic disease and the identification by PET scan of macroscopic metastatic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnA1uipPWCys-crCu0nI_sfW6udTcc2eYEGgH0surb3rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mrlt1CqtQ%253D%253D&md5=91097b6aa9a4ee4d2a2f52bf263f4984</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2011.10247.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2011.10247.x%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DMeyer%26aufirst%3DN.%26aulast%3DZerdoud%26aufirst%3DS.%26aulast%3DJulian%26aufirst%3DA.%26aulast%3DChevreau%26aufirst%3DC.%26aulast%3DPayoux%26aufirst%3DP.%26aulast%3DCourbon%26aufirst%3DF.%26atitle%3DFluorodeoxyglucose%2520positron%2520emission%2520tomography%2520fails%2520to%2520detect%2520distant%2520metastases%2520at%2520initial%2520staging%2520of%2520melanoma%2520patients%2520with%2520metastatic%2520involvement%2520of%2520sentinel%2520lymph%2520node%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2011%26volume%3D164%26spage%3D1235%26epage%3D1240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Minn, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vihinen, P.</span><span> </span><span class="NLM_article-title">Melanoma imaging with highly specific PET probes: Ready for prime time?</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=5-7&author=H.+Minnauthor=P.+Vihinen&title=Melanoma+imaging+with+highly+specific+PET+probes%3A+Ready+for+prime+time%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMinn%26aufirst%3DH.%26aulast%3DVihinen%26aufirst%3DP.%26atitle%3DMelanoma%2520imaging%2520with%2520highly%2520specific%2520PET%2520probes%253A%2520Ready%2520for%2520prime%2520time%253F%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2011%26volume%3D52%26spage%3D5%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Sturm, R. A.</span><span> </span><span class="NLM_article-title">Skin colour and skin cancer - MC1R, the genetic link</span> <span class="citation_source-journal">Melanoma Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1097%2F00008390-200209000-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=12394181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVOisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=405-416&author=R.+A.+Sturm&title=Skin+colour+and+skin+cancer+-+MC1R%2C+the+genetic+link"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Skin colour and skin cancer - MC1R, the genetic link</span></div><div class="casAuthors">Sturm, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Melanoma Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">405-416</span>CODEN:
                <span class="NLM_cas:coden">MREEEH</span>;
        ISSN:<span class="NLM_cas:issn">0960-8931</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Pigmentary traits such as red hair, fair skin, lack of tanning ability and propensity to freckle (the RHC phenotype) were identified as genetic risk factors for both melanoma and non-melanocytic skin cancers when combined with the environmental risk factor of high UV light exposure.  The human melanocortin-1 receptor (MC1R) is a key determinant of the pigmentation process and can account in large part for the diverse range of variation in human pigmentation phenotypes and skin phototypes.  The coding sequence is highly polymorphic in human populations, with several of these variant forms of the receptor now known to be assocd. with the RHC phenotype.  We have examd. MC1R variant allele frequencies in the general population and in a collection of adolescent dizygotic and monozygotic twins with defined pigmentation characteristics.  Variant allele frequencies were also detd. in several case-control studies of sporadic melanoma, basal cell carcinoma and squamous cell carcinoma, and in familial melanoma kindreds collected within Australia.  These studies have shown that 3 RHC alleles - Arg151Cys, Arg160Trp and Asp294His - were assocd. with increased risk in all forms of skin cancer and with penetrance and age of onset in familial melanoma in CDKN2A mutation carriers.  There is a significant RHC allele heterozygote carrier effect on skin phototype and skin cancer risk, which indicates that variant MC1R alleles do not behave in a strictly recessive manner.  Ultimately, the genetic and chem. assessment of melanin synthesis rather than skin color will be the best indicator for skin cancer risk, and such genetic assocn. studies combined with functional anal. of MC1R variant alleles should provide the link to understanding skin phototypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSlNKqRPktlbVg90H21EOLACvtfcHk0liORzyYEvKe4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVOisr4%253D&md5=3e7a370dc1b0e813addf3f1deca6e088</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1097%2F00008390-200209000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00008390-200209000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DSturm%26aufirst%3DR.%2BA.%26atitle%3DSkin%2520colour%2520and%2520skin%2520cancer%2520-%2520MC1R%252C%2520the%2520genetic%2520link%26jtitle%3DMelanoma%2520Res.%26date%3D2002%26volume%3D12%26spage%3D405%26epage%3D416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Miao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitener, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, T. P.</span><span> </span><span class="NLM_article-title">Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1177</span><span class="NLM_x">–</span> <span class="NLM_lpage">1184</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc034069i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlOmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2003&pages=1177-1184&author=Y.+Miaoauthor=D.+Whitenerauthor=W.+Fengauthor=N.+K.+Owenauthor=J.+Chenauthor=T.+P.+Quinn&title=Evaluation+of+the+human+melanoma+targeting+properties+of+radiolabeled+alpha-melanocyte+stimulating+hormone+peptide+analogues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the Human Melanoma Targeting Properties of Radiolabeled α-Melanocyte Stimulating Hormone Peptide Analogues</span></div><div class="casAuthors">Miao, Yubin; Whitener, Donna; Feng, Weiwei; Owen, Nellie K.; Chen, Jianqing; Quinn, Thomas P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1177-1184</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The purpose of this study was to evaluate the human MC1 receptor-mediated melanoma targeting properties of two metal cyclized α-MSH peptide analogs, 188Re-(Arg11)CCMSH and 188Re-CCMSH.  Initially, the presence and d. of the MC1 receptor were detd. on a bank of human melanoma cell lines.  All eight human melanoma cell lines tested in this study displayed the MC1 receptor at a d. of 900 to 5700 receptors per cell.  Receptor affinity and biodistribution properties of 188Re-(Arg11)CCMSH and 188Re-CCMSH were evaluated in a cultured TXM13 human melanoma-xenografted Scid mouse model.  Biodistribution results demonstrated that 3.06 ± 0.68 %ID/g of 188Re-(Arg11)CCMSH accumulated in the tumors 1 h postinjection and greater than 65% of the activity at 1 h postinjection remained in the tumors at 4 h after dose administration.  Whole body clearance of 188Re-(Arg11)CCMSH was very rapid, with approx. 82% of injected dose cleared through urinary system at 4 h postinjection.  There was very little activity in blood and major organs such as liver, lung, and muscle except for the kidney.  188Re-CCMSH exhibited similar tumor uptake and retention in TXM13 human melanoma-xenografted Scid mice as 188Re-(Arg11)CCMSH.  However, the kidney uptake value of 188Re-CCMSH was two times higher than that of 188Re-(Arg11)CCMSH.  The results of this study indicate that the MC1 receptor is present on the surface of a large no. of human melanoma cells, which makes the MC1 receptor a good imaging or therapeutic target.  Moreover, the biodistribution properties of 188Re-(Arg11)CCMSH and 188Re-CCMSH highlight their potential as therapeutic agents for human melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVLaDK3J0sirVg90H21EOLACvtfcHk0liORzyYEvKe4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlOmsr4%253D&md5=c86c29a23da9eff01178cccb3e035ed9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fbc034069i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc034069i%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DY.%26aulast%3DWhitener%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DW.%26aulast%3DOwen%26aufirst%3DN.%2BK.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DQuinn%26aufirst%3DT.%2BP.%26atitle%3DEvaluation%2520of%2520the%2520human%2520melanoma%2520targeting%2520properties%2520of%2520radiolabeled%2520alpha-melanocyte%2520stimulating%2520hormone%2520peptide%2520analogues%26jtitle%3DBioconjugate%2520Chem.%26date%3D2003%26volume%3D14%26spage%3D1177%26epage%3D1184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gershman, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sklar, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Y.</span><span> </span><span class="NLM_article-title">Metastatic melanoma imaging with an <sup>111</sup>In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide</span> <span class="citation_source-journal">Nucl. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">276</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1016%2Fj.nucmedbio.2009.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=19324272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvVOrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=267-276&author=H.+Guoauthor=N.+Shenoyauthor=B.+M.+Gershmanauthor=J.+Yangauthor=L.+A.+Sklarauthor=Y.+Miao&title=Metastatic+melanoma+imaging+with+an+111In-labeled+lactam+bridge-cyclized+alpha-melanocyte+stimulating+hormone+peptide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Metastatic melanoma imaging with an 111In-labeled lactam bridge-cyclized α-melanocyte-stimulating hormone peptide</span></div><div class="casAuthors">Guo, Haixun; Shenoy, Nalini; Gershman, Benjamin M.; Yang, Jianquan; Sklar, Larry A.; Miao, Yubin</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-276</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Introduction: The purpose of this study was to examine whether a novel lactam bridge-cyclized 111In-labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-Gly-Glu-c[Lys-Nle-Glu-His--Phe-Arg-Trp-Gly-Arg-Pro-Val-Asp] {DOTA-GlyGlu-CycMSH} could be an effective imaging probe for metastatic melanoma detection.  Methods: 111In-DOTA-GlyGlu-CycMSH was prepd. and purified by reverse-phase high-performance liq. chromatog. (RP-HPLC).  The internalization and efflux of 111In-DOTA-GlyGlu-CycMSH were examd. in B16/F10 melanoma cells.  The biodistribution of 111In-DOTA-GlyGlu-CycMSH was detd. in B16/F10 pulmonary metastatic melanoma-bearing and normal C57 mice.  Pulmonary metastatic melanoma imaging was performed by small-animal single-photon emission computed tomog. (SPECT)/CT (Nano-SPECT/CT) using 111In-DOTA-GlyGlu-CycMSH as an imaging probe and compared with 2-[18F]fluoro-2-deoxy-glucose ([18F]FDG) positron emission tomog. (PET) imaging.  Results: 111In-DOTA-GlyGlu-CycMSH was readily prepd. with greater than 95% radiolabeling yield. 111In-DOTA-GlyGlu-CycMSH displayed rapid internalization and extended efflux in B16/F10 cells.  111In-DOTA-GlyGlu-CycMSH exhibited significantly (P<.05) higher uptakes (2.00±0.74%ID/g at 2 h post-injection and 1.83±0.12%ID/g at 4 h post-injection) in metastatic melanoma-bearing lung than that in normal lung (0.08±0.08%ID/g and 0.05±0.05%ID/g at 2 and 4 h post-injection, resp.).  The activity accumulation in normal organs was low (<0.5%ID/g) except for the kidneys 2 and 4 h post-injection.  B16/F10 pulmonary melanoma metastases were clearly visualized with 111In-DOTA-GlyGlu-CycMSH 2 h post-injection rather than with [18F]FDG 1 h post-injection.  Conclusions: 111In-DOTA-GlyGlu-CycMSH exhibited favorable metastatic melanoma-targeting and -imaging properties, highlighting its potential as an effective imaging probe for metastatic melanoma detection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS5-8BSvRDU7Vg90H21EOLACvtfcHk0li97vOEiRJczA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvVOrs7s%253D&md5=e2ccf662da2c0c05841c6e8b93f91c53</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2009.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2009.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DShenoy%26aufirst%3DN.%26aulast%3DGershman%26aufirst%3DB.%2BM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DSklar%26aufirst%3DL.%2BA.%26aulast%3DMiao%26aufirst%3DY.%26atitle%3DMetastatic%2520melanoma%2520imaging%2520with%2520an%2520111In-labeled%2520lactam%2520bridge-cyclized%2520alpha-melanocyte%2520stimulating%2520hormone%2520peptide%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2009%26volume%3D36%26spage%3D267%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Cheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandekar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambhir, S. S.</span><span> </span><span class="NLM_article-title">Small-animal PET of melanocortin 1 receptor expression using a <sup>18</sup>F-labeled alpha-melanocyte-stimulating hormone analog</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">987</span><span class="NLM_x">–</span> <span class="NLM_lpage">994</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=987-994&author=Z.+Chengauthor=L.+Zhangauthor=E.+Gravesauthor=Z.+Xiongauthor=M.+Dandekarauthor=X.+Chenauthor=S.+S.+Gambhir&title=Small-animal+PET+of+melanocortin+1+receptor+expression+using+a+18F-labeled+alpha-melanocyte-stimulating+hormone+analog"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGraves%26aufirst%3DE.%26aulast%3DXiong%26aufirst%3DZ.%26aulast%3DDandekar%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGambhir%26aufirst%3DS.%2BS.%26atitle%3DSmall-animal%2520PET%2520of%2520melanocortin%25201%2520receptor%2520expression%2520using%2520a%252018F-labeled%2520alpha-melanocyte-stimulating%2520hormone%2520analog%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2007%26volume%3D48%26spage%3D987%26epage%3D994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Ren, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subbarayan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambhir, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Z.</span><span> </span><span class="NLM_article-title">PET of Malignant melanoma using labeled metallopeptides</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1865</span><span class="NLM_x">–</span> <span class="NLM_lpage">1872</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=1865-1872&author=G.+Renauthor=Z.+Liuauthor=Z.+Miaoauthor=H.+Liuauthor=M.+Subbarayanauthor=F.+T.+Chinauthor=L.+Zhangauthor=S.+S.+Gambhirauthor=Z.+Cheng&title=PET+of+Malignant+melanoma+using+labeled+metallopeptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSubbarayan%26aufirst%3DM.%26aulast%3DChin%26aufirst%3DF.%2BT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGambhir%26aufirst%3DS.%2BS.%26aulast%3DCheng%26aufirst%3DZ.%26atitle%3DPET%2520of%2520Malignant%2520melanoma%2520using%2520labeled%2520metallopeptides%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2009%26volume%3D50%26spage%3D1865%26epage%3D1872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Ren, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Z.</span><span> </span><span class="NLM_article-title">Radiofluorinated rhenium cyclized α-MSH analogues for PET imaging of melanocortin receptor 1</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2355</span><span class="NLM_x">–</span> <span class="NLM_lpage">2360</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc100391a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWhsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=2355-2360&author=G.+Renauthor=S.+Liuauthor=H.+Liuauthor=Z.+Miaoauthor=Z.+Cheng&title=Radiofluorinated+rhenium+cyclized+%CE%B1-MSH+analogues+for+PET+imaging+of+melanocortin+receptor+1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Radiofluorinated Rhenium Cyclized α-MSH Analogues for PET Imaging of Melanocortin Receptor 1</span></div><div class="casAuthors">Ren, Gang; Liu, Shuanlong; Liu, Hongguang; Miao, Zheng; Cheng, Zhen</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2355-2360</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to accomplish in vivo mol. imaging of melanoma biomarker melanocortin 1 receptor (MC1R), several α-MSH (α-MSH) analogs have been labeled with N-succinimidyl-4-18F-fluorobenzoate (18F-SFB) and studied as positron emission tomog. (PET) probes in our recent studies.  To further pursue a radiofluorinated α-MSH peptide with high clin. translation potential, we utilized 4-nitrophenyl 2-18F-fluoropropionate (18F-NFP) to radiofluorinate the transition metal rhenium cyclized α-MSH metallopeptides for PET imaging of MC1R pos. malignant melanoma.  Metallopeptides Ac-d,Lys-ReCCMSH(Arg11) (two isomers, namely RMSH-1 and RMSH-2) were synthesized using conventional solid phase peptide synthesis chem. and rhenium cyclization reaction.  The two isomers were then conjugated with 19F-NFP or 18F-NFP.  The resulting cold or radiofluorinated metallopeptides, 18/19F-FP-RMSH-1 and 18/19F-FP-RMSH-2, were further evaluated for their in vitro receptor binding affinities, in vivo biodistribution, and small-animal PET imaging properties.  The binding affinities of 19F-FP-RMSH-1 and 19F-FP-RMSH-2 were detd. to be within low nanomolar range.  In vivo studies revealed that both 18F-labeled metallopeptides possessed good tumor uptake in the B16F10 murine model with high MC1R expression, while possessing much lower uptake in A375M human melanoma xenografts.  Moreover, 18F-FP-RMSH-1 displayed more favorable in vivo performance in terms of higher tumor uptake and much lower accumulation in the kidney and liver, when compared to that of 18F-FP-RMSH-2 at 2 h postinjection (p.i.). 18F-FP-RMSH-1 also displayed lower liver and lung uptake when compared with that of the same peptide labeled with 18F-SFB (named as 18F-FB-RMSH-1).  Small animal PET imaging of 18F-FP-RMSH-1 in mice bearing B16F10 tumors at 1 and 2 h showed good tumor imaging quality.  As expected, much lower tumor uptake and poorer tumor/normal organ contrast were obsd. for A375M model compared to those of the B16F10 model. 18F-FP-RMSH-1 also exhibited higher tumor uptake and better tumor retention when compared with 18F-FB-RMSH-1. 18F-FP-RMSH-1 demonstrates significant advantages over 18F-FB-RMSH-1 and 18F-FP-RMSH-2.  It is a promising PET probe for imaging MC1R pos. melanoma and MC1R expression in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIgR0Y5vfCj7Vg90H21EOLACvtfcHk0li97vOEiRJczA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWhsbfJ&md5=f6b101d037e51662c80c5e439cab65e6</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fbc100391a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc100391a%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DZ.%26atitle%3DRadiofluorinated%2520rhenium%2520cyclized%2520%25CE%25B1-MSH%2520analogues%2520for%2520PET%2520imaging%2520of%2520melanocortin%2520receptor%25201%26jtitle%3DBioconjugate%2520Chem.%26date%3D2010%26volume%3D21%26spage%3D2355%26epage%3D2360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Eisenhut, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hull, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Just, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorgas, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberkorn, U.</span><span> </span><span class="NLM_article-title">Radioiodinated <i>N</i>-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: Structure–affinity relationships, metabolic fate, and intracellular localization</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3913</span><span class="NLM_x">–</span> <span class="NLM_lpage">3922</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm991079p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3913-3922&author=M.+Eisenhutauthor=W.+E.+Hullauthor=A.+Mohammedauthor=W.+Mierauthor=D.+Layauthor=W.+Justauthor=K.+Gorgasauthor=W.+D.+Lehmannauthor=U.+Haberkorn&title=Radioiodinated+N-%282-diethylaminoethyl%29benzamide+derivatives+with+high+melanoma+uptake%3A+Structure%E2%80%93affinity+relationships%2C+metabolic+fate%2C+and+intracellular+localization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm991079p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm991079p%26sid%3Dliteratum%253Aachs%26aulast%3DEisenhut%26aufirst%3DM.%26aulast%3DHull%26aufirst%3DW.%2BE.%26aulast%3DMohammed%26aufirst%3DA.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DLay%26aufirst%3DD.%26aulast%3DJust%26aufirst%3DW.%26aulast%3DGorgas%26aufirst%3DK.%26aulast%3DLehmann%26aufirst%3DW.%2BD.%26aulast%3DHaberkorn%26aufirst%3DU.%26atitle%3DRadioiodinated%2520N-%25282-diethylaminoethyl%2529benzamide%2520derivatives%2520with%2520high%2520melanoma%2520uptake%253A%2520Structure%25E2%2580%2593affinity%2520relationships%252C%2520metabolic%2520fate%252C%2520and%2520intracellular%2520localization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3913%26epage%3D3922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Chezal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labarre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lartigue, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galmier, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decombat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavignon, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maublant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teulade, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madelmont, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moins, N.</span><span> </span><span class="NLM_article-title">Evaluation of radiolabeled (hetero)aromatic analogues of <i>N</i>-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3133</span><span class="NLM_x">–</span> <span class="NLM_lpage">3144</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701424g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3133-3144&author=J.+M.+Chezalauthor=J.+Paponauthor=P.+Labarreauthor=C.+Lartigueauthor=M.+J.+Galmierauthor=C.+Decombatauthor=O.+Chavignonauthor=J.+Maublantauthor=J.+C.+Teuladeauthor=J.+C.+Madelmontauthor=N.+Moins&title=Evaluation+of+radiolabeled+%28hetero%29aromatic+analogues+of+N-%282-diethylaminoethyl%29-4-iodobenzamide+for+imaging+and+targeted+radionuclide+therapy+of+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm701424g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701424g%26sid%3Dliteratum%253Aachs%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26aulast%3DPapon%26aufirst%3DJ.%26aulast%3DLabarre%26aufirst%3DP.%26aulast%3DLartigue%26aufirst%3DC.%26aulast%3DGalmier%26aufirst%3DM.%2BJ.%26aulast%3DDecombat%26aufirst%3DC.%26aulast%3DChavignon%26aufirst%3DO.%26aulast%3DMaublant%26aufirst%3DJ.%26aulast%3DTeulade%26aufirst%3DJ.%2BC.%26aulast%3DMadelmont%26aufirst%3DJ.%2BC.%26aulast%3DMoins%26aufirst%3DN.%26atitle%3DEvaluation%2520of%2520radiolabeled%2520%2528hetero%2529aromatic%2520analogues%2520of%2520N-%25282-diethylaminoethyl%2529-4-iodobenzamide%2520for%2520imaging%2520and%2520targeted%2520radionuclide%2520therapy%2520of%2520melanoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3133%26epage%3D3144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Madelmont, J. C.; Chezal, J. M.; Moins, N.; Teulade, J. C.; Chavignon, O.</span><span> </span><span class="NLM_article-title">Labeled analogues of halobenzamides as radiopharmaceuticals</span>. World Patent WO2008012782,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=J.+C.+Madelmont&author=J.+M.+Chezal&author=N.+Moins&author=J.+C.+Teulade&author=O.+Chavignon&title=Labeled+analogues+of+halobenzamides+as+radiopharmaceuticals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMadelmont%26aufirst%3DJ.%2BC.%26atitle%3DLabeled%2520analogues%2520of%2520halobenzamides%2520as%2520radiopharmaceuticals%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Greguric, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denoyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballantyne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghofer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roselt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, T. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourdier, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neels, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorow, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loc’h, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsifis, A.</span><span> </span><span class="NLM_article-title">Discovery of [<sup>18</sup>F]<i>N</i>-(2-(diethylamino)ethyl)-6-fluoronicotinamide: A melanoma positron emission tomography imaging radiotracer with high tumour to body contrast ratio and rapid renal clearance</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5299</span><span class="NLM_x">–</span> <span class="NLM_lpage">5302</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9008423" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5299-5302&author=I.+Greguricauthor=S.+R.+Taylorauthor=D.+Denoyerauthor=P.+Ballantyneauthor=P.+Berghoferauthor=P.+Roseltauthor=T.+Q.+Phamauthor=F.+Mattnerauthor=T.+Bourdierauthor=O.+C.+Neelsauthor=D.+S.+Dorowauthor=C.+Loc%E2%80%99hauthor=R.+J.+Hicksauthor=A.+Katsifis&title=Discovery+of+%5B18F%5DN-%282-%28diethylamino%29ethyl%29-6-fluoronicotinamide%3A+A+melanoma+positron+emission+tomography+imaging+radiotracer+with+high+tumour+to+body+contrast+ratio+and+rapid+renal+clearance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm9008423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9008423%26sid%3Dliteratum%253Aachs%26aulast%3DGreguric%26aufirst%3DI.%26aulast%3DTaylor%26aufirst%3DS.%2BR.%26aulast%3DDenoyer%26aufirst%3DD.%26aulast%3DBallantyne%26aufirst%3DP.%26aulast%3DBerghofer%26aufirst%3DP.%26aulast%3DRoselt%26aufirst%3DP.%26aulast%3DPham%26aufirst%3DT.%2BQ.%26aulast%3DMattner%26aufirst%3DF.%26aulast%3DBourdier%26aufirst%3DT.%26aulast%3DNeels%26aufirst%3DO.%2BC.%26aulast%3DDorow%26aufirst%3DD.%2BS.%26aulast%3DLoc%25E2%2580%2599h%26aufirst%3DC.%26aulast%3DHicks%26aufirst%3DR.%2BJ.%26aulast%3DKatsifis%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520%255B18F%255DN-%25282-%2528diethylamino%2529ethyl%2529-6-fluoronicotinamide%253A%2520A%2520melanoma%2520positron%2520emission%2520tomography%2520imaging%2520radiotracer%2520with%2520high%2520tumour%2520to%2520body%2520contrast%2520ratio%2520and%2520rapid%2520renal%2520clearance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5299%26epage%3D5302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Denoyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greguric, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roselt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neels, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aide, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsifis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorow, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, R. J.</span><span> </span><span class="NLM_article-title">High-contrast PET of melanoma using [<sup>18</sup>F]MEL050, a selective probe for melanin with predominantly renal clearance</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=441-447&author=D.+Denoyerauthor=I.+Greguricauthor=P.+Roseltauthor=O.+C.+Neelsauthor=N.+Aideauthor=S.+R.+Taylorauthor=A.+Katsifisauthor=D.+S.+Dorowauthor=R.+J.+Hicks&title=High-contrast+PET+of+melanoma+using+%5B18F%5DMEL050%2C+a+selective+probe+for+melanin+with+predominantly+renal+clearance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDenoyer%26aufirst%3DD.%26aulast%3DGreguric%26aufirst%3DI.%26aulast%3DRoselt%26aufirst%3DP.%26aulast%3DNeels%26aufirst%3DO.%2BC.%26aulast%3DAide%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BR.%26aulast%3DKatsifis%26aufirst%3DA.%26aulast%3DDorow%26aufirst%3DD.%2BS.%26aulast%3DHicks%26aufirst%3DR.%2BJ.%26atitle%3DHigh-contrast%2520PET%2520of%2520melanoma%2520using%2520%255B18F%255DMEL050%252C%2520a%2520selective%2520probe%2520for%2520melanin%2520with%2520predominantly%2520renal%2520clearance%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2010%26volume%3D51%26spage%3D441%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Rbah-Vidal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cachin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Askienazy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dollé, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degoul, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miot-Noirault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moins, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auzeloux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chezal, J. M.</span><span> </span><span class="NLM_article-title">Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [<sup>18</sup>F]ICF01006, a highly promising melanoma PET tracer</span> <span class="citation_source-journal">Eur. J. Nucl. Med. Mol. Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1449</span><span class="NLM_x">–</span> <span class="NLM_lpage">1461</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1007%2Fs00259-012-2168-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=22707183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKis7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=1449-1461&author=L.+Rbah-Vidalauthor=A.+Vidalauthor=S.+Besseauthor=F.+Cachinauthor=M.+Bonnetauthor=L.+Audinauthor=S.+Askienazyauthor=F.+Doll%C3%A9author=F.+Degoulauthor=E.+Miot-Noiraultauthor=N.+Moinsauthor=P.+Auzelouxauthor=J.+M.+Chezal&title=Early+detection+and+longitudinal+monitoring+of+experimental+primary+and+disseminated+melanoma+using+%5B18F%5DICF01006%2C+a+highly+promising+melanoma+PET+tracer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [18F]ICF01006, a highly promising melanoma PET tracer</span></div><div class="casAuthors">Rbah-Vidal, Latifa; Vidal, Aurelien; Besse, Sophie; Cachin, Florent; Bonnet, Mathilde; Audin, Laurent; Askienazy, Serge; Dolle, Frederic; Degoul, Francoise; Miot-Noirault, Elisabeth; Moins, Nicole; Auzeloux, Philippe; Chezal, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1449-1461</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose Here, we report a new and rapid radiosynthesis of 18F-N-[2-(diethylamino)ethyl]-6-fluoro-pyridine-3-carboxamide ([18F]ICF01006), a mol. with a high specificity for melanotic tissue, and its evaluation in a murine model for early specific detection of pigmented primary and disseminated melanoma.  Methods [18F]ICF01006 was synthesized using a new one-step bromine-for-fluorine nucleophilic heteroarom. substitution.  Melanoma models were induced by s.c. (primary tumor) or i.v. (lung colonies) injection of B16BL6 melanoma cells in C57BL/6J mice.  The relevance and sensitivity of positron emission tomog. (PET) imaging using [18F]ICF01006 were evaluated at different stages of tumoral growth and compared to 18F-fluorodeoxyglucose ([18F]FDG).  Results The fully automated radiosynthesis of [18F]ICF01006 led to a radiochem. yield of 61 % and a radiochem. purity >99 % (specific activity 70-80 GBq/μmol; total synthesis time 42 min).  Tumors were visualized before they were palpable as early as 1 h post-injection with [18F]ICF01006 tumoral uptake of 1.64 ± 0.57, 3.40 ± 1.47 and 11.44 ± 2.67 percentage of injected dose per g of tissue (%ID/g) at days 3, 5 and 14, resp. [18F]ICF01006 PET imaging also allowed detection of melanoma pulmonary colonies from day 9 after tumor cell inoculation, with a lung radiotracer accumulation correlated with melanoma invasion.  At day 21, radioactivity uptake in lungs reached a value of 5.23 ± 2.08 %ID/g (vs. 0.41 ± 0.90 %ID/g in control mice).  In the two models, comparison with [18F]FDG showed that both radiotracers were able to detect melanoma lesions, but [18F]ICF01006 was superior in terms of contrast and specificity.  Conclusion Our promising results provide further preclin. data, reinforcing the excellent potential of [18F]ICF01006 PET imaging for early specific diagnosis and follow-up of melanin-pos. disseminated melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6icg8of-5SrVg90H21EOLACvtfcHk0lg9tBo1_SVDHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKis7nM&md5=52a508a0f0a56f9b0b1f07d513995934</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs00259-012-2168-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-012-2168-y%26sid%3Dliteratum%253Aachs%26aulast%3DRbah-Vidal%26aufirst%3DL.%26aulast%3DVidal%26aufirst%3DA.%26aulast%3DBesse%26aufirst%3DS.%26aulast%3DCachin%26aufirst%3DF.%26aulast%3DBonnet%26aufirst%3DM.%26aulast%3DAudin%26aufirst%3DL.%26aulast%3DAskienazy%26aufirst%3DS.%26aulast%3DDoll%25C3%25A9%26aufirst%3DF.%26aulast%3DDegoul%26aufirst%3DF.%26aulast%3DMiot-Noirault%26aufirst%3DE.%26aulast%3DMoins%26aufirst%3DN.%26aulast%3DAuzeloux%26aufirst%3DP.%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26atitle%3DEarly%2520detection%2520and%2520longitudinal%2520monitoring%2520of%2520experimental%2520primary%2520and%2520disseminated%2520melanoma%2520using%2520%255B18F%255DICF01006%252C%2520a%2520highly%2520promising%2520melanoma%2520PET%2520tracer%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2012%26volume%3D39%26spage%3D1449%26epage%3D1461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Bonnet-Duquennoy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishellany, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labarre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerquin-Kern, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardette, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maublant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penault-Llorca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miot-Noirault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cayre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madelmont, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chezal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moins, N.</span><span> </span><span class="NLM_article-title">Targeted radionuclide therapy of melanoma: Anti-tumoural efficacy studies of a new <sup>131</sup>I labelled potential agent</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">708</span><span class="NLM_x">–</span> <span class="NLM_lpage">716</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1002%2Fijc.24413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=19437532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsleqt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2009&pages=708-716&author=M.+Bonnet-Duquennoyauthor=J.+Paponauthor=F.+Mishellanyauthor=P.+Labarreauthor=J.+L.+Guerquin-Kernauthor=T.+D.+Wuauthor=M.+Gardetteauthor=J.+Maublantauthor=F.+Penault-Llorcaauthor=E.+Miot-Noiraultauthor=A.+Cayreauthor=J.+C.+Madelmontauthor=J.+M.+Chezalauthor=N.+Moins&title=Targeted+radionuclide+therapy+of+melanoma%3A+Anti-tumoural+efficacy+studies+of+a+new+131I+labelled+potential+agent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted radionuclide therapy of melanoma: Anti-tumoural efficacy studies of a new 131I labelled potential agent</span></div><div class="casAuthors">Bonnet-Duquennoy, Mathilde; Papon, Janine; Mishellany, Florence; Labarre, Pierre; Guerquin-Kern, Jean-Luc; Wu, Ting-Di; Gardette, Maryline; Maublant, Jean; Penault-Llorca, Frederique; Miot-Noirault, Elisabeth; Cayre, Anne; Madelmont, Jean-Claude; Chezal, Jean-Michel; Moins, Nicole</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">708-716</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">In recent years, there has been dramatic worldwide increase in incidence of malignant melanoma.  Although localised disease is often curable by surgical excision, metastatic melanoma is inherently resistant to most treatments.  In this context, targeted radionuclide therapy could be an efficient alternative.  After pharmacomodulation study, we selected a quinoxaline deriv. mol. (ICF01012) for its high, specific and long-lasting uptake in melanoma with rapid clearance from nontarget organs providing suitable dosimetry parameters for targeted radiotherapy.  Aim of this study was to investigate, in vivo, efficacy of [131I]ICF01012 on nonmetastatic B16F0, metastatic B16Bl6 or human M4Beu melanoma tumors.  First, colocalisation of ICF01012 with melanin by SIMS imaging was obsd.  Second, we showed that treatment drastically inhibited growth of B16F0, B16Bl6 and M4beu tumors whereas [131I]NaI or unlabeled ICF01012 treatment was without significant effect.  Histol. anal. and measure of PCNA proliferation marker expression showed that residual B16 tumor cellsexhibit a significant loss of aggressiveness after treatment.  This effect is assocd. with a lengthening of the treated-mice survival time.  Moreover, with B16Bl6 model, 55% of the untreated mice had lung metastases whereas no metastasis was counted on treated group.  Our data demonstrated a strong anti-tumoral effect of [131I]ICF01012 for radionuclide therapy on murine and human in vivo pigmented melanoma models, whatever their dissemination profiles and their melanin content be.  Further studies will attempt to optimize therapy protocol by increasing the balance between the anti-tumoral effect and the safety on nontarget organs. © 2009 UICC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8zBsnkS4UObVg90H21EOLACvtfcHk0lg9tBo1_SVDHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsleqt78%253D&md5=f74ebc292d1b6c8004b547d2946e8323</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fijc.24413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.24413%26sid%3Dliteratum%253Aachs%26aulast%3DBonnet-Duquennoy%26aufirst%3DM.%26aulast%3DPapon%26aufirst%3DJ.%26aulast%3DMishellany%26aufirst%3DF.%26aulast%3DLabarre%26aufirst%3DP.%26aulast%3DGuerquin-Kern%26aufirst%3DJ.%2BL.%26aulast%3DWu%26aufirst%3DT.%2BD.%26aulast%3DGardette%26aufirst%3DM.%26aulast%3DMaublant%26aufirst%3DJ.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DMiot-Noirault%26aufirst%3DE.%26aulast%3DCayre%26aufirst%3DA.%26aulast%3DMadelmont%26aufirst%3DJ.%2BC.%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26aulast%3DMoins%26aufirst%3DN.%26atitle%3DTargeted%2520radionuclide%2520therapy%2520of%2520melanoma%253A%2520Anti-tumoural%2520efficacy%2520studies%2520of%2520a%2520new%2520131I%2520labelled%2520potential%2520agent%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2009%26volume%3D125%26spage%3D708%26epage%3D716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Bonnet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishellany, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cayre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penault-Llorca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madelmont, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miot-Noirault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chezal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moins, N.</span><span> </span><span class="NLM_article-title">Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution</span> <span class="citation_source-journal">Pigm. Cell Melanoma Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1</span><span class="NLM_x">–</span> <span class="NLM_lpage">e11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=e1-e11&author=M.+Bonnetauthor=F.+Mishellanyauthor=J.+Paponauthor=A.+Cayreauthor=F.+Penault-Llorcaauthor=J.+C.+Madelmontauthor=E.+Miot-Noiraultauthor=J.+M.+Chezalauthor=N.+Moins&title=Anti-melanoma+efficacy+of+internal+radionuclide+therapy+in+relation+to+melanin+target+distribution"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonnet%26aufirst%3DM.%26aulast%3DMishellany%26aufirst%3DF.%26aulast%3DPapon%26aufirst%3DJ.%26aulast%3DCayre%26aufirst%3DA.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DMadelmont%26aufirst%3DJ.%2BC.%26aulast%3DMiot-Noirault%26aufirst%3DE.%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26aulast%3DMoins%26aufirst%3DN.%26atitle%3DAnti-melanoma%2520efficacy%2520of%2520internal%2520radionuclide%2520therapy%2520in%2520relation%2520to%2520melanin%2520target%2520distribution%26jtitle%3DPigm.%2520Cell%2520Melanoma%2520Res.%26date%3D2010%26volume%3D23%26spage%3De1%26epage%3De11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Boisgard, R.; Chezal, J. M.; Dollé, F.; Kuhnast, B.; Madelmont, J. C.; Maisonial, A.; Miot-Noirault, E.; Moins, N.; Papon, J.; Tavitian, B.</span><span> </span><span class="NLM_article-title">Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors</span>. World Patent WO2009095872,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Boisgard&author=J.+M.+Chezal&author=F.+Doll%C3%A9&author=B.+Kuhnast&author=J.+C.+Madelmont&author=A.+Maisonial&author=E.+Miot-Noirault&author=N.+Moins&author=J.+Papon&author=B.+Tavitian&title=Labelled+analogues+of+halobenzamides+as+multimodal+radiopharmaceuticals+and+their+precursors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoisgard%26aufirst%3DR.%26atitle%3DLabelled%2520analogues%2520of%2520halobenzamides%2520as%2520multimodal%2520radiopharmaceuticals%2520and%2520their%2520precursors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Auzeloux, P.; Billaud, E. M. F.; Chezal, J. M.; Madelmont, J. C.; Maisonial, A.; Miot-Noirault, E.; Papon, J.; Rbah-Vidal, L.; Vidal, A.</span><span> </span><span class="NLM_article-title">Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors</span>. PCT/IB2013/053106,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=P.+Auzeloux&author=E.+M.+F.+Billaud&author=J.+M.+Chezal&author=J.+C.+Madelmont&author=A.+Maisonial&author=E.+Miot-Noirault&author=J.+Papon&author=L.+Rbah-Vidal&author=A.+Vidal&title=Labelled+quinoxaline+derivatives+as+multimodal+radiopharmaceuticals+and+their+precursors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAuzeloux%26aufirst%3DP.%26atitle%3DLabelled%2520quinoxaline%2520derivatives%2520as%2520multimodal%2520radiopharmaceuticals%2520and%2520their%2520precursors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Maisonial, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhnast, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boisgard, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auzeloux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rbah, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet-Duquennoy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miot-Noirault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galmier, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Askienazy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dollé, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavitian, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madelmont, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moins, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chezal, J. M.</span><span> </span><span class="NLM_article-title">Single photon emission computed tomography/positron emission tomography imaging and targeted radionuclide therapy of melanoma: new multimodal fluorinated and iodinated radiotracers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2745</span><span class="NLM_x">–</span> <span class="NLM_lpage">2766</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101574q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2745-2766&author=A.+Maisonialauthor=B.+Kuhnastauthor=J.+Paponauthor=R.+Boisgardauthor=M.+Bayleauthor=A.+Vidalauthor=P.+Auzelouxauthor=L.+Rbahauthor=M.+Bonnet-Duquennoyauthor=E.+Miot-Noiraultauthor=M.+J.+Galmierauthor=M.+Borelauthor=S.+Askienazyauthor=F.+Doll%C3%A9author=B.+Tavitianauthor=J.+C.+Madelmontauthor=N.+Moinsauthor=J.+M.+Chezal&title=Single+photon+emission+computed+tomography%2Fpositron+emission+tomography+imaging+and+targeted+radionuclide+therapy+of+melanoma%3A+new+multimodal+fluorinated+and+iodinated+radiotracers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm101574q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101574q%26sid%3Dliteratum%253Aachs%26aulast%3DMaisonial%26aufirst%3DA.%26aulast%3DKuhnast%26aufirst%3DB.%26aulast%3DPapon%26aufirst%3DJ.%26aulast%3DBoisgard%26aufirst%3DR.%26aulast%3DBayle%26aufirst%3DM.%26aulast%3DVidal%26aufirst%3DA.%26aulast%3DAuzeloux%26aufirst%3DP.%26aulast%3DRbah%26aufirst%3DL.%26aulast%3DBonnet-Duquennoy%26aufirst%3DM.%26aulast%3DMiot-Noirault%26aufirst%3DE.%26aulast%3DGalmier%26aufirst%3DM.%2BJ.%26aulast%3DBorel%26aufirst%3DM.%26aulast%3DAskienazy%26aufirst%3DS.%26aulast%3DDoll%25C3%25A9%26aufirst%3DF.%26aulast%3DTavitian%26aufirst%3DB.%26aulast%3DMadelmont%26aufirst%3DJ.%2BC.%26aulast%3DMoins%26aufirst%3DN.%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26atitle%3DSingle%2520photon%2520emission%2520computed%2520tomography%252Fpositron%2520emission%2520tomography%2520imaging%2520and%2520targeted%2520radionuclide%2520therapy%2520of%2520melanoma%253A%2520new%2520multimodal%2520fluorinated%2520and%2520iodinated%2520radiotracers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2745%26epage%3D2766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Maisonial, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billaud, E. M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rbah-Vidal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galmier, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrit, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Askienazy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madelmont, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auzeloux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miot-Noirault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chezal, J. M.</span><span> </span><span class="NLM_article-title">Synthesis, radioiodination and <i>in vivo</i> screening of novel potent iodinated and fluorinated radiotracers as melanoma imaging and therapeutic probes</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">840</span><span class="NLM_x">–</span> <span class="NLM_lpage">853</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2013&pages=840-853&author=A.+Maisonialauthor=E.+M.+F.+Billaudauthor=S.+Besseauthor=L.+Rbah-Vidalauthor=J.+Paponauthor=L.+Audinauthor=M.+Bayleauthor=M.+J.+Galmierauthor=S.+Tarritauthor=M.+Borelauthor=S.+Askienazyauthor=J.+C.+Madelmontauthor=M.+Moinsauthor=P.+Auzelouxauthor=E.+Miot-Noiraultauthor=J.+M.+Chezal&title=Synthesis%2C+radioiodination+and+in+vivo+screening+of+novel+potent+iodinated+and+fluorinated+radiotracers+as+melanoma+imaging+and+therapeutic+probes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaisonial%26aufirst%3DA.%26aulast%3DBillaud%26aufirst%3DE.%2BM.%2BF.%26aulast%3DBesse%26aufirst%3DS.%26aulast%3DRbah-Vidal%26aufirst%3DL.%26aulast%3DPapon%26aufirst%3DJ.%26aulast%3DAudin%26aufirst%3DL.%26aulast%3DBayle%26aufirst%3DM.%26aulast%3DGalmier%26aufirst%3DM.%2BJ.%26aulast%3DTarrit%26aufirst%3DS.%26aulast%3DBorel%26aufirst%3DM.%26aulast%3DAskienazy%26aufirst%3DS.%26aulast%3DMadelmont%26aufirst%3DJ.%2BC.%26aulast%3DMoins%26aufirst%3DM.%26aulast%3DAuzeloux%26aufirst%3DP.%26aulast%3DMiot-Noirault%26aufirst%3DE.%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26atitle%3DSynthesis%252C%2520radioiodination%2520and%2520in%2520vivo%2520screening%2520of%2520novel%2520potent%2520iodinated%2520and%2520fluorinated%2520radiotracers%2520as%2520melanoma%2520imaging%2520and%2520therapeutic%2520probes%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D63%26spage%3D840%26epage%3D853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Cai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, D.</span><span> </span><span class="NLM_article-title">Sequential reaction process to assemble polysubstituted indolizidines, quinolizidines and quinolizidine analogues</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">5697</span><span class="NLM_x">–</span> <span class="NLM_lpage">5708</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=5697-5708&author=G.+Caiauthor=W.+Zhuauthor=D.+Ma&title=Sequential+reaction+process+to+assemble+polysubstituted+indolizidines%2C+quinolizidines+and+quinolizidine+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DD.%26atitle%3DSequential%2520reaction%2520process%2520to%2520assemble%2520polysubstituted%2520indolizidines%252C%2520quinolizidines%2520and%2520quinolizidine%2520analogues%26jtitle%3DTetrahedron%26date%3D2006%26volume%3D62%26spage%3D5697%26epage%3D5708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Jones, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holtz, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edward, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cragoe, E. J.,  Jr.</span><span> </span><span class="NLM_article-title">6-Substituted 5-chloro-1,3-dihydro-2H-imidazo[4,5-b]pyrazin-2-ones with hypotensive activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00263a029" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1973&pages=537-542&author=J.+H.+Jonesauthor=W.+J.+Holtzauthor=J.+Edwardauthor=E.+J.+Cragoe&title=6-Substituted+5-chloro-1%2C3-dihydro-2H-imidazo%5B4%2C5-b%5Dpyrazin-2-ones+with+hypotensive+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm00263a029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00263a029%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DJ.%2BH.%26aulast%3DHoltz%26aufirst%3DW.%2BJ.%26aulast%3DEdward%26aufirst%3DJ.%26aulast%3DCragoe%26aufirst%3DE.%2BJ.%26atitle%3D6-Substituted%25205-chloro-1%252C3-dihydro-2H-imidazo%255B4%252C5-b%255Dpyrazin-2-ones%2520with%2520hypotensive%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1973%26volume%3D16%26spage%3D537%26epage%3D542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Denoyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labarre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miot-Noirault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galmier, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madelmont, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chezal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moins, N.</span><span> </span><span class="NLM_article-title">Development of a high-performance liquid chromatographic method for the determination of a new potent radioiodinated melanoma imaging and therapeutic agent</span> <span class="citation_source-journal">J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">875</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">418</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1016%2Fj.jchromb.2008.09.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=18838313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlGhur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=875&publication_year=2008&pages=411-418&author=D.+Denoyerauthor=P.+Labarreauthor=J.+Paponauthor=E.+Miot-Noiraultauthor=M.+J.+Galmierauthor=J.+C.+Madelmontauthor=J.+M.+Chezalauthor=N.+Moins&title=Development+of+a+high-performance+liquid+chromatographic+method+for+the+determination+of+a+new+potent+radioiodinated+melanoma+imaging+and+therapeutic+agent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a high-performance liquid chromatographic method for the determination of a new potent radioiodinated melanoma imaging and therapeutic agent</span></div><div class="casAuthors">Denoyer, Delphine; Labarre, Pierre; Papon, Janine; Miot-Noirault, Elisabeth; Galmier, Marie-Josephe; Madelmont, Jean-Claude; Chezal, Jean-Michel; Moins, Nicole</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">875</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">411-418</span>CODEN:
                <span class="NLM_cas:coden">JCBAAI</span>;
        ISSN:<span class="NLM_cas:issn">1570-0232</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">N-(2-diethylaminoethyl)-6-iodoquinoxaline-2-carbamide (ICF 01012) is a new melanoma imaging agent showing promising properties for application in internal radionuclide therapy.  We developed an anal. protocol for detection of ICF 01012 in biol. samples using HPLC.  The proposed method was first validated using std. of ICF 01012 and four potent metabolites of this compd. and then applied to follow the metabolic fate of [125I]ICF 01012 after injection in melanoma-bearing mice.  The results demonstrate that this method exhibits a good linearity (r2 = 0.9947), specificity and acceptable accuracy.  This simple method appears convenient and sufficient for pharmacokinetic studies on [125I]ICF 01012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS4d_A7e4q77Vg90H21EOLACvtfcHk0lhXGrS3WMs-0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlGhur%252FI&md5=b5e2ee335742720ac4c02eefce938349</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.jchromb.2008.09.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchromb.2008.09.021%26sid%3Dliteratum%253Aachs%26aulast%3DDenoyer%26aufirst%3DD.%26aulast%3DLabarre%26aufirst%3DP.%26aulast%3DPapon%26aufirst%3DJ.%26aulast%3DMiot-Noirault%26aufirst%3DE.%26aulast%3DGalmier%26aufirst%3DM.%2BJ.%26aulast%3DMadelmont%26aufirst%3DJ.%2BC.%26aulast%3DChezal%26aufirst%3DJ.%2BM.%26aulast%3DMoins%26aufirst%3DN.%26atitle%3DDevelopment%2520of%2520a%2520high-performance%2520liquid%2520chromatographic%2520method%2520for%2520the%2520determination%2520of%2520a%2520new%2520potent%2520radioiodinated%2520melanoma%2520imaging%2520and%2520therapeutic%2520agent%26jtitle%3DJ.%2520Chromatogr.%252C%2520B%253A%2520Anal.%2520Technol.%2520Biomed.%2520Life%2520Sci.%26date%3D2008%26volume%3D875%26spage%3D411%26epage%3D418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Trost, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, Z. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joege, T.</span><span> </span><span class="NLM_article-title">A chemoselective reduction of alkynes to (E)-alkenes</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">7922</span><span class="NLM_x">–</span> <span class="NLM_lpage">7923</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja026457l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADC%252BD38XksFahtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=7922-7923&author=B.+M.+Trostauthor=Z.+T.+Ballauthor=T.+Joege&title=A+chemoselective+reduction+of+alkynes+to+%28E%29-alkenes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A Chemoselective Reduction of Alkynes to (E)-Alkenes</span></div><div class="casAuthors">Trost, Barry M.; Ball, Zachary T.; Joege, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">7922-7923</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The trans redn. of all types of alkynes to give (E)-olefins is achieved through a two-stage trans hydrosilylation and protodesilylation.  Reaction of an alkyne and a silane with the ruthenium catalyst [Cp*Ru(MeCN)3]PF6 results in clean hydrosilylation to give only the (Z)-trans addn. product at ambient temp. with catalyst loadings of 1-5 mol %.  The crude vinylsilane products are then protodesilylated by the action of cuprous iodide and TBAF at room temp. to 35°.  The reaction is compatible with many sensitive functional groups and provides a general trans-alkyne redn. not possible by other means.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVUlhi2OJFc7Vg90H21EOLACvtfcHk0lhXGrS3WMs-0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksFahtbY%253D&md5=4579c102575fc24bd38d1f8242770f4a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fja026457l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja026457l%26sid%3Dliteratum%253Aachs%26aulast%3DTrost%26aufirst%3DB.%2BM.%26aulast%3DBall%26aufirst%3DZ.%2BT.%26aulast%3DJoege%26aufirst%3DT.%26atitle%3DA%2520chemoselective%2520reduction%2520of%2520alkynes%2520to%2520%2528E%2529-alkenes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D7922%26epage%3D7923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Fürstner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radkowski, K.</span><span> </span><span class="NLM_article-title">A chemo- and stereoselective reduction of cycloalkynes to (E)-cycloalkenes</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_fpage">2182</span><span class="NLM_x">–</span> <span class="NLM_lpage">2183</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=2182-2183&author=A.+F%C3%BCrstnerauthor=K.+Radkowski&title=A+chemo-+and+stereoselective+reduction+of+cycloalkynes+to+%28E%29-cycloalkenes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DF%25C3%25BCrstner%26aufirst%3DA.%26aulast%3DRadkowski%26aufirst%3DK.%26atitle%3DA%2520chemo-%2520and%2520stereoselective%2520reduction%2520of%2520cycloalkynes%2520to%2520%2528E%2529-cycloalkenes%26jtitle%3DChem.%2520Commun.%26date%3D2002%26spage%3D2182%26epage%3D2183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Hara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishi, H.</span><span> </span><span class="NLM_article-title">Development of <sup>18</sup>F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=187-199&author=T.+Haraauthor=N.+Kosakaauthor=H.+Kishi&title=Development+of+18F-fluoroethylcholine+for+cancer+imaging+with+PET%3A+synthesis%2C+biochemistry%2C+and+prostate+cancer+imaging"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHara%26aufirst%3DT.%26aulast%3DKosaka%26aufirst%3DN.%26aulast%3DKishi%26aufirst%3DH.%26atitle%3DDevelopment%2520of%252018F-fluoroethylcholine%2520for%2520cancer%2520imaging%2520with%2520PET%253A%2520synthesis%252C%2520biochemistry%252C%2520and%2520prostate%2520cancer%2520imaging%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2002%26volume%3D43%26spage%3D187%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Wester, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiss, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senekowitsch-Schmidtke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwaiger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stöcklin, G.</span><span> </span><span class="NLM_article-title">Synthesis and radiopharmacology of <i>O</i>-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine for tumour imaging</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1999&pages=205-212&author=H.+J.+Westerauthor=M.+Herzauthor=W.+Weberauthor=P.+Heissauthor=R.+Senekowitsch-Schmidtkeauthor=M.+Schwaigerauthor=G.+St%C3%B6cklin&title=Synthesis+and+radiopharmacology+of+O-%282-%5B18F%5Dfluoroethyl%29-L-tyrosine+for+tumour+imaging"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWester%26aufirst%3DH.%2BJ.%26aulast%3DHerz%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DW.%26aulast%3DHeiss%26aufirst%3DP.%26aulast%3DSenekowitsch-Schmidtke%26aufirst%3DR.%26aulast%3DSchwaiger%26aufirst%3DM.%26aulast%3DSt%25C3%25B6cklin%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520radiopharmacology%2520of%2520O-%25282-%255B18F%255Dfluoroethyl%2529-L-tyrosine%2520for%2520tumour%2520imaging%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D1999%26volume%3D40%26spage%3D205%26epage%3D212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Armarego, W. L. F.; Perrin, D. D.</span> <span class="citation_source-book">Purification of laboratory chemicals</span>, <span class="NLM_edition">4</span>th ed.; <span class="NLM_publisher-name">Butterworth-Heinemann Eds.; Redd Educational and Professional Publishing Ltd</span>: <span class="NLM_publisher-loc">Oxford</span>,<span class="NLM_x"> </span><span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=W.+L.+F.+Armarego&author=D.+D.+Perrin&title=Purification+of+laboratory+chemicals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DArmarego%26aufirst%3DW.%2BL.%2BF.%26btitle%3DPurification%2520of%2520laboratory%2520chemicals%26pub%3DButterworth-Heinemann%2520Eds.%253B%2520Redd%2520Educational%2520and%2520Professional%2520Publishing%2520Ltd%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Mock, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkle, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vavrek, M. T.</span><span> </span><span class="NLM_article-title">A color spot test for the detection of Kryptofix 2.2.2 in [<sup>18</sup>F]FDG preparations</span> <span class="citation_source-journal">Nucl. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm400877v&amp;key=10.1016%2FS0969-8051%2896%2900212-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm400877v&amp;key=9089712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm400877v&amp;key=1%3ACAS%3A528%3ADyaK2sXitlOmu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1997&pages=193-195&author=B.+H.+Mockauthor=W.+Winkleauthor=M.+T.+Vavrek&title=A+color+spot+test+for+the+detection+of+Kryptofix+2.2.2+in+%5B18F%5DFDG+preparations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A color spot test for the detection of kryptofix 222 in [18F]FDG preparations</span></div><div class="casAuthors">Mock, Bruce H.; Winkle, Wendy; Vavrek, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">193-195</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0883-2897</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A color spot test is described that can confirm the absence of Kryptofix 2.2.2 in 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) in less than 5 min.  Pretreated strips of plastic-backed silica gel 60 thin-layer chromatog. medium, satd. with iodoplatinate reagent, are over-spotted with sep. droplets of final product [18F]FDG and Kryptofix std. solns.  A blue-black circular spot is clearly visible at Kryptofix concns. as low as 2 μg/mL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5OqWCUUb5C7Vg90H21EOLACvtfcHk0lg73w8JDIBFDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXitlOmu7k%253D&md5=38f706f2485adda9884f329e9a7b09e5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0969-8051%2896%2900212-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-8051%252896%252900212-0%26sid%3Dliteratum%253Aachs%26aulast%3DMock%26aufirst%3DB.%2BH.%26aulast%3DWinkle%26aufirst%3DW.%26aulast%3DVavrek%26aufirst%3DM.%2BT.%26atitle%3DA%2520color%2520spot%2520test%2520for%2520the%2520detection%2520of%2520Kryptofix%25202.2.2%2520in%2520%255B18F%255DFDG%2520preparations%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D1997%26volume%3D24%26spage%3D193%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, B. M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaquero, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pomper, M. G.</span><span> </span><span class="NLM_article-title">Performance evaluation of GE healthcare eXplore VISTA dual-ring small-animal PET scanner</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1891</span><span class="NLM_x">–</span> <span class="NLM_lpage">1900</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=1891-1900&author=Y.+Wangauthor=J.+Seidelauthor=B.+M.+W.+Tsuiauthor=J.+J.+Vaqueroauthor=M.+G.+Pomper&title=Performance+evaluation+of+GE+healthcare+eXplore+VISTA+dual-ring+small-animal+PET+scanner"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSeidel%26aufirst%3DJ.%26aulast%3DTsui%26aufirst%3DB.%2BM.%2BW.%26aulast%3DVaquero%26aufirst%3DJ.%2BJ.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26atitle%3DPerformance%2520evaluation%2520of%2520GE%2520healthcare%2520eXplore%2520VISTA%2520dual-ring%2520small-animal%2520PET%2520scanner%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2006%26volume%3D47%26spage%3D1891%26epage%3D1900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm400877v&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm400877v%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-21%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm400877v" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67991e24cc47234a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
